PRODUCT MONOGRAPH

INCLUDING PATIENT MEDICATION INFORMATION

^{Pr}TRAZIMERA[®]

Trastuzumab

Lyophilized Powder, 440 mg/vial and 150 mg/vial, Intravenous Infusion Professed Antineoplastic

Pfizer Canada ULC

17300 Trans-Canada Highway Kirkland, Québec H9J 2M5

Submission Control Number: 249937

[®] Pfizer Inc. Pfizer Canada ULC, Licensee Date of Initial Authorization: AUG 15, 2019 Date of Revision: JUN 18, 2021

RECENT MAJOR LABEL CHANGES

4 Dosage and Administration, 4.3 Reconstitution	12/2020
7 Warnings and Precautions	12/2020
7 Warnings and Precautions, 7.1.2 Breast-feeding	12/2020
8 Adverse Reactions, 8.3 Post-Market Adverse Reactions	12/2020
Patient Medication Information – Breast Cancer	12/2020
Patient Medication Information – Gastric Cancer	12/2020
1 Indications	04/2021

TABLE OF CONTENTS

Sections or subsections that are not applicable at the time of authorization are not listed.

RECEN	T MAJ	OR LABEL CHANGES	2
TABLE	OF CO	NTENTS	2
PART I	: HEAL	TH PROFESSIONAL INFORMATION	5
1	INDIC	CATIONS	5
	1.1	Pediatrics	6
	1.2	Geriatrics	6
2	CONT	RAINDICATIONS	6
3	SERIC	OUS WARNINGS AND PRECAUTIONS BOX	6
4	DOSA	GE AND ADMINISTRATION	7
	4.1	Dosing Considerations	7
	4.2	Recommended Dose and Dosage Adjustment	7
	4.3	Reconstitution	9
	4.4	Administration 1	1
	4.5	Missed Dose 1	1
5	OVER	DOSAGE 1	L 2
6	DOSA	GE FORMS, STRENGTHS, COMPOSITION AND PACKAGING	L 2
7	WAR	NINGS AND PRECAUTIONS 1	L 3
	7.1	Special Populations	25
	7.1.1	Pregnant Women2	25
	7.1.2	Breast-feeding	26

	7.1.3	Pediatrics	
	7.1.4	Geriatrics	
8	ADVE	RSE REACTIONS	27
	8.2	Clinical Trial Adverse Reactions	27
	8.3	Less Common Clinical Trial Adverse Reactions	63
	8.5	Post-Market Adverse Reactions	68
9	DRUG	INTERACTIONS	69
	9.2	Drug Interactions Overview	69
	9.4	Drug-Drug Interactions	69
	9.5	Drug-Food Interactions	70
	9.6	Drug-Herb Interactions	
	9.7	Drug-Laboratory Test Interactions	
10	CLINI	CAL PHARMACOLOGY	70
	10.1	Mechanism of Action	
	10.3	Pharmacokinetics	
11	STOR	AGE, STABILITY AND DISPOSAL	
12	SPEC	AL HANDLING INSTRUCTIONS	
PART	II: SCIE	NTIFIC INFORMATION	
13	PHAR	MACEUTICAL INFORMATION	
14	CLINI	CAL TRIALS	
	14.1	Efficacy and safety studies	
	14.2	Study Results	
	14.3	Comparative Bioavailability Studies	
	14.3.3	1 Pharmacokinetics	
	14.4	Immunogenicity	79
	14.5	Clinical Trials - Reference Biologic Drug	80
15	MICR	OBIOLOGY	
16	NON-	CLINICAL TOXICOLOGY	
	16.1	Comparative Non-Clinical Pharmacology and Toxicology	110
	16.1.3	Comparative Non-Clinical Pharmacodynamics	110
	16.1.2	2 Comparative Toxicology	

17	SUPPORTING PRODUCT MONOGRAPHS	110
PATIEN	NT MEDICATION INFORMATION	

Trazimera (trastuzumab) is a biosimilar biologic drug (biosimilar) to Herceptin[®].

PART I: HEALTH PROFESSIONAL INFORMATION

1 INDICATIONS

Trazimera (trastuzumab) is indicated for:

Early Breast Cancer (EBC)

- the treatment of patients with early stage breast cancer with ECOG 0-1 status, whose tumours overexpress HER2
 - following surgery and after chemotherapy
 - following adjuvant chemotherapy consisting of doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel
 - in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin.

For detailed information on the inclusion criteria for the clinical trials of trastuzumab in early breast cancer (EBC) according to the TNM (Tumour, Node, Metastasis) classification system, see **14.5 Clinical Trials - Reference Biologic Drug** section.

Based on the analysis of the HERA trial, the benefit of the adjuvant treatment with trastuzumab for low risk patients not given adjuvant chemotherapy are unknown.

The comparative efficacy and safety between different chemotherapy regimens (i.e. concurrent versus sequential, anthracycline containing versus non-anthracycline containing) was not studied.

Metastatic Breast Cancer (MBC)

• the treatment of patients with metastatic breast cancer (MBC) whose tumours overexpress HER2.

The benefits of treatment with trastuzumab in patients who do not overexpress HER2 (HER2 overexpression 0 as defined by a validated immunohistochemical [IHC] assay or who exhibit lower-level overexpression (HER2 overexpression 1+ as defined by a validated immunohistochemical [IHC] assay, and the subgroup of patients with HER2 overexpression 2+ as defined by a validated immunohistochemical [IHC] assay that corresponds to 1+ scoring by the investigative clinical trial assay), are unclear (see **7 WARNINGS AND PRECAUTIONS**: <u>Selection of Patients / Diagnostic Tests</u>).

Trazimera (trastuzumab) can be used in combination with Perjeta[®] (pertuzumab) and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. For information on the use of Trazimera in combination with Perjeta and docetaxel, consult the Product Monograph for Perjeta.

Metastatic Gastric Cancer

• use in combination with capecitabine or intravenous 5-fluorouracil and cisplatin for the treatment of patients with HER2 positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction who have not received prior anti-cancer treatment for their metastatic disease.

Trazimera should only be administered to patients with metastatic gastric cancer (MGC) whose tumours have HER2 overexpression as defined by IHC2+ confirmed by FISH+, or IHC 3+ as determined by an accurate and validated assay.

Indications have been granted on the basis of similarity between Trazimera and the reference biologic drug Herceptin.

1.1 Pediatrics

The safety and effectiveness of trastuzumab in pediatric patients have not been established; therefore, Health Canada has not authorized an indication for pediatric use.

1.2 Geriatrics

The reported clinical experience is not adequate to determine whether older patients respond differently to trastuzumab treatment than younger patients (see **7 WARNINGS AND PRECAUTIONS**, **7.1.4 Geriatrics**).

2 CONTRAINDICATIONS

Trazimera is contraindicated in patients with known hypersensitivity to trastuzumab, Chinese Hamster Ovary (CHO) cell proteins, or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see **6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING**.

When using in combination with Perjeta (pertuzumab) and docetaxel, consult Product Monographs for Perjeta and docetaxel for further information on these drugs.

3 SERIOUS WARNINGS AND PRECAUTIONS BOX

Serious Warnings and Precautions

There is a risk of medication errors between Trazimera (trastuzumab) and Kadcyla[®] (trastuzumab emtansine). In order to minimize this risk, check the vial labels to ensure that the drug being prepared and administered is Trazimera (trastuzumab) and not Kadcyla (trastuzumab emtansine). Trazimera should be prescribed using both the trade name and non- proprietary name (see **4 DOSAGE AND ADMINISTRATION**, **4.1 Dosing Considerations**).

Cardiotoxicity

Trazimera can result in the development of ventricular dysfunction and congestive heart failure. In the adjuvant treatment setting, the incidence of cardiac dysfunction was higher in patients who received trastuzumab plus chemotherapy versus chemotherapy alone. An increase in the incidence of symptomatic and asymptomatic cardiac events was observed when trastuzumab was administered after anthracycline-containing chemotherapy compared to administration with a non-anthracycline regimen of docetaxel and carboplatin. The incidence was more marked when trastuzumab was administered concurrently with a taxane than when administered sequentially to a taxane. In the metastatic setting, the incidence and severity of cardiac dysfunction was particularly high in patients who received trastuzumab concurrently with anthracyclines and cyclophosphamide (see **7 WARNINGS AND PRECAUTIONS, Cardiovascular**).

Evaluate left ventricular function in all patients prior to and during treatment with Trazimera (see **7 WARNINGS AND PRECAUTIONS, Cardiovascular**).

Infusion Reactions; Pulmonary Toxicity

Trazimera administration can result in serious infusion reactions and pulmonary toxicity. Fatal

infusion reactions have been reported. In most cases, symptoms occurred during or within 24 hours of administration of trastuzumab. Trazimera infusion should be interrupted for patients experiencing dyspnea or clinically significant hypotension. Patients should be monitored until signs and symptoms completely resolve. Discontinue Trazimera for infusion reactions manifesting as anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome (see **7 WARNINGS AND PRECAUTIONS**).

Embryo-Fetal Toxicity

Exposure to trastuzumab during pregnancy can result in impairment of fetal renal growth and/or renal function impairment resulting in oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, intrauterine growth retardation and neonatal death (see **7 WARNINGS AND PRECAUTIONS**, **7.1 Special Populations**, **7.1.1 Pregnant Women**).

4 DOSAGE AND ADMINISTRATION

4.1 Dosing Considerations

- There is a risk of medication errors between Trazimera (trastuzumab) and Kadcyla (trastuzumab emtansine). In order to prevent medication errors, it is important to check the vial labels to ensure that the drug being prepared and administered is Trazimera (trastuzumab) and not Kadcyla (trastuzumab emtansine). Ensure that the recommended Trazimera (trastuzumab) dose is administered (see **4.2 Recommended Dose and Dosage Adjustment** section).
- Trazimera should be prescribed using both the trade name and non-proprietary name. Do not substitute Trazimera for or with Kadcyla (trastuzumab emtansine).
- When using in combination with Perjeta (pertuzumab) and docetaxel for treatment of patients with HER-2-positive metastatic breast cancer, consult Product Monographs for Perjeta and docetaxel for further information, such as dose adjustment, sequence of administration of each medication and duration of treatment.

4.2 Recommended Dose and Dosage Adjustment

Early Breast Cancer (EBC)

3-Weekly Schedule: The recommended initial loading dose is 8 mg/kg Trazimera (trastuzumab) administered as a 90-minute infusion. The recommended maintenance dose is 6 mg/kg Trazimera 3 weeks later and then 6 mg/kg repeated at 3-weekly intervals administered as infusions over approximately 90 minutes. If the prior dose was well tolerated, the dose can be administered as a 30-minute infusion. Do not administer as an IV push or bolus (see **4.4 Administration**).

Weekly schedule: As a weekly regimen, the recommended initial loading dose of Trazimera is 4 mg/kg followed by 2 mg/kg every week. See **14.5 Clinical Trials - Reference Biologic Drug** section for chemotherapy combination dosing.

Metastatic Breast Cancer (MBC)

Weekly schedule: The recommended initial loading dose is 4 mg/kg Trazimera administered as a 90minute infusion. The recommended weekly maintenance dose is 2 mg/kg Trazimera and can be administered as a 30-minute infusion if the initial loading dose was well tolerated. Trazimera may be administered in an outpatient setting. **Do not administer as an IV push or bolus** (see **4.4 Administration**).

Metastatic Gastric Cancer (MGC)

3-Weekly Schedule: The recommended initial loading dose is 8 mg/kg Trazimera administered as a 90minute infusion. The recommended maintenance dose is 6 mg/kg Trazimera 3 weeks later and then 6 mg/kg repeated at 3-weekly intervals administered as infusions over approximately 90 minutes. If the prior dose was well tolerated, the dose can be administered as a 30-minute infusion. **Do not administer as an IV push or bolus** (see **4.4Administration**)

Duration of Treatment

In clinical studies, patients with MBC or MGC were treated with trastuzumab until progression of disease. Patients with EBC should be treated for 1 year or until disease recurrence or unacceptable cardiac toxicity, whichever occurs first (see **7 WARNINGS AND PRECAUTIONS, Cardiovascular**). Extending treatment in EBC beyond one year is not recommended (see **14.5 Clinical Trials - Reference Biologic Drug, Early Breast Cancer (EBC)**, <u>HERA</u>).

Dose Reduction

No reductions in the dose of trastuzumab were made during clinical trials. Patients may continue therapy with Trazimera during periods of reversible, chemotherapy-induced myelosuppression, but they should be monitored carefully for complications of neutropenia during this time. The specific instructions to reduce or hold the dose of chemotherapy should be followed.

Table 1 depicts the criteria for permanent discontinuation of trastuzumab for cardiac dysfunction inpivotal studies in adjuvant breast cancer.

Table 1 - Criteria for Permanent Discontinuation for Cardiac Dysfunction in Pivotal Studies in Adjuvant Breast Cancer

STUDY	If Symptomatic Congestive Heart Failure (CHF)	If Held for Asymptomatic LVEF Decrease (per algorithm used in each study protocol)
HERA	Permanent discontinuation required	Permanent discontinuation required if trastuzumab held for 2 consecutive cycles
NSABP B-31, NCCTG N9831 and BCIRG-006	Permanent discontinuation required	Permanent discontinuation required if trastuzumab held for 2 consecutive cycles, or for 3 intermittent cycles; investigator may choose to discontinue permanently sooner

Dose Holding

Monitoring of Cardiac Function (also see **7 WARNINGS AND PRECAUTIONS**, Cardiovascular, Cardiotoxicity)

Table 2 - Recommendations for Continuation or Withdrawal of Trastuzumab Therapy in AsymptomaticPatients Based on Serial Measurements of Left Ventricular Ejection Fraction (LVEF)^a(Adapted from the Canadian Consensus Guidelines*)

Relationship of	Asymptomatic decrease in LVEF from baseline			
LVEF to LLN	≤ 10 percentage points	10–15 percentage points	≥ 15 percentage points	
Within radiology facility's normal limits	Continue trastuzumab	Continue trastuzumab	Hold trastuzumab and repeat MUGA or ECHO after 4 weeks	
1–5 percentage points below LLN	Continue trastuzumab ^b	Hold trastuzumab and repeat MUGA or ECHO after 4 Weeks ^{b,c}	Hold trastuzumab and repeat MUGA or ECHO after 4 weeks ^{c,d}	
≥6 percentage points below LLN	Continue trastuzumab and repeat MUGA or ECHO after 4 weeks ^d	Hold trastuzumab and repeat MUGA or ECHO after 4 Weeks ^{c,d}	Hold trastuzumab and repeat MUGA or ECHO after 4 weeks ^{c,d}	

^a Based on NSABP B-31 trial protocol. Modified to include recommendations for cardiology consultation or treatment of cardiac dysfunction (or both) when appropriate, as indicated in the subsequent footnotes.

^b Consider cardiac assessment and initiation of angiotensin converting-enzyme inhibitor therapy.

^c After two holds, consider permanent discontinuation of trastuzumab.

^d Initiate angiotensin converting-enzyme inhibitor therapy and refer to cardiologist. LLN = lower limit of normal; MUGA = multiple-gated acquisition scan; ECHO = echocardiography.

*Source: Mackey JR, Clemons M, Côté MA, et al. Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group. Curr Oncol. 2008 Jan;15(1):24-35.

For the frequency of cardiac monitoring see **7 WARNINGS AND PRECAUTIONS**, Cardiovascular, Cardiotoxicity.

The safety and effectiveness of trastuzumab in pediatric patients have not been established. Health Canada has not authorized an indication for pediatric use.

No dosage adjustment required in hepatic or renal impairment.

4.3 Reconstitution

Preparation for Administration

Use appropriate aseptic technique.

<u>440 mg vial</u>

Each 440 mg vial of Trazimera should be reconstituted with 20 mL of Bacteriostatic Water for Injection (BWFI, supplied), containing 1.1% benzyl alcohol as a preservative, to yield a multi-dose solution containing 21 mg/mL trastuzumab. Store reconstituted Trazimera at 2°C - 8°C. When reconstituted with BWFI, discard unused Trazimera after 28 days.

In patients with known hypersensitivity to benzyl alcohol, reconstitute Trazimera with 20 mL Sterile Water for Injection (SWFI, not supplied) without preservative to yield a single use solution (see **7 WARNINGS AND PRECAUTIONS**). If SWFI is used for reconstitution, the reconstituted solution should be used as soon as possible from a microbiological point of view and no later than 48 hours after reconstitution. Any remaining reconstituted solution should be discarded.

150 mg vial

Each 150 mg vial of Trazimera should be reconstituted with 7.2 mL SWFI (not supplied) to yield a single-dose solution containing 21 mg/mL trastuzumab. The reconstituted solution should be used as soon as possible from a microbiological point of view and no later than 48 hours after reconstitution. Any remaining reconstituted solution should be discarded.

Trazimera should not be mixed or diluted with other drugs. Infusions of Trazimera should not be administered or mixed with dextrose or glucose solutions. Use of other reconstitution diluents should be avoided.

Trazimera should be carefully handled during reconstitution. Causing excessive foaming during reconstitution or shaking the reconstituted solution may result in problems with the amount of Trazimera that can be withdrawn from the vial.

Vial Contents	Volume of Diluent to be Added to Vial	Nominal Concentration per mL
lyophilized powder containing 440 mg trastuzumab	20 mL of BWFI (supplied) or 20 mL of SWFI (not supplied)	21 mg/mL
lyophilized powder containing 150 mg of trastuzumab	7.2 mL of SWFI (not supplied)	21 mg/mL

Table 3 - Reconstitution

- 1. Using a sterile syringe, slowly inject the diluent in the vial containing the lyophilized Trazimera.
- 2. Swirl vial gently to aid reconstitution. **Do not shake.**

Slight foaming of the product upon reconstitution is not unusual. Allow the vial to stand undisturbed for approximately 5 minutes. The reconstituted Trazimera results in a clear to slightly opalescent and colorless to pale yellow-brown solution and should be essentially free of visible particulates.

Determine the volume of the solution required:

Weekly Schedule: based on a loading dose of 4 mg trastuzumab/kg body weight or a maintenance dose of 2 mg trastuzumab/kg body weight:

Volume (mL) = [Body Weight (kg) x Dose (4 mg/kg for loading OR 2 mg/kg for maintenance)]

21 mg/mL (concentration of reconstituted solution)

3-Weekly Schedule: based on a loading dose of 8 mg trastuzumab/kg body weight, or a subsequent 3 weekly dose of 6 mg trastuzumab/kg body weight:

Volume (mL) = [Body Weight (kg) x Dose (8 mg/kg for loading OR 6 mg/kg for maintenance)]

21 mg/mL (concentration of reconstituted solution)

The appropriate amount of solution should be withdrawn from the vial and added to an infusion bag containing 250 mL of 0.9% sodium chloride solution. Do not use with **dextrose or glucose solution**. The bag should be gently inverted to mix the solution in order to avoid foaming. The reconstituted Trazimera results in a clear to slightly opalescent and colorless to pale yellow-brown solution. Parenteral drug products should be inspected visually for particulates and discolouration prior to administration. No incompatibilities between Trazimera and polyvinylchloride, polyethylene, polypropylene or ethylene vinyl acetate bags or glass IV bottles have been observed.

4.4 Administration

Weekly Schedule: Treatment may be administered in an outpatient setting by administration of a 4 mg/kg loading dose of Trazimera by intravenous (IV) infusion over 90 minutes. **Do not administer as an IV push or bolus**. Patients should be observed for fever and chills or other infusion associated symptoms. Serious adverse reactions to infusions of trastuzumab including dyspnea, hypotension, hypertension, wheezing, bronchospasm, tachycardia, reduced oxygen saturation and respiratory distress have been reported infrequently (also see **8 ADVERSE REACTIONS**). Interruption of the infusion may help control such symptoms. The infusion may be resumed when symptoms abate.

If prior infusion was well tolerated, subsequent weekly doses of 2 mg/kg Trazimera may be administered over 30 minutes (see **4.2 Recommended Dose and Dosage Adjustment**). Patients should still be observed for fever and chills or other infusion-associated symptoms (see **8 ADVERSE REACTIONS**).

3-Weekly Schedule: Treatment may be administered in an outpatient setting by administration of a 8 mg/kg loading dose of Trazimera by intravenous (IV) infusion over 90 minutes. **Do not administer as an IV push or bolus**. Patients should be observed for fever and chills or other infusion associated symptoms (see **8 ADVERSE REACTIONS**). Interruption of the infusion may help control such symptoms. The infusion may be resumed when symptoms abate.

If prior infusion was well tolerated, subsequent 3-weekly doses of 6 mg/kg Trazimera may be administered over 30 minutes (see **4.2 Recommended Dose and Dosage Adjustment**). Patients should still be observed for fever and chills or other infusion-associated symptoms (see **8 ADVERSE REACTIONS**).

4.5 Missed Dose

Weekly schedule: If the patient has missed a dose of Trazimera by one week or less, then the usual maintenance dose (2 mg/kg) should be given as soon as possible (do not wait until the next planned cycle). Subsequent maintenance Trazimera doses of 2 mg/kg should be administered 7 days later according to the weekly schedule.

If the patient has missed a dose of Trazimera by more than one week, a re-loading dose of Trazimera should be administered (4 mg/kg over approximately 90 minutes) as soon as possible. Subsequent maintenance Trazimera doses of 2 mg/kg should be administered 7 days later according to the weekly schedule.

3-Weekly Schedule: If the patient has missed a dose of Trazimera by one week or less, then the usual maintenance dose (6 mg/kg) should be administered as soon as possible (do not wait until the next

planned cycle). Subsequent maintenance Trazimera doses of 6 mg/kg should be administered 21 days later according to the 3-weekly schedule.

If the patient has missed a dose of Trazimera by more than one week, a re-loading dose of Trazimera should be administered (8 mg/kg over approximately 90 minutes) as soon as possible. Subsequent maintenance Trazimera doses of 6 mg/kg should be administered 21 days later according to the 3-weekly schedule.

5 OVERDOSAGE

There is no experience with overdosage in human clinical trials. Single doses higher than 500 mg (10 mg/kg) have not been tested.

Ensure that the recommended Trazimera (trastuzumab) dose and NOT Kadcyla (trastuzumab emtansine) dose is administered. For information on the risk of Kadcyla overdose due to medication errors, see Kadcyla Product Monograph.

For management of a suspected drug overdose, contact your regional poison control centre.

6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

To help ensure the traceability of biologic products, including biosimilars, health professionals should recognise the importance of recording both the brand name and the non-proprietary (active ingredient) name as well as other product-specific identifiers such as the Drug Identification Number (DIN) and the batch/lot number of the product supplied.

Table 4 – Dosage	Forms, Strengths,	Composition and	d Packaging

Route of Administration	Dosage Form / Strength/Composition	Non-medicinal Ingredients
Intravenous Infusion	Lyophilized powder for reconstitution	L-histidine, L-histidine hydrochloride monohydrate, polysorbate 20 and sucrose
	440 mg/vial	
	150 mg/vial	

Composition:

Trazimera (trastuzumab) is a sterile, white preservative-free lyophilized powder for intravenous (IV) administration.

Each 440 mg vial of Trazimera contains 440 mg trastuzumab, L-histidine, L-histidine hydrochloride monohydrate, polysorbate 20 and sucrose.

Each 150 mg vial of Trazimera contains 150 mg trastuzumab, L-histidine, L-histidine hydrochloride monohydrate, polysorbate 20 and sucrose.

The Trazimera vial stopper is not made with natural rubber latex.

Availability:

<u>440 mg vial</u>

Trazimera is supplied as a lyophilized, sterile powder or cake containing 440 mg trastuzumab per vial.

BWFI is supplied as a 20 mL vial of sterile solution containing 1.1% benzyl alcohol as an antimicrobial preservative.

Each carton contains one vial of 440 mg Trazimera and one vial of 20 mL of BWFI containing 1.1% benzyl alcohol.

<u>150 mg vial</u>

Trazimera is supplied as a lyophilized, sterile powder or cake containing 150 mg trastuzumab per vial.

Each carton contains one vial of 150 mg Trazimera.

Description

Trazimera (trastuzumab) is a biosimilar to Herceptin. It consists of a humanized immunoglobulin G1 (IgG1) kappa monoclonal antibody (mAb) with two identical heavy (H) chains and two identical light (L) chains, covalently linked with four inter-chain disulfide bonds.

The humanized antibody against HER2 is produced by a mammalian cell (Chinese Hamster Ovary [CHO]) suspension culture.

Trazimera (trastuzumab) selectively binds with high affinity to extra cellular domain (ECD) of the human epidermal growth factor receptor 2 (HER2).

7 WARNINGS AND PRECAUTIONS

Please see 3 SERIOUS WARNINGS AND PRECAUTIONS BOX.

General

Therapy with Trazimera should only be initiated under supervision of a physician experienced in the treatment of cancer patients.

When using in combination with Perjeta (pertuzumab) and docetaxel, consult Product Monographs for Perjeta and docetaxel for further information on these drugs.

In order to improve traceability of biological medicinal products, the trade name and the batch number of the administered product should be clearly recorded (or stated) in the patient file.

Early Breast Cancer (EBC)

The safety of the various combination chemotherapy regimens prior to trastuzumab therapy was not separately analyzed in the HERA trial. The data provided reflects the safety and efficacy of trastuzumab for the recommended 1-year treatment duration.

Benzyl Alcohol

Benzyl alcohol, used as a preservative in BWFI, has been associated with toxicity in neonates and children up to 3 years old. For patients with a known hypersensitivity to benzyl alcohol (the preservative in BWFI), reconstitute Trazimera with Sterile Water for Injection (SWFI). If SWFI is used for reconstitution, the reconstituted solution should be used as soon as possible from a microbiological point of view and no later than 48 hours after reconstitution. Any remaining reconstituted solution should be discarded (see **4 DOSAGE AND ADMINISTRATION**).

Cardiovascular

Cardiotoxicity: Administration of Trazimera can result in the development of ventricular dysfunction and congestive heart failure. In the adjuvant treatment setting, the incidence of cardiac dysfunction was higher in patients who received trastuzumab plus chemotherapy versus chemotherapy alone. In patients with EBC, an increase in the incidence of symptomatic and asymptomatic cardiac events was observed when trastuzumab was administered after anthracycline-containing chemotherapy compared to administration with a non-anthracycline regimen of docetaxel and carboplatin. The incidence was more marked when trastuzumab was administered concurrently with a taxane than when administered sequentially to a taxane. In the metastatic setting, the incidence and severity of cardiac dysfunction were particularly high in patients who received trastuzumab concurrently with anthracyclines and cyclophosphamide. The incidence of cardiac adverse events was also higher in patients with previous exposure to anthracyclines based on post-marketing data.

Because the half-life of trastuzumab, using a population pharmacokinetic method, is approximately 28.5 days (95% CI, 25.5 - 32.8 days), trastuzumab may persist in the circulation for approximately 24 weeks (range: 22-28 weeks) after stopping treatment with trastuzumab. Since the use of an anthracycline during this period could possibly be associated with an increased risk of cardiac dysfunction, a thorough assessment of the risks versus the potential benefits is recommended in addition to careful cardiac monitoring. If possible, physicians should avoid anthracycline based therapy while trastuzumab persists in the circulation.

Patients who receive Trazimera either as a component of adjuvant treatment or as a treatment for metastatic HER2 positive breast cancer may experience signs and symptoms of cardiac dysfunction such as dyspnea, increased cough, paroxysmal nocturnal dyspnea, peripheral edema, S3 gallop, or reduced ejection fraction. Cardiac dysfunction associated with therapy with trastuzumab may be severe and has been associated with disabling cardiac failure, death, and mural thrombosis leading to stroke.

Left ventricular function should be evaluated in all patients prior to and during treatment with Trazimera. If LVEF drops 10 ejection points from baseline and/or to below 50%, Trazimera should be withheld and a repeat LVEF assessment performed within approximately 3 weeks. If LVEF has not improved, or declined further, discontinuation of Trazimera should be strongly considered, unless the benefits for the individual patient are deemed to outweigh the risks. The scientific basis of cardiac dysfunction has been incompletely investigated in pre-clinical studies.

Extreme caution should be exercised in treating patients with pre-existing cardiac dysfunction, and in EBC, in those patients with an LVEF of 55% or less. Candidates for treatment with Trazimera as part of adjuvant treatment for operable breast cancer or for MBC, especially those with prior anthracycline and cyclophosphamide (AC) exposure, should undergo thorough baseline cardiac assessment including history and physical exam, electrocardiogram (ECG) and either 2D echocardiogram or multiple gated acquisition (MUGA) scan. A careful risk-benefit assessment should be made before deciding to treat with Trazimera. Cardiac assessments, as performed at baseline, should be repeated every 3 months during treatment and every 6 months following discontinuation of treatment until 24 months from the last administration of Trazimera. In patients with EBC who receive anthracycline containing chemotherapy further monitoring is recommended and should occur yearly up to 5 years from the last administration of Trazimera, or longer if a continued decrease of LVEF is observed. Monitoring may help to identify patients who develop cardiac dysfunction. Patients who develop asymptomatic cardiac dysfunction may benefit from more frequent monitoring (e.g. every 6-8 weeks). If patients have a continued decrease in left ventricular function, but remain asymptomatic, the physician should consider discontinuing therapy if no clinical benefit of therapy with Trazimera has been seen.

If symptomatic cardiac failure develops during therapy with Trazimera, it should be treated with the standard medications for this purpose. Discontinuation of Trazimera should be strongly considered in patients who develop clinically significant congestive heart failure. In the MBC clinical trials, approximately two-thirds of patients with cardiac dysfunction were treated for cardiac symptoms, most patients responded to appropriate medical therapy (which may include one or more of the following: diuretics, angiotensin-converting enzyme inhibitors, β - blockers, angiotensin II receptor blockers, or cardiac glycosides) often including discontinuation of trastuzumab. The safety of continuation or resumption of trastuzumab in patients who have previously experienced cardiac toxicity has not been prospectively studied.

Early Breast Cancer (EBC)

Trazimera and anthracyclines should not be given concurrently in the adjuvant treatment setting.

Risk factors for a cardiac event identified in four large adjuvant studies included advanced age (> 50 years), low level of baseline and declining LVEF (< 55%), low LVEF prior to or following the initiation of paclitaxel treatment, trastuzumab treatment, and prior or concurrent use of anti- hypertensive medications. In patients receiving trastuzumab after completion of adjuvant chemotherapy the risk of cardiac dysfunction was associated with a higher cumulative dose of anthracycline given prior to initiation of trastuzumab and a high body mass index (BMI > 25 kg/m²).

In EBC, the following patients were excluded from the HERA, JA (NSABP B-31 and NCCTG N9831) and BCIRG006 trials there are no data about the benefit risk balance, and therefore treatment cannot be recommended in such patients:

- history of myocardial infarction (MI),
- angina pectoris requiring medication,
- history of or present CHF (NYHA II –IV),
- other cardiomyopathy,
- cardiac arrhythmia requiring medication,
- clinically significant cardiac valvular disease,
- poorly controlled hypertension (hypertension controlled by standard medication eligible) and
- clinically significant pericardial effusion.

The safety of continuation or resumption of trastuzumab in patients who have previously experienced cardiac toxicity has not been prospectively studied. According to the narrative reports of cardiac events, about half of the events had resolved completely by the time of the interim analysis. Please see **Table 6** below.

For patients with EBC, cardiac assessments, as performed at baseline, should be repeated every 3 months during treatment and every 6 months following discontinuation of treatment until 24 months from the last administration of trastuzumab. In patients who receive anthracycline containing chemotherapy further monitoring is recommended and should occur yearly up to 5 years from the last administration of trastuzumab, or longer if a continued decrease of LVEF is observed.

A high index of clinical suspicion is warranted for discontinuing treatment in the setting of cardiopulmonary symptoms. Close monitoring of cardiac function should be carried out for all patients and adequate treatment for CHF should be administered regardless of the discontinuation of trastuzumab therapy. Please see **Table 2** in **4 DOSAGE AND ADMINISTRATION**: **Dose Holding**, Monitoring of Cardiac Function, for information on continuation and discontinuation of trastuzumab based on interval LVEF assessments.

<u>HERA</u>

In the HERA trial, cardiac monitoring (electrocardiogram [ECG], left ventricular ejection fraction [LVEF], signs/symptoms and cardiac questionnaire) was performed at baseline and regularly throughout the study. The assessment schedule for cardiac monitoring was at months 3 and 6 and then every 6 months until month 36 (3 years from the date of therapy) and in month 60 (5 years from the date of therapy). In addition, LVEF was measured at 48 months (4 years from the date of therapy) and followed up every 12 months from year 6 to year 10.

When trastuzumab was administered after completion of adjuvant chemotherapy, NYHA class III-IV heart failure was observed in 0.6% of patients in the one-year arm after a median follow- up of 12 months.

Table 5a - Absolute Numbers and Rates of Cardiac Endpoints in HERA (Median follow-up of 12 months)

HERA study	Observation	Trastuzumab
	n (%)	n (%)
	N=1708	N=1678
Primary cardiac endpoint	1 (0.1%)	10 (0.6%)
Secondary cardiac endpoint	9 (0.5%)	51 (3.0%)
Total "cardiac endpoints"	10 (0.6%)	61 (3.6%)

Table 5b - Absolute Numbers and Rates of Cardiac Endpoints in HERA

(Median follow-up of 8 years)

HERA study	Observation	Trastuzumab
	n (%)	1 year arm
	N=1744	n (%)
		N=1682
Primary cardiac endpoint	2 (0.1%)	14 (0.8%)
Events after 1 year	0 (0.0%)	1 (0.1%)
Secondary cardiac endpoint	15 (0.9%)	78 (4.6%)
		(69 – excluding patients
		with primary endpoint)
Events after 1 year	7 (0.4%)	14 (0.8%)
		(13 – excluding patients
		with primary endpoint)
Total "cardiac endpoints"	17 (1.0%)	83 (4.9%)

Table 6a - Median Time to Return to Baseline LVEF/ Stabilizations of LVEF in the HERA Trial (Median follow-up of 8 years) - Primary Cardiac Endpoint

HERA study	Primary Cardiac Endpoint		
	Observation (n = 2)	Trastuzumab 1-year (n=14)	
Return to baseline LVEF	0	11 (79%)	
Median time to return to baseline LVEF	-	218 d	

Stabilization of LVEF	0	5 (36%)

Table 6b - Median Time to Return to Baseline LVEF/ Stabilizations of LVEF in the HERA Trial (Median follow-up of 8 years) - Secondary Cardiac Endpoint

HERA study	Secondary Cardiac Endpoint (excluding patients with primary cardiac endpoint)			
	Observation Trastuzumab 1-year			
	(n = 15) (n=69)			
Return to baseline LVEF	10 (67%) 60 (87%)			
Median time to return to baseline LVEF	189 d	240 d		
Stabilization of LVEF	4 (27%)	18 (26%)		

A significant drop in left ventricular ejection fraction (LVEF) is defined as an absolute decrease of 10 EF points or more from baseline and to below 50%, measured by MUGA scan or echocardiogram.

A **primary cardiac endpoint** was defined as the occurrence at any time after randomization but prior to any new therapy for recurrent disease of symptomatic congestive heart failure of NYHA class III or IV, confirmed by a cardiologist and a significant drop in LVEF, or cardiac death.

A **secondary cardiac endpoint** was defined as asymptomatic (NYHA class I) or mildly symptomatic (NYHA class II) cardiac dysfunction with a significant LVEF drop. In addition, events which did not meet the above criteria for a secondary cardiac endpoint but which in the opinion of the Cardiac Advisory Board should be classed as secondary cardiac endpoints were included.

After a median follow-up of 3.6 years the incidences of severe CHF, symptomatic CHF and at least one significant LVEF decrease (an absolute decline of at least 10% from baseline LVEF and to less than 50%) after 1 year of trastuzumab therapy was 0.8%, 1.9% and 9.8%, respectively.

After a median follow-up of 8 years the incidence of severe CHF (NYHA III & IV) in the trastuzumab 1year treatment arm was 0.8%, and the rate of mild symptomatic and asymptomatic left ventricular dysfunction was 4.6%. At least one LVEF assessment was missing for 20.8% of patients in the observation only arm and 32.0% of patients in the trastuzumab 1-year arm. During the follow-up until month 60, at least one LVEF assessment was missed for 18.0% of patients in the observation only arm and 17.9% of patients in the trastuzumab1-year arm.

Reversibility of severe CHF (defined as a sequence of at least two consecutive LVEF values \geq 50% after the event) was evident for 71.4% of trastuzumab-treated patients. Reversibility of mild symptomatic and asymptomatic left ventricular dysfunction was demonstrated for 79.5% of patients. Approximately 17% (14/83) of cardiac endpoints occurred after completion of trastuzumab in the trastuzumab one-year arm.

Joint Analysis: NSABP B-31 and NCCTG N9831

Cardiac dysfunction adverse events were defined in both B-31 and N9831 as symptomatic cardiac events and asymptomatic LVEF events. Symptomatic cardiac events were reviewed and confirmed by the cardiac committee of each study and included the occurrence of symptomatic congestive heart failure with objective findings and confirmation by imaging, deaths due to cardiac causes (CHF, MI, or documented primary arrhythmia) and probable cardiac deaths (sudden death without documented etiology). Asymptomatic LVEF events were defined as absolute drop in LVEF \geq 10% to < 55% or an absolute drop in LVEF of \geq 5% to below the institution's lower limit of normal (LLN). In study B-31, 15.5% of patients discontinued trastuzumab due to asymptomatic LVEF decrease (12.2%), CHF (2.2%) or Cardiac diagnosis other than CHF (1.1%) in the trastuzumab + chemotherapy arm; no patients in the chemotherapy alone arm discontinued treatment for these reasons. In all analyses the rate of cardiac dysfunction was higher in patients in the trastuzumab + chemotherapy arm compared with those in the chemotherapy alone arm. From the paclitaxel baseline to the six month, nine month and eighteen month assessment, the average change in LVEF was more pronounced in the trastuzumab + chemotherapy arm (-4.2%, -5.1% and -3.1% in the trastuzumab + chemotherapy alone arm, respectively versus -0.5%, -0.4% and -0.9% in the chemotherapy alone arm, respectively).

Table 7 - Joint Analysis: (NSABP B-31 and NCCTG N9831)

The Incidence and Type of Cardiac Events (Median Duration of More Than 8 Years** Safety Follow up)

	B-	31	N9	831	B-31 +	N9831
	AC → T	AC→ T + H	AC → T	AC→ T + H	AC → T	AC→ T + H
	(n=889)	(n=1031)	(n=766)	(n=969)	(n=1655)	(n=2000)
Symptomatic CHF (non-	11	38	5	24	16	62
death)	(1.2%)	(3.7%)	(0.7%)	(2.5%)	(1.0%)ª	(3.1%) ^b
Cardiac death	2	1	3	1	5	2
	(0.2%) ^c	(0.1%)	(0.4%)	(0.1%)	(0.3%) ^c	(0.1%)
Death due to CHF, MI,	0	0	2	1	2	1
or primary arrhythmia	(0.0%)	(0.0%)	(0.3%)	(0.1%)	(0.1%)	(0.1%)
Sudden death without	2	1	1	0	3	1
documented etiology	(0.2%)	(0.1%)	(0.1%)	(0.0%)	(0.2%)	(0.1%)
Any cardiac or asymptomatic LVEF events	270 (30.4%)	401 (38.9%)	209 (27.3%)	367 (37.9%)	479 (28.9%)	768 (38.4%)
Drop in LVEF of 10 points compared with baseline to below 55*	236 (26.5%)	376 (36.5%)	184 (24.0%)	340 (35.1%)	420 (25.4%)	716 (35.8%)
Drop in LVEF of 5 points compared with baseline to below the lower limit of normal*	161 (18.1%)	267 (25.9%)	127 (16.6%)	238 (24.6%)	288 (17.4%)	505 (25.3%)

A=doxorubicin; C=cyclophosphamide; CHF=congestive heart failure; H=trastuzumab; LVEF=left ventricular ejection fraction; MI=myocardial infarction; T=paclitaxel.

*Asymptomatic LVEF per protocol events at any time after AC initiation: 1. Drop in LVEF of 10 points compared with AC baseline LVEF to below 55. or 2. Drop in LVEF of 5 points compared with AC baseline LVEF to below the lower limit of normal.

** In the joint analysis safety population, the median duration of follow-up was 8.1 years for the AC \rightarrow T + H group and 8.5 years for the AC \rightarrow T group

^a 16 AC \rightarrow T patients had adjudicated and confirmed symptomatic CHF out of the 62 possible CHF patients reviewed by the study committees.

^b 62 AC \rightarrow T +H patients had adjudicated and confirmed symptomatic CHF out of the 135 possible CHF patients reviewed by the study committees.

 $^{\circ}$ A patient received AC \rightarrow T in study B-31; not included here and had "emphysema" listed on autopsy.

At 3 years, the cardiac event rate in patients receiving AC \rightarrow TH (doxorubicin plus cyclophosphamide followed by paclitaxel + trastuzumab) was estimated at 3.2%, compared with 0.9% in AC \rightarrow T treated patients. Between 5 and 7 years of follow-up, an additional patient in each treatment group experienced a cardiac event; the cardiac event rate at 9 years follow-up in patients receiving AC \rightarrow TH was estimated at 3.2%, compared with 1.0% in AC \rightarrow T treated patients. **Table 8** summarizes the follow-up information for 84 patients (52 from study B-31 and 32 from studyN9831) for whom symptomatic CHF was adjudicated and confirmed by the study committee.

Table 8 - Joint Analysis (NSABP B-31 and NCCTG N9831)

Follow-Up of Symptomatic CHF Events (Median Duration of More Than 8 Years* Safety Follow up) (Patients from the Joint Safety Population with Symptomatic CHF Confirmed by Study Committee)

	B-	31	N9	831	Joint A	nalysis		
	$AC \rightarrow T$	AC \rightarrow T+H	AC \rightarrow T	AC \rightarrow T+H	$AC \rightarrow T$	AC \rightarrow T+H		
	(n = 11)	(n= 38)	(n = 5)	(n = 24)	(n = 16)	(n = 62)		
Months from o	Months from onset to first overall recovery							
Ν	4	22	0	9	4	31		
Mean	10.1	21.5	NA	10.5	10.1	18.3		
(SD)	(2.2)	(11.1)		(8.6)	(4.4)	(11.5)		
Median	10.2	16.6	NA	6.6	10.2	14.5		
Range	8-12	9-50	NA	3-31	8-12	3-50		
Current overall	recovery status							
Recovery								
(LVEF ≥50%	3	8	0	7	3	15		
and no	(27.3%)	(21.1%)	(0.0%)	(29.2%)	(18.8%)	(24.2%)		
symptoms)								
No recovery	2	7	3	6	5	13		
(LVEF <50%	_		-	-				
or symptoms)	(18.2%)	(18.4%)	(60.0%)	(25.0%)	(31.3%)	(21.0%)		
Unknown	6	23	2	11	8	34		
	(54.5%)	(60.5%)	(40.0%)	(45.8%)	(50.0%)	(54.8%)		

A=doxorubicin; C=cyclophosphamide; H=trastuzumab; LVEF=left ventricular ejection fraction; SD=standard deviation; T=paclitaxel;

* = In the joint analysis safety population, the median duration of follow-up was 8.1 years for the AC \rightarrow T + H group and 8.5 years for the AC \rightarrow T group.

Following initiation of paclitaxel therapy, 344 patients treated with AC \rightarrow TH (18.5%) experienced an LVEF percentage decrease of \geq 10 points from paclitaxel baseline to < 50 points, compared with 82 patients treated with AC \rightarrow T (7.0%) at a median follow-up of 8.1 years for the AC \rightarrow TH group. The per patient incidence of new onset cardiac dysfunction, after initiation of paclitaxel therapy, as determined by LVEF, remained unchanged compared to the analysis performed at a median follow up of 2.0 years in the AC \rightarrow TH group.

An independent clinical review was performed on 62 patients with symptomatic congestive heart failure in the trastuzumab + chemotherapy arm to assess treatment and resolution status. Most patients were treated with oral medications commonly used to manage congestive heart failure. Complete or partial LVEF recovery was documented in 56 patients (90.3%), with complete recovery in 17 of these patients (27.4%) and partial recovery in 39 of these patients (62.9%), compared to 6 patients (9.7%) experiencing no recovery. This analysis also showed evidence of reversibility of left ventricular dysfunction in 64.5% of patients who experienced a symptomatic CHF in the AC \rightarrow TH group being asymptomatic at the latest follow up.

Risk factors for a cardiac event included trastuzumab treatment, increased age, prior or current use of anti-hypertensive medications and low LVEF prior to or following the initiation of paclitaxel treatment. In the trastuzumab + chemotherapy arm, the risk of a cardiac event increased with the number of these

risk factors present. In study B-31, there was no association between the incidence of cardiac events and either radiation to the left side of the chest or smoking.

BCIRG006

In study BCIRG006, cardiac events were defined as congestive heart failure (CHF; grade 3 or 4 cardiac left ventricular function [CLVF], per the NCI-CTC, v 2.0), grade 3 or 4 cardiac arrhythmia, grade 3 or 4 cardiac ischemia/infarction, cardiac death and serious adverse events with cardiac etiology not predefined as a cardiac event in the protocol but assessed as being a significant cardiac event by the Independent Cardiac Review Panel (ICRP). Asymptomatic LVEF events were defined as an absolute decline in LVEF value of > 15 % from baseline to a value that was below the institution's lower limit of normal (LLN). [Note: asymptomatic LVEF events defined in HERA as: a drop in LVEF of at least 10 EF points from baseline and to below 50%, and in the JA as: absolute drop in LVEF \geq 10% to < 55% or an absolute drop in LVEF of \geq 5% to below the institution's LLN.]

Table 9 summarizes symptomatic cardiac events reported at any time during the study.

Table 9 - Symptomatic Cardiac Events per the Independent Cardiac Review Panel (ICRP) Occurring atAny Time during the Study (Safety Population) 5 Year Follow Up

	AC→T	AC→TH	тсн
Event Type	(n=1041)	(n <i>=</i> 1077)	(n <i>=</i> 1056)
CHF (Grade 3/4 CLVF)	6 (0.6%)	20 (1.9%)	4 (0.4%)
Grade 3/4 cardiac ischemia/infarction	0	3 (0.3%)	2 (0.2%)
Grade 3/4 arrhythmia	6 (0.6%)	3 (0.3%)	6 (0.6%)
Cardiac death	0	0	0
Any symptomatic cardiac event	10 (1.0%)	25 (2.3%)	12 (1.1%)

AC→T=doxorubicin plus cyclophosphamide, followed by docetaxel; AC→TH=doxorubicin plus cyclophosphamide, followed by docetaxel plus trastuzumab; CHF=congestive heart failure; CLVF=cardiac left ventricular function; TCH=docetaxel, carboplatin, and trastuzumab.

At 5.5 years, the rates of symptomatic cardiac or LVEF events were 1.0%, 2.3%, and 1.1% in the AC→T (doxorubicin plus cyclophosphamide, followed by docetaxel), AC→TH (doxorubicin plus cyclophosphamide, followed by docetaxel plus trastuzumab), and TCH (docetaxel, carboplatin and trastuzumab) treatment arms, respectively. For symptomatic CHF (Grade 3 - 4), the 5-year rates were 0.6%, 1.9%, and 0.4% in the AC→T, AC→TH, and TCH treatment arms, respectively. The overall risk of developing symptomatic cardiac events was similar for patients in AC→T and TCH arms. There was an increased risk of developing a symptomatic cardiac event for patients in the AC→TH arm, where the cumulative rate of symptomatic cardiac or LVEF events was 2.3% compared to approximately 1% in the two comparator arms (AC→T and TCH, respectively).

In BCIRG006 study, 155 patients treated with AC \rightarrow TH (14.4%) experienced an LVEF decrease of \geq 10% from baseline to < 50%, compared with 79 (7.6%) patients treated with AC \rightarrow T and 63 (6.0%) patients treated with TCH.

Table 10 presents the incidence of symptomatic and asymptomatic LVEF events.

Table 10. - Asymptomatic and Symptomatic LVEF Declines by Baseline Events, Using the Same Assessment Method as Baseline (Safety Population) 5 Year Follow Up

Event Type	AC→T (n=1041)	AC-→TH (n=1077)	TCH (n=1056)
Absolute decline of >15% from baseline and to a value below the LLN	50 (4.8%)	111 (10.3%)	42 (4.0%)
Absolute decline of >10% from baseline and to a value <50%	71 (6.8%)	137 (12.7%)	50 (4.7%)
Symptomatic and/or asymptomatic decline of >15%, below the LLN	56 (5.4%)	128 (11.9%)	57 (5.4%)

 $AC \rightarrow T$ =doxorubicin plus cyclophosphamide, followed by docetaxel; $AC \rightarrow TH$ =doxorubicin plus cyclophosphamide, followed by docetaxel plus trastuzumab; ANC =absolute neutrophil count; LLN =lower limit of normal; TCH =docetaxel, carboplatin, and trastuzumab.

Metastatic Breast Cancer (MBC)

Trastuzumab and anthracyclines should not be given concurrently in the MBC setting.

In particular, moderate to severe cardiac dysfunction has been observed in MBC patients treated with trastuzumab in combination with an anthracycline (doxorubicin or epirubicin) and cyclophosphamide (see ADVERSE REACTIONS). The clinical status of patients in the trials who developed congestive heart failure were classified for severity using the New York Heart Association classification system (I-IVⁱ where IV is the most severe level of cardiac failure). (See **Table 11**).

Table 11 - Incidence and Severity of Cardiac Dysfunction in Metastatic Breast Cancer Patients

	Trastuzumab + Anthracycline + Cyclophosphamide ^b	Anthracycline + cyclophosphamide ^b	Trastuzumab + paclitaxel ^b	Paclitaxel ^b	Trastuzumab ^a alone
	(n = 143)	(n = 135)	(n = 91)	(n = 95)	(n = 388)
Any cardiac dysfunction	27%	7%	12%	1%	4%
Class III-IV	16%	3%	2%	1%	3%

^a Single agent studies H0551g, H0649g and H0650g.

^b Randomized Phase III study comparing chemotherapy plus trastuzumab to chemotherapy alone, where chemotherapy is either anthracycline/cyclophosphamide or paclitaxel.

ⁱNew York Heart Association Functional Classification

- Class I: Patients with cardiac disease but without resulting limitations of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea or anginal pain.
- Class II: Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea or anginal pain.
- Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation, dyspnea or anginal pain.
- Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.

In a subsequent trial with prospective monitoring of cardiac function, the incidence of symptomatic heart failure was 2.2% in patients receiving trastuzumab and docetaxel, compared with 0% in patients receiving docetaxel alone. In the MBC trials, the probability of cardiac dysfunction was highest in patients who received trastuzumab concurrently with anthracyclines. The MBC data suggest that advanced age may increase the probability of cardiac dysfunction.

Pre-existing cardiac disease or prior cardiotoxic therapy (e.g., anthracycline or radiation therapy) to the chest may decrease the ability to tolerate therapy with trastuzumab; however, the data is not adequate

to evaluate correlation between cardiac dysfunction observed with trastuzumab and these factors in patients with HER2 positive MBC.

Thrombosis/Embolism

Thrombosis/embolism has been observed in patients who receive trastuzumab + chemotherapy in both the adjuvant and metastatic treatment setting, and in rare cases, has been fatal (see **8** ADVERSE **REACTIONS** section).

Driving and Operating Machinery

Trastuzumab has a minor influence on the ability to drive and use machines. Dizziness and somnolence may occur during treatment with trastuzumab. Patients experiencing infusion-related symptoms should be advised not to drive or use machines until symptoms resolve completely.

Hematologic

Exacerbation of Chemotherapy-Induced Neutropenia: In randomized, controlled clinical trials in both adjuvant and MBC designed to assess the impact of the addition of trastuzumab on chemotherapy, the per-patient incidences of moderate to severe neutropenia and of febrile neutropenia were higher in patients receiving trastuzumab in combination with myelosuppressive chemotherapy compared with those receiving chemotherapy alone.

Using NCI-CTC criteria, in the adjuvant HERA trial, 0.4% of patients treated with trastuzumab experienced a shift of 3 or 4 grades from baseline, compared with 0.6% in the observation arm.

In the adjuvant studies, NSABP B-31 and NCCTG N9831, there were 6 deaths due to septicemia or severe neutropenia. Five deaths occurred on the chemotherapy alone arm: 2 patients died of pneumonia with febrile neutropenia and 3 patients died of septicemia. One death occurred on the trastuzumab + chemotherapy arm and the patient died of infection/neutropenic fever with lung infiltrates. All except 2 septicemia deaths occurred during protocol treatment period.

In the post-marketing setting in MBC, deaths due to sepsis in patients with severe neutropenia have been reported in patients receiving trastuzumab and myelosuppressive chemotherapy, although in controlled MBC clinical trials (pre- and post-marketing), the incidence of septic death was not significantly increased.

The pathophysiologic basis for exacerbation of neutropenia has not been determined; the effect of trastuzumab on the pharmacokinetics of chemotherapeutic agents has not been fully evaluated. If neutropenia occurs, the appropriate management should be instituted as per local practice/guidelines and the labelled instructions for chemotherapy agents should be followed with regard to dose interruption or dose reduction (see **4 DOSAGE AND ADMINISTRATION: 4.2 Recommended Dose and Dosage Adjustment, Dose Reduction**).

Immune

Immunogenicity:

Samples for assessment of human anti-human antibody (HAHA) were not collected in studies of adjuvant breast cancer. Of 903 patients that have been evaluated in the MBC trials, human anti-human antibody (HAHA) to trastuzumab was detected in 1 patient who had no allergic manifestations.

Hypersensitivity Reactions Including Anaphylaxis, Infusion-Associated Reactions and Pulmonary Events:

Administration of trastuzumab can result in severe hypersensitivity reactions (including anaphylaxis),

infusion reactions and pulmonary events. In rare cases, these reactions have been fatal. See discussion below.

There are no data regarding the most appropriate method of identification of patients who may safely be retreated with trastuzumab after experiencing a severe reaction. Trastuzumab has been readministered to some patients who fully recovered from a previous severe reaction. Prior to readministration of trastuzumab the majority of these patients were prophylactically treated with premedications including antihistamines and/or corticosteroids. While some of these patients tolerated retreatment, others had severe reactions again despite the use of prophylactic pre-medications.

Hypersensitivity Reactions Including Anaphylaxis:

Severe hypersensitivity reactions have been infrequently reported in patients treated with trastuzumab. Signs and symptoms include anaphylaxis, urticaria, bronchospasm, angioedema, and/or hypotension. In some cases, the reactions have been fatal. The onset of symptoms generally occurred during an infusion, but there have also been reports of symptom onset after the completion of an infusion. Reactions were most commonly reported in association with the initial infusion. In HERA 1 observation and 10 trastuzumab treated patients experienced hypersensitivity. Eight out of the 10 events were considered related to trastuzumab treatment. The incidence of allergic reactions in the Joint Analysis (chemotherapy alone versus trastuzumab + chemotherapy: 3.6% versus 3.1% in study B-31 and 1.1% versus 0.3% in study N9831) was comparable between the two treatment arms in both studies. In study BCIRG006, the incidence of allergic reactions according to the NCI-CTC v 2.0 classification was 9.4%, 12.3% and 14.9% in AC→T, AC→TH and TCH arms, respectively.

Infusional administration of trastuzumab should be interrupted in all patients with severe hypersensitivity reactions. In the event of a hypersensitivity reaction, appropriate medical therapy should be administered, which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen. Patients should be evaluated and carefully monitored until complete resolution of signs and symptoms.

Infusion-Related Reactions (IRRs):

IRRs are known to occur with trastuzumab. Pre- medication may be used to reduce risk of occurrence of IRRs.

Serious IRRs to infusions of trastuzumab including dyspnea, hypotension, hypertension, wheezing, bronchospasm, tachycardia, reduced oxygen saturation and respiratory distress, supraventricular tachyarrhythmia and urticaria have been reported (see **8 ADVERSE REACTIONS**). Patients should be observed for IRRs. Interruption of an IV infusion may help control such symptoms and the infusion may be resumed when symptoms abate. These symptoms can be treated with an analgesic/antipyretic such as meperidine or paracetamol, or an antihistamine such as diphenhydramine. Serious reactions have been treated successfully with supportive therapy such as oxygen, beta-agonists and corticosteroids (see **8 ADVERSE REACTIONS**). The appropriate management of patients with uncontrolled hypertension or history of hypertension should be considered prior to infusion with trastuzumab.

These severe reactions were usually associated with the first infusion of trastuzumab and generally occurred during or immediately following the infusion. For some patients, symptoms later worsened and led to further pulmonary complications. Initial improvement followed by clinical deterioration and delayed reactions with rapid clinical deterioration have also been reported. Fatalities have occurred within hours and up to one week following infusion. On very rare occasions, patients have experienced the onset of infusion symptoms or pulmonary symptoms more than six hours after the start of the infusion of trastuzumab. Patients should be warned of the possibility of such a late onset and should be instructed to contact their physician if those symptoms occur. In rare cases, these reactions are

associated with a clinical course culminating in a fatal outcome. Patients who are experiencing dyspnea at rest due to complications of advanced malignancy and comorbidities may be at increased risk of a fatal infusion reaction. Therefore, these patients should be treated with extreme caution and the risk versus benefit be considered for each patient.

Pulmonary Events:

Severe pulmonary events leading to death have been reported with the use of trastuzumab in the adjuvant breast cancer clinical studies and the post-marketing MBC setting. These events may occur as part of an infusion-related reaction or with a delayed onset (See **Infusion-Related Reactions (IRRs)** subsection of **7 WARNINGS AND PRECAUTIONS**), and were reported to occur at varying latencies, from within 24 hours to over 30 days, since the start of treatment with trastuzumab. Cases of interstitial lung disease (which often present with dyspnea) including lung infiltrates, pneumonitis, pleural effusion, respiratory distress, acute pulmonary edema, respiratory insufficiency, acute respiratory distress syndrome, and pneumonia have been reported. Risk factors associated with interstitial lung disease include prior or concomitant therapy with other anti-neoplastic therapies known to be associated with it such as taxanes, gemcitabine, vinorelbine and radiation therapy. Patients with dyspnea at rest due to complications of advanced malignancy and co-morbidities may be at increased risk of pulmonary events. Therefore, these patients should not be treated with trastuzumab.

Other severe events reported rarely in the post-marketing MBC setting include pneumonitis and pulmonary fibrosis. All of the confirmed cases of pulmonary fibrosis received to date are characterized by one or more significant confounding factors including pre-existing lung disease and prior/concomitant chemotherapy such as cyclophosphamide. However, a causal relationship between trastuzumab and pulmonary fibrosis cannot be excluded.

Monitoring and Laboratory Tests

Selection of Patients / Diagnostic Tests

Early Breast Cancer (EBC)/Metastatic Breast Cancer (MBC)

Trazimera should only be used in patients whose tumours overexpress HER2 as determined by immunohistochemistry. CISH or FISH testing for HER2 status also may be used, provided that the testing is done in experienced laboratories that have validated the test.

To ensure accurate and reproducible results, the protocol described in the package insert of an appropriate diagnostic test needs to be strictly followed. However, based on the current scientific knowledge, no standard test can be recommended at this time. There is no standard method of staining and no standard for the type of antibodies used. The grading for overexpression is subjective, and the signal may fade with time on stored slides.

The test method for HER2 overexpression used to determine eligibility of patients for inclusion in the MBC clinical trials employed immunohistochemical staining for HER2 of fixed material from tissue biopsy using the murine monoclonal antibodies CB11 and 4D5. Patients classified as staining 2+ or 3+ were included, while those staining 0 or 1+ were excluded. Greater than 70% of patients enrolled exhibited 3+ overexpression. The data suggest that beneficial effects were greater among those patients with higher levels of overexpression of HER2.

In the studies, an investigative clinical trial assay was employed which utilized a 0 to 3+ scale. The degree of HER2 overexpression indicated by different test methods may not correlate with that used as the eligibility criterion for inclusion in the clinical trials. For example, the HercepTest kit (registered Trade-Mark of Genentech, Inc.) also utilizes a scale of 0 to 3+. A reading of 3+ with HercepTest is likely to

correspond to that of a 2+ or 3+ with the investigative clinical trial assay. A 2+ reading with the HercepTest would likely incorporate a significant number of patients who were scored as 1+ by the investigative clinical trial assay. These patients (1+) would not have met the inclusion criteria. Test methods having increased sensitivity, relative to the investigative clinical trial assay, may alter the benefit-to-risk ratio compared to that seen in the clinical trials. In deciding which patients should receive Trazimera, the risk of cardiac dysfunction (see **7 WARNINGS and PRECAUTIONS**) must be weighed against the potential benefits of treatment, especially for those not in the high range of HER2 overexpression.

For inclusion criteria in terms of HER2 expression in clinical trials in EBC see 14 CLINICAL TRIALS section.

Metastatic Gastric Cancer (MGC)

Trazimera should only be administered to patients with MGC whose tumours have HER2 overexpression as determined by validated immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) testing. The testing should be done in experienced laboratories that have validated the test.

Patients are eligible for Trazimera treatment if they demonstrate strong HER2 protein overexpression, defined by a 3+ score by IHC, or a 2+ score by IHC and a positive FISH result.

7.1 Special Populations

7.1.1 Pregnant Women

Reproduction studies have been conducted in cynomolgus monkeys at doses up to 25 times the weekly human maintenance dose of 2 mg/kg trastuzumab and have revealed no evidence of impaired fertility or harm to the fetus. However, when assessing the risk of reproductive toxicity in humans, it is important to consider the significance of the rodent form of the HER2 receptor in normal embryonic development and the embryonic death in mutant mice lacking this receptor. Placental transfer of trastuzumab during the early (days 20-50 of gestation) and late (days 120-150 of gestation) fetal development period was observed.

Trastuzumab can cause fetal harm when administered to a pregnant woman. In the post- marketing setting, cases of impairment of fetal renal growth and/or renal function impairment, intrauterine growth retardation and skeletal abnormalities in association with oligohydramnios during the second and third trimesters, some associated with fatal pulmonary hypoplasia of the fetus, have been reported in pregnant women receiving trastuzumab. Also, the causal role of trastuzumab cannot be excluded nor confirmed in two cases of interventricular septal defects reported in infants exposed to trastuzumab in utero. In one of these two cases, spontaneous closure of the defect occurred nine months postpartum. No follow up information regarding closure of the defect was available in the second case. HER 2 is known to be expressed in many embryonic tissues. Women of childbearing potential should be advised to use effective contraception during treatment with trastuzumab and for at least 7 months after treatment has concluded. Women who become pregnant should be advised of the possibility of harm to the fetus. If a pregnant woman is treated with trastuzumab, close monitoring by a multidisciplinary team is desirable.

Women using trastuzumab during pregnancy should be monitored for oligohydramnios. If oligohydramnios occurs, fetal testing should be done that is appropriate for gestational age and consistent with community standards of care. Additional intravenous (IV) hydration has been helpful when oligohydramnios has occurred following administration of other chemotherapy agents; however, the effects of additional IV hydration with trastuzumab treatment are not known.

There are no adequate and well-controlled studies in pregnant women and it is not known whether trastuzumab can affect reproductive capacity. Animal reproduction studies revealed no evidence of impaired fertility or harm to the fetus. Because animal reproduction studies are not always predictive of human response, trastuzumab should not be used during pregnancy unless the potential benefit for the mother outweighs the potential risk to the fetus.

7.1.2 Breast-feeding

A study conducted in lactating cynomolgus monkeys at doses 25 times the weekly human maintenance dose of 2 mg/kg trastuzumab from days 120 to 150 of pregnancy demonstrated that trastuzumab is secreted in the milk postpartum. The exposure to trastuzumab in utero and the presence of trastuzumab in the serum of infant monkeys was not associated with any adverse effects on their growth or development from birth to 1 month of age. It is not known whether trastuzumab is excreted in human milk. As human IgG is excreted in human milk, and the potential for absorption and harm to the infant is unknown, a decision should be made whether to discontinue nursing, or discontinue drug, taking into account the elimination half-life of trastuzumab and the importance of the drug to the mother.

7.1.3 Pediatrics

The safety and effectiveness of trastuzumab in pediatric patients have not been established; therefore, Health Canada has not authorized an indication for pediatric use.

7.1.4 Geriatrics

Geriatrics (> 65 years of age): trastuzumab has been administered in clinical studies to 386 patients who were 65 years of age or over (253 in the adjuvant treatment and 133 in MBC treatment settings). The risk of cardiac dysfunction was increased in geriatric patients as compared to younger patients in both those receiving treatment for metastatic disease and those receiving adjuvant therapy in studies NSABP B-31 and NCCTG N9831, and BCIRG006. Age \geq 60 years was associated with increased risk of shorter time to first symptomatic cardiac event in study BCIRG-006 (based on 35 cardiac events in 2066 patients) (for the definition of cardiac events in each study see **7 WARNINGS AND PRECAUTIONS**, **Cardiotoxicity, Early Breast Cancer**). Limitations in data collection and differences in study design of the 4 studies of trastuzumab in adjuvant treatment of breast cancer preclude a determination of whether the toxicity profile of trastuzumab in older patients is different from younger patients. The reported clinical experience is not adequate to determine whether the efficacy improvements (as measured by ORR, TTP, OS, and DFS) of trastuzumab treatment of metastatic disease or adjuvant treatment of EBC.

In ToGA (BO18255) study in MGC, of the 294 patients treated with trastuzumab, 108 (37%) were 65 years of age or older, while 13 (4.4%) were 75 and over. No overall differences in safety or effectiveness were observed.

The risk of hematologic toxicities (leukopenia and thrombocytopenia) may be increased in geriatric patients.

Data suggest that the disposition of trastuzumab is not altered based on age (see **10 CLINICAL PHARMACOLOGY**: **10.3 Pharmacokinetics**). In clinical studies, elderly patients did not receive reduced doses of trastuzumab.

8 ADVERSE REACTIONS

The adverse drug reaction profiles reported in clinical studies that compared Trazimera to the reference biologic drug were comparable. The description of adverse reactions in this section is based on clinical experience with the reference biologic drug.

8.2 Clinical Trial Adverse Reactions

Clinical trials are conducted under very specific conditions. The adverse reaction rates observed in the clinical trials; therefore, may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials may be useful in identifying and approximating rates of adverse drug reactions in real-world use.

Early Breast Cancer (EBC)

<u>HERA</u>

(adjuvant sequential: use of trastuzumab following surgery and after chemotherapy)

Please see **7 WARNINGS AND PRECAUTIONS**: **Cardiovascular/Cardiotoxicity/Early Breast Cancer** - **Tables 5** and **6** for a description of the absolute numbers and rates of cardiac endpoints in HERA as well as the median time to return to baseline LVEF/ stabilizations of LVEF in the HERA trial.

The HERA trial is a randomised, open label study in patients with HER2 positive EBC. **Table 12** displays adverse events which were reported after 8 years of median follow up in \geq 1% of patients, by study treatment.

Table 12 - Adverse Events Reported in ≥ 1% of HERA Study Patients, by Study Treatment Final AnalysisAfter 8 years of Median Follow Up According to MedDRA v 15.0 Classification

Adverse Event Term	Observation Only N = 1744 No. (%)	Trastuzumab 1 year N = 1682 No. (%)
Blood and Lymphatic System Disorders		
Anemia	4 (<1)	15 (<1)
Cardiac Disorders	· · ·	
Cardiac Failure Congestive	19 (1)	93 (6)*
Palpitations	20 (1)	73 (4)
Tachycardia	5 (<1)	25 (1)
Ear and Labyrinth Disorders		
Vertigo	14 (<1)	33 (2)
Tinnitus	6 (<1)	7 (<1)
Eye Disorders		
Conjunctivitis	7 (<1)	21 (1)
Vision blurred	6 (<1)	16 (<1)
Lacrimation Increased	1 (<1)	12 (<1)
Gastrointestinal Disorders		
Diarrhea	23 (1)	156 (9)
Nausea	37 (2)	134 (8)
Vomiting	17 (<1)	76 (5)
Constipation	27 (2)	55 (3)
Abdominal Pain	25 (1)	60 (4)
Abdominal Pain Upper	30 (2)	45 (3)

Adverse Event Term	Observation Only N = 1744	Trastuzumab 1 year N = 1682
	No. (%)	No. (%)
Dyspepsia	14 (<1)	42 (2)
Stomatitis	1 (<1)	33 (2)
Gastritis	17 (<1)	27 (2)
Hemorrhoids	8 (<1)	18 (1)
MouthUlceration	2 (<1)	13 (<1)
General Disorders and Administration Site Co		10 (12)
Fatigue	83 (5)	198 (12)
Edema Peripheral	64 (4)	114 (7)
Pyrexia	12 (<1)	119 (7)
Asthenia	42 (2)	102 (6)
Chills	1 (<1)	101 (6)
Chest Pain	36 (2)	65 (4)
Influenza Like Illness	7 (<1)	51 (3)
Pain	24 (1)	23 (1)
Spinal Pain	21 (1)	21 (1)
Chest Discomfort	6 (<1)	27 (2)
Axillary Pain	17 (<1)	18 (1)
Edema	10 (<1)	23 (1)
Mucosal Inflammation	1 (<1)	18 (1)
Malaise	1 (<1)	18 (1)
Immune System Disorders	- (-)	(_/
Seasonal Allergy	6 (<1)	14 (<1)
Infections and Infestations [#]		
Nasopharyngitis	65 (4)	192 (11)
Influenza	17 (<1)	95 (6)
Upper Respiratory Tract Inflection	31 (2)	53 (3)
Urinary Tract Infection	19 (1)	54 (3)
Rhinitis	11 (<1)	44 (3)
Bronchitis	25 (1)	36 (2)
Cystitis	15 (<1)	28 (2)
Sinusitis	7 (<1)	36 (2)
Pharyngitis	12 (<1)	33 (2)
Herpes Zoster	14 (<1)	31 (2)
Lower Respiratory Tract Infection	14 (<1)	17 (1)
Gastroenteritis	10 (<1)	9 (<1)
Oral Herpes	5 (<1)	15 (<1)
Cellulitis	6 (<1)	14 (<1)
Vaginal Infection	10 (<1)	13 (<1)
Ear Infection	6 (<1)	9 (<1)
Localised Infection	-	18 (1)
Injury, Poisoning and Procedural Complicatio	ns	
Confusion	12 (<1)	13 (<1)
Investigations		
Ejection Fraction Decreased	11 (<1)	64 (4)
Weight Increased	23 (1)	42 (2)

Adverse Event Term	Observation Only N = 1744	Trastuzumab 1 year N = 1682
	No. (%)	No. (%)
Weight Decreased	10 (<1)	10 (<1)
Metabolism and Nutrition Disorders		
Decreased Appetite	17 (<1)	25 (1)
Hypercholesterolemia	15 (<1)	16 (<1)
Musculoskeletal and Connective Tissue Diso		
Arthralgia	148 (8)	223 (13)
Back Pain	105 (6)	145 (9)
Pain in Extremity	73 (4)	94 (6)
Musculoskeletal Pain	66 (4)	75 (4)
Myalgia	28 (2)	86 (5)
Muscle Spasms	13 (<1)	68 (4)
Bone Pain	31 (2)	54 (3)
Musculoskeletal Chest Pain	37 (2)	43 (3)
Osteoporosis	29 (2)	30 (2)
Neck Pain	18 (1)	29 (2)
Osteoarthritis	18 (1)	28 (2)
Osteopenia	12 (<1)	19 (1)
Musculoskeletal Stiffness	8 (<1)	14 (<1)
Neoplasms Benign, Malignant and Unspecifi		
Contralateral Breast Cancer	10 (<1)	23 (1)
Uterine Leiomyoma	7 (<1)	9 (<1)
Nervous System Disorders	· · · · · · · · · · · · · · · · · · ·	
Headache	73 (4)	199 (12)
Dizziness	39 (2)	80 (5)
Paraesthesia	21 (1)	42 (2)
Hypoaesthesia	15 (<1)	25 (1)
Lethargy	8 (<1)	20 (1)
Migraine	3 (<1)	15 (<1)
Peripheral Sensory Neuropathy	6 (<1)	14 (<1)
Pregnancy, Puerperium and Perinatal Condit	ions	
Pregnancy	11 (<1)	22 (1)
Psychiatric Disorders		
Depression	59 (3)	87 (5)
Insomnia	49 (3)	94 (6)
Anxiety	32 (2)	56 (3)
Sleep Disorder	5 (<1)	13 (<1)
Renal and Urinary Disorders		
Dysuria	3 (<1)	20 (1)
Reproductive System and Breast Disorders		
Breast Pain	26 (1)	36 (2)
Vaginal Haemorrhage	20 (1)	23 (1)
Vulvovaginal Dryness	16 (<1)	23 (1)
Breast Mass	22 (1)	17 (1)
Vaginal Discharge	9 (<1)	15 (<1)
Endometrial Hyperplasia	13 (<1)	17 (1)

Adverse Event Term	Observation Only N = 1744	Trastuzumab 1 year N = 1682
	No. (%)	No. (%)
Respiratory, Thoracic and Mediastinal Disord		
Cough	61 (3)	116 (7)
Dyspnoea	46 (3)	81 (5)
Oropharyngeal Pain	14 (<1)	40 (2)
Epistaxis	3 (<1)	29 (2)
Dyspnoea Exertional	16 (<1)	32 (2)
Rhinorrhoea	5 (<1)	27 (2)
Nasal Dryness	1 (<1)	25 (1)
Asthma	7 (<1)	9 (<1)
Skin and Subcutaneous Tissue Disorders	· · · · ·	
Rash	25 (1)	98 (6)
Onychoclasis	2 (<1)	53 (3)
Nail Disorder	2 (<1)	52 (3)
Pruritus	14 (<1)	58 (3)
Dry Skin	4 (<1)	22 (1)
Erythema	8 (<1)	39 (2)
Alopecia	6 (<1)	18 (1)
Scar Pain	18 (1)	21 (1)
Eczema	9 (<1)	19 (1)
Hyperhidrosis	10 (<1)	17 (1)
Urticaria	4 (<1)	13 (<1)
Acne	3 (<1)	17 (1)
Vascular Disorders		
Hot Flush	129 (7)	163 (10)
Hypertension	61 (3)	104 (6)
Lymphoedema	69 (4)	80 (5)
Flushing	10 (<1)	14 (<1)
Hypotension	4 (<1)	14 (<1)

Multiple occurrences of the same adverse even in one individual counted only once.

*69 out of the total 93 Cardiac Failure Congestive events reported in the 1-year trastuzumab arm occurred within 365 days from randomization.

#Serious adverse reactions of cellulitis and erysipelas were also reported in the HERA study.

In HERA, after a median follow-up of 12 months, 1 observation and 10 trastuzumab treated patients experienced hypersensitivity. Eight out of the 10 events were considered related to trastuzumab treatment.

In total, in the trastuzumab 1-year arm, 124 patients (7%) withdrew from trastuzumab treatment due to adverse events, and 2 patients (< 1%) withdrew from the post-treatment follow- up phase due to adverse events, based on the withdrawal criteria in the HERA study protocol.

Please see **Tables 6a** and **6b** in **7 WARNINGS AND PRECAUTIONS**: **Cardiovascular**, **Cardiotoxicity**, **Early Breast Cancer** for information on the median time to return to baseline LVEF and stabilizations of LVEF after 8 years of median follow-up in the HERA trial.

<u>Joint Analysis – NSABP Study B-31 and NCCTG Study N9831</u> (adjuvant concurrent: use of trastuzumab in combination with paclitaxel)

Cardiac failure/dysfunction, pulmonary events, and exacerbation of chemotherapy-induced neutropenia were the most serious adverse reactions in the two randomized, controlled adjuvant breast cancer studies (NSABP study B-31 and NCCTG study N9831, see **14 CLINICAL TRIALS**). Please refer to **7 WARNINGS AND PRECAUTIONS** section for detailed description of these reactions and **Table 7** for a description of the incidence and type of cardiac events seen in the Joint Analysis.

Adverse events according to the National Cancer Institute - Common Terminology Criteria NCI- CTC v 2.0 classification occurring at a frequency of > 1% for NSABP-B31 and NCCTG N9831, are summarized in **Tables 13** and **14** respectively.

Adverse Event Term ^a		AC - T (n = 885)			AC - T + H (n = 1030)	
	Any Grade	Grades 3–4	Grade 5	Any Grade	Grades 3–4	Grade 5
Allergy/immunology						
Allergic reaction*	33 (3.7%)	10 (1.1%)	(0.0%)	35 (3.4%)	12 (1.2%)	(0.0%)
Allergic rhinitis	11 (1.2%)	(0.0%)	(0.0%)	29 (2.8%)	(0.0%)	(0.0%)
Blood/bone marrow	•	·			·	
Hemoglobin (HGB)*	156 (17.6%)	27 (3.1%)	(0.0%)	209 (20.3%)	33 (3.2%)	(0.0%)
Leukocytes (total WBC)	152 (17.2%)	95 (10.7%)	(0.0%)	201 (19.5%)	103 (10.0%)	(0.0%)
Lymphopenia	43 (4.9%)	27 (3.1%)	(0.0%)	54 (5.2%)	31 (3.0%)	(0.0%)
Neutrophils/granulocytes	112 (12.7%)	88 (9.9%)	(0.0%)	134 (13.0%)	107 (10.4%)	(0.0%)
Platelets	22 (2.5%)	11 (1.2%)	(0.0%)	23 (2.2%)	12 (1.2%)	(0.0%)
Cardiovascular (general)						
Cardiac-left ventricular						
function*	47 (5.3%)	7 (0.8%)	(0.0%)	151 (14.7%)	35 (3.4%)	(0.0%)
Edema	26 (2.9%)	1 (0.1%)	(0.0%)	50 (4.9%)	(0.0%)	(0.0%)
Hypertension	6 (0.7%)	4 (0.5%)	(0.0%)	25 (2.4%)	17 (1.7%)	(0.0%)
Thrombosis/embolism*	24 (2.7%)	23 (2.6%)	(0.0%)	39 (3.8%)	35 (3.4%)	(0.0%)
Constitutional symptoms						
Fatigue*	323 (36.5%)	54 (6.1%)	(0.0%)	426 (41.4%)	58 (5.6%)	(0.0%)
Fever (in the absence of						
neutropenia)*	21 (2.4%)	2 (0.2%)	(0.0%)	38 (3.7%)	7 (0.7%)	(0.0%)
Sweating (diaphoresis)	10 (1.1%)	(0.0%)	(0.0%)	19 (1.8%)	(0.0%)	(0.0%)
Weight gain	5 (0.6%)	1 (0.1%)	(0.0%)	14 (1.4%)	3 (0.3%)	(0.0%)
Dermatology/skin						
Alopecia	285 (32.2%)	3 (0.3%)	(0.0%)	354 (34.4%)	2 (0.2%)	(0.0%)
Nail changes	10 (1.1%)	(0.0%)	(0.0%)	30 (2.9%)	1 (0.1%)	(0.0%)
Pruritus	18 (2.0%)	1 (0.1%)	(0.0%)	18 (1.7%)	3 (0.3%)	(0.0%)
Radiation dermatitis	20 (2.3%)	3 (0.3%)	(0.0%)	31 (3.0%)	10 (1.0%)	(0.0%)
Rash/desquamation*	88 (9.9%)	12 (1.4%)	(0.0%)	130 (12.6%)	6 (0.6%)	(0.0%)
Skin-other	14 (1.6%)	2 (0.2%)	(0.0%)	25 (2.4%)	2 (0.2%)	(0.0%)
Wound-infectious	7 (0.8%)	4 (0.5%)	(0.0%)	15 (1.5%)	8 (0.8%)	(0.0%)
Endocrine	•	•		•	•	

Table 13 - Adverse Events of Any Grade with Incidence ≥ 1% in Study B-31 (Final Analysis after Median Follow-up of 8.1 years in the AC - T+H Group) According to NCI-CTC v 2.0 Classification

Adverse Event Term ^a		AC - T (n = 885)	AC - T + H (n = 1030)			
	Any Grade	Grades 3–4	Grade 5	Any Grade	Grades 3–4	Grade 5
Hot flashes/flushes	157 (17.7%)	2 (0.2%)	(0.0%)	197 (19.1%)	(0.0%)	(0.0%)
Gastrointestinal	-	·		•	•	
Anorexia*	71 (8.0%)	12 (1.4%)	(0.0%)	64 (6.2%)	11 (1.1%)	(0.0%)
Constipation*	81 (9.2%)	7 (0.8%)	(0.0%)	123 (11.9%)	5 (0.5%)	(0.0%)
Dehydration	22 (2.5%)	7 (0.8%)	(0.0%)	28 (2.7%)	5 (0.5%)	(0.0%)
Diarrhea without						
prior colostomy*	83 (9.4%)	23 (2.6%)	(0.0%)	112 (10.9%)	26 (2.5%)	(0.0%)
Dyspepsia	46 (5.2%)	2 (0.2%)	(0.0%)	51 (5.0%)	2 (0.2%)	(0.0%)
GI-other	14 (1.6%)	2 (0.2%)	(0.0%)	24 (2.3%)	4 (0.4%)	(0.0%)
Nausea*	309 (34.9%)	70 (7.9%)	(0.0%)	356 (34.6%)	69 (6.7%)	(0.0%)
Stomatitis/pharyngitis*	151 (17.1%)	6 (0.7%)	(0.0%)	179 (17.4%)	10 (1.0%)	(0.0%)
Taste disturbance (dysgeusia)	13 (1.5%)	(0.0%)	(0.0%)	25 (2.4%)	(0.0%)	(0.0%)
Vomiting*	232 (26.2%)	66 (7.5%)	(0.0%)	247 (24.0%)	64 (6.2%)	(0.0%)
Hemorrhage						
Vaginal bleeding	4 (0.5%)	(0.0%)	(0.0%)	18 (1.8%)	(0.0%)	(0.0%)
Hepatic						
SGOT (AST) (serum glutamic						
oxaloacetic transaminase)*	18 (2.0%)	6 (0.7%)	(0.0%)	27 (2.6%)	5 (0.5%)	(0.0%)
SGPT (ALT) serum glutamic						
pyruvic transaminase *	26 (2.9%)	5 (0.6%)	(0.0%)	33 (3.2%)	5 (0.5%)	(0.0%)
Infection/febrile neutropenia						
Febrile neutropenia*	42 (4.7%)	42 (4.7%)	(0.0%)	39 (3.8%)	39 (3.8%)	(0.0%)
Infection*	246 (27.8%)	124 (14.0%)	3 (0.3%)	341 (33.1%)	140 (13.6%)	(0.0%)
Lymphatics						
Lymphatics	9 (1.0%)	(0.0%)	(0.0%)	25 (2.4%)	(0.0%)	(0.0%)
Metabolic/laboratory						
Hyperglycemia	118 (13.3%)	46 (5.2%)	(0.0%)	139 (13.5%)	49 (4.8%)	(0.0%)
Hypoglycemia	6 (0.7%)	2 (0.2%)	(0.0%)	12 (1.2%)	6 (0.6%)	(0.0%)
Musculoskeletal						
Joint, muscle, bone-other	11 (1.2%)	2 (0.2%)	(0.0%)	19 (1.8%)	2 (0.2%)	(0.0%)
Neurology			. ,			
Ataxia (incoordination)	1 (0.1%)	(0.0%)	(0.0%)	11 (1.1%)	2 (0.2%)	(0.0%)
Dizziness/lightheadedness	30 (3.4%)	5 (0.6%)	(0.0%)	36 (3.5%)	6 (0.6%)	(0.0%)
Insomnia	35 (4.0%)	2 (0.2%)	(0.0%)	60 (5.8%)	6 (0.6%)	(0.0%)
Mood alteration-	. ,	, ,	, ,	, ,	. ,	,
anxiety/agitation	44 (5.0%)	5 (0.6%)	(0.0%)	46 (4.5%)	9 (0.9%)	(0.0%)
Mood alteration-depression	56 (6.3%)	10 (1.1%)	(0.0%)	71 (6.9%)	11 (1.1%)	(0.0%)
Neuropathy-motor*	45 (5.1%)	17 (1.9%)	(0.0%)	51 (5.0%)	16 (1.6%)	(0.0%)
Neuropathy-sensory*	203 (22.9%)	59 (6.7%)	(0.0%)	235 (22.8%)	43 (4.2%)	(0.0%)
Syncope (fainting)	8 (0.9%)	8 (0.9%)	(0.0%)	12 (1.2%)	12 (1.2%)	(0.0%)
Ocular/visual	-		· · ·			
Dry Eye	13 (1.5%)	(0.0%)	(0.0%)	9 (0.9%)	(0.0%)	(0.0%)
Tearing (watery eyes)	6 (0.7%)	(0.0%)	(0.0%)	12 (1.2%)	(0.0%)	(0.0%)

Adverse Event Term ^a		AC - T (n = 885)	AC - T + H (n = 1030)			
	Any Grade	Grades 3–4	Grade 5	Any Grade	Grades 3–4	Grade 5
Vision-blurred vision	11 (1.2%)	(0.0%)	(0.0%)	22 (2.1%)	(0.0%)	(0.0%)
Pain			, ,		, ,	, ,
Abdominal pain or cramping	25 (2.8%)	12 (1.4%)	(0.0%)	24 (2.3%)	6 (0.6%)	(0.0%)
Arthralgia (joint pain)*	273 (30.8%)	57 (6.4%)	(0.0%)	329 (31.9%)	68 (6.6%)	(0.0%)
Bone pain	46 (5.2%)	14 (1.6%)	(0.0%)	60 (5.8%)	11 (1.1%)	(0.0%)
Chest pain	14 (1.6%)	4 (0.5%)	(0.0%)	36 (3.5%)	4 (0.4%)	(0.0%)
Headache*	80 (9.0%)	20 (2.3%)	(0.0%)	127 (12.3%)	30 (2.9%)	(0.0%)
Myalgia (muscle pain)*	293 (33.1%)	83 (9.4%)	(0.0%)	362 (35.1%)	65 (6.3%)	(0.0%)
Neuropathic pain	11 (1.2%)	4 (0.5%)	(0.0%)	20 (1.9%)	6 (0.6%)	(0.0%)
Pain-other	50 (5.6%)	10 (1.1%)	(0.0%)	78 (7.6%)	10 (1.0%)	(0.0%)
Pulmonary						
Cough	9 (1.0%)	1 (0.1%)	(0.0%)	32 (3.0%)	2 (0.2%)	(0.0%)
Dyspnea (shortness of breath)	63 (7.1%)	21 (2.4%)	(0.0%)	144 (14.0%)	24 (2.3%)	(0.0%)
Pulmonary-other	7 (0.8%)	3 (0.3%)	(0.0%)	15 (1.5%)	4 (0.4%)	(0.0%)
Renal/genitourinary						
Dysuria (painful urination)	9 (1.0%)	1 (0.1%)	(0.0%)	11 (1.1%)	1 (0.1%)	(0.0%)
Urinary frequency/urgency	7 (0.8%)	3 (0.3%)	(0.0%)	11 (1.1%)	2 (0.2%)	(0.0%)
Vaginitis (not due to infection)	10 (1.1%)	1 (0.1%)	(0.0%)	4 (0.4%)	1 (0.1%)	(0.0%)
Sexual/reproductive function						
Irregular menses (change from baseline)	35 (4.0%)	27 (3.1%)	(0.0%)	44 (4.3%)	37 (3.6%)	(0.0%)
Vaginal dryness	12 (1.4%)	(0.0%)	(0.0%)	26 (2.5%)	1 (0.1%)	(0.0%)

^aNCIC CTC terminology

A = doxorubicin; C = cyclophosphamide; GI = gastrointestinal; H = trastuzumab; T = paclitaxel; WBC = white blood cell. Note: Only Grade 3–5 events, treatment-related Grade 2 events, Grade 2–5 cardiac left ventricular dysfunction, and Grade 2–5dyspnea were collected during and 3 months following protocol treatment.

The term "febrile neutropenia" refers to febrile neutropenia with no evidence of infection; decreased neutrophils were not intended to be collected.

* Adverse event term is itemized on the Adverse Event CRF.

Table 14 - Adverse Events of Any Grade with Incidence ≥ 1% in Study N9831 (Final Analysis after Median Follow-up of 8.1 years in the AC - T+H Group) According to NCI-CTC v 2.0 Classification

Adverse Event Term ^a		AC - T (n =766)			AC - T + H (n = 969)	
	Any Grade	Grades 3–4	Grade 5	Any Grade	Grades 3–4	Grade 5
Allergy/immunology						
Allergic reaction*	9 (1.2%)	9 (1.2%)	(0.0%)	3 (0.3%)	3 (0.3%)	(0.0%)
Blood/bone marrow						
Leukocytes (total WBC)*	59 (7.7%)	58 (7.6%)	1 (0.1%)	82 (8.5%)	82 (8.5%)	(0.0%)
Neutrophils/granulocytes*	209 (27.3%)	208 (27.2%)	1 (0.1%)	286 (29.5%)	286 (29.5%)	(0.0%)
Cardiovascular (arrhythmia)						
Palpitations	12 (1.6%)	(0.0%)	(0.0%)	15 (1.5%)	(0.0%)	(0.0%)
Cardiovascular (general)						

Adverse Event Term ^a		AC - T (n =766)			AC - T + H (n = 969)	
	Any Grade	Grades 3–4	Grade 5	Any Grade	Grades 3–4	Grade 5
Cardiac- ischemia/infarction*	9 (1.2%)	7 (0.9%)	(0.0%)	13 (1.3%)	7 (0.7%)	(0.0%)
Cardiac-left ventricular function*	73 (9.5%)	1 (0.1%)	(0.0%)	219 (22.6%)	21 (2.2%)	(0.0%)
Edema	8 (1.0%)	(0.0%)	(0.0%)	15 (1.5%)	(0.0%)	(0.0%)
Hypertension	7 (0.9%)	3 (0.4%)	(0.0%)	12 (1.2%)	6 (0.6%)	(0.0%)
Thrombosis/embolism*	22 (2.9%)	20 (2.6%)	2 (0.3%)	18 (1.9%)	18 (1.9%)	(0.0%)
Constitutional symptoms						
Fatigue*	34 (4.4%)	34 (4.4%)	(0.0%)	41 (4.2%)	41 (4.2%)	(0.0%)
Dermatology/skin						
Nail changes*	50 (6.5%)	(0.0%)	(0.0%)	116 (12.0%)	(0.0%)	(0.0%)
Gastrointestinal						
Diarrhea without prior colostomy*	5 (0.7%)	5 (0.7%)	(0.0%)	33 (3.4%)	33 (3.4%)	(0.0%)
Nausea*	40 (5.2%)	40 (5.2%)	(0.0%)	53 (5.5%)	53 (5.5%)	(0.0%)
Vomiting*	39 (5.1%)	39 (5.1%)	(0.0%)	36 (3.7%)	36 (3.7%)	(0.0%)
Infection/febrile neutroper	nia					
Febrile neutropenia*	33 (4.3%)	32 (4.2%)	1 (0.1%)	57 (5.9%)	57 (5.9%)	(0.0%)
Infection*	38 (5.0%)	38 (5.0%)	(0.0%)	71 (7.3%)	70 (7.2%)	1 (0.1%)
Metabolic/laboratory						
Hyperglycemia	14 (1.8%)	14 (1.8%)	(0.0%)	9 (0.9%)	9 (0.9%)	(0.0%)
Neurology						
Neuropathy-motor*	38 (5.0%)	8 (1.0%)	(0.0%)	42 (4.3%)	13 (1.3%)	(0.0%)
Neuropathy-sensory*	132 (17.2%)	29 (3.8%)	(0.0%)	174 (18.0%)	46 (4.7%)	(0.0%)
Pain						
Arthralgia (joint pain)*	75 (9.8%)	10 (1.3%)	(0.0%)	133 (13.7%)	18 (1.9%)	(0.0%)
Chest pain	5 (0.7%)	1 (0.1%)	(0.0%)	13 (1.3%)	5 (0.5%)	(0.0%)
Myalgia (muscle pain)*	62 (8.1%)	10 (1.3%)	(0.0%)	110 (11.4%)	10 (1.0%)	(0.0%)
Pulmonary						
Dyspnea (shortness of breath)	3 (0.4%)	3 (0.4%)	(0.0%)	29 (3.0%)	24 (2.5%)	(0.0%)
Pneumonitis/Pulmonary infiltrates*	8 (1.0%)	7 (0.9%)	1 (0.1%)	10 (1.0%)	9 (0.9%)	(0.0%)

^a NCIC CTC terminology

A = doxorubicin; AE = adverse event; C = cyclophosphamide; H = trastuzumab; T = paclitaxel; WBC = white blood cell. Note: Only treatment-related Grade 4 and 5 hematologic toxicities, Grade 3–5 non-hematologic toxicities, Grade 1 = cardina toxicities, as well as Grade 2 = 5 atthrates, multiple and pauropathy, mater, and pauropathy

Grade 1–5 cardiac toxicities, as well as Grade 2–5 arthralgia, myalgia, nail changes, neuropathy–motor, and neuropathy– sensory adverse events were collected during the treatment period. During the post-treatment follow-up period, only Grade 3–5 cardiac ischemia/infarction, thrombosis/embolism, pneumonitis/pulmonary infiltrates, and lymphatic events were collected.

*Adverse event term is itemized on the Adverse Event CRF.

BCIRG-006

(adjuvant concurrent: use of trastuzumab in combination with docetaxel)

Adverse events according to the National Cancer Institute - Common Terminology Criteria NCI- CTC v 2.0 classification occurring at a frequency of \geq 1% for study BCIRG-006 are summarized in **Table 15**. For

adverse events that could not be classified according to the NCI-CTC, the Coding Symbols for Thesaurus of Adverse Reaction Terms (COSTART) coding dictionary was used (see **Table 16**).

	Any Grade	Grade 3 or 4	Any Grade	Grade 3 or 4	Any Grade	Grade 3 or 4
	AC→T	AC→T	AC→TH	AC→TH	TCH	TCH
NCI-CTC term	(n=1041)	(n=1041)	(n=1077)	(n=1077)	(n=1056)	(n=1056)
Allergy/immunology	1 • •					
Allergic reaction/						
hypersensitivity (including	98	12	133	19	157	28
drug fever)	(9.4%)	(1.2%)	(12.3%)	(1.8%)	(14.9%)	(2.7%)
Allergic rhinitis (including						
sneezing, nasal stuffiness,	83	1	138		97	1
postnasal drip)	(8.0%)	(0.0%)	(12.8%)	(0.0%)	(9.2%)	(0.0%)
Auditory/hearing						
Earache (otalgia)	32	10	30		17	
Ediache (Otalgia)	(3.1%)	(0.0%)	(2.8%)	(0.0%)	(1.6%)	(0.0%)
Inner ear/hearing	26	1	33	(0.0%)	34	1
· · · · ·	(2.5%)	(0.1%)	(3.1%)	(0.0%)	(3.2%)	(0.1%)
Blood/bone marrow						
Neutrophils/granulocytes	23	21	34	24	20	19
(ANC/AGC)	(2.2%)	(2.0%)	(3.2%)	(2.2%)	(1.9%)	(1.8%)
Cardiovascular (general)	1	1	1	•		
Cardiac left ventricular	30	6	81	22	27	1
function	(2.9%)	(0.6%)	(7.5%)	(2.0%)	(2.6%)	(0.1%)
Edema	30 (2.9%)	(0.0%)	37 (3.4%)	(0.0%)	33 (3.1%)	1 (0.1%)
Hypertension	37	12	52	23	61	33
rypertension	(3.6%)	(1.2%)	(4.8%)	(2.1%)	(5.8%)	(3.1%)
Hypotension	20	1	31	(0.0%)	19	2
	(1.9%)	(0.1%)	(2.9%)	(0.078)	(1.8%)	(0.2%)
Pericardial effusion/	14 (1.3%)	(0.0%)	19 (1.8%)	(0.0%)	17 (1.6%)	(0.1%)
pericarditis	14		22		9	
Phlebitis (superficial)	(1.3%)	(0.0%)	(2.0%)	(0.0%)	(0.9%)	(0.0%)
Thus who sis /such aligns	17	16	21	19	30	28
Thrombosis/embolism	(1.6%)	(1.5%)	(1.9%)	(1.8%)	(2.8%)	(2.7%)
Cardiovascular (arrhythmia	a)					
Dalaitations	73		88		96	
Palpitations	(7.0%)	(0.0%)	(8.2%)	(0.0%)	(9.1%)	(0.0%)
Sinus tachycardia	46	4	44	1	55	
	(4.4%)	(0.4%)	(4.1%)	(0.1%)	(5.2%)	(0.0%)
Supraventricular	11	5	8	4	10	E
arrhythmias (SVT/atrial	(1.1%)	5 (0.5%)	8 (0.7%)	(0.4%)	(0.9%)	5 (0.5%)
fibrillation/flutter)	(1.170)	(0.5%)	(0.7%)	(0.4%)	(0.9%)	(0.5%)
Constitutional symptoms						
Fatigue (lethargy, malaise,	858	70	905	80	879	76
asthenia)	(82.4%)	(6.7%)	(84.0%)	(7.4%)	(83.2%)	(7.2%)

Table 15 - Adverse Events of Any Grade with Incidence ≥ 1% in Study BCIRG-006 (5 Year Follow Up) According to NCI-CTC v 2.0 Classification

	Any Grade	Grade 3 or 4	Any Grade	Grade 3 or 4	Any Grade	Grade 3 or 4
NCI-CTC term	AC→T (n=1041)	AC→T (n=1041)	AC→TH (n=1077)	AC→TH (n=1077)	TCH (n=1056)	TCH (n=1056)
Fever (in the absence of	, ,		, ,		. ,	
neutropenia, where				_		-
neutropenia is defined	144	2	170	5	115	6
as AGC < 1.0 x 109/l)	(13.8%)	(0.2%)	(15.8%)	(0.5%)	(10.9%)	(0.6%)
Rigors, chills	53 (5.1%)	(0.0%)	86 (8.0%)	(0.0%)	75 (7.1%)	(0.0%)
Sweating (diaphoresis)	68 (6.5%)	(0.0%)	66 (6.1%)	(0.0%)	72 (6.8%)	(0.0%)
Woight goin	205	10	253	6	255	9
Weight gain	(19.7%)	(1.0%)	(23.5%)	(0.6%)	(24.1%)	(0.9%)
Weight loss	82	2	100	2	69	3
_	(7.9%)	(0.2%)	(9.3%)	(0.2%)	(6.5%)	(0.3%)
Dermatology/skin	1025		1060		1016	2
Alopecia	(98.5%)	(0.0%)	(98.4%)	(0.0%)	(96.2%)	(0.2%)
Bruising (in absence of						
grade 3 or 4	17	(0.00()	17	(0.00())	25	(0,00())
thrombocytopenia)	(1.6%)	(0.0%)	(1.6%)	(0.0%)	(2.4%)	(0.0%)
Dry skin	74 (7.1%)	(0.0%)	96 (8.9%)	(0.0%)	60 (5.7%)	(0.0%)
Flushing	46 (4.4%)	(0.0%)	56 (5.2%)	(0.0%)	76 (7.2%)	(0.0%)
Hand-foot skin reaction	85 (8.2%)	20 (1.9%)	77 (7.1%)	15 (1.4%)	30 (2.8%)	(0.0%)
Injection site reaction	64	3	61	1	78	2
Injection site reaction	(6.1%)	(0.3%)	(5.7%)	(0.1%)	(7.4%)	(0.2%)
Nail changes	512 (49.2%)	(0.0%)	472 (43.8%)	(0.0%)	302 (28.6%)	(0.0%)
Pigmentation changes	65	(0.00())	67	(2, 22/)	48	(0.00())
(e.g. vitiligo)	(6.2%)	(0.0%)	(6.2%)	(0.0%)	(4.5%)	(0.0%)
Pruritus	29	(0.0%)	34	1	51	1
	(2.8%)		(3.2%)	(0.1%)	(4.8%)	(0.1%)
Radiation dermatitis	187 (18.0%)	5 (0.5%)	192 (17.8%)	9 (0.8%)	242 (22.9%)	8 (0.8%)
	295	18	369	(0.8%)	348	9
Rash/desquamation	(28.3%)	(1.7%)	(34.3%)	(1.3%)	(33.0%)	(0.9%)
Wound- infectious	22	4	33	6	38	9
	(2.1%)	(0.4%)	(3.1%)	(0.6%)	(3.6%)	(0.9%)
Wound Non-infectious	6 (0.6%)	(0.0%)	11 (1.0%)	(0.0%)	17 (1.6%)	(0.0%)
Gastrointestinal	(0.0%)		(1.0%)		(1.0%)	
	222	6	224	5	238	6
Anorexia	(21.3%)	(0.6%)	(20.8%)	(0.5%)	(22.5%)	(0.6%)
Constinution	396	8	389	15	351	6
Constipation	(38.0%)	(0.8%)	(36.1%)	(1.4%)	(33.2%)	(0.6%)
Dehydration	30	5	39	4	42	5
	(2.9%)	(0.5%)	(3.6%)	(0.4%)	(4.0%)	(0.5%)

	Any Grade	Grade 3 or 4	Any Grade	Grade 3 or 4	Any Grade	Grade 3 or 4
NCI-CTC term	AC→T (n=1041)	AC→T (n=1041)	AC→TH (n=1077)	AC→TH (n=1077)	TCH (n=1056)	TCH (n=1056)
Diarrhea patients without colostomy	447 (42.9%)	32 (3.1%)	548 (50.9%)	60 (5.6%)	660 (62.5%)	57 (5.4%)
Dyspepsia/ heartburn	205 (19.7%)	5 (0.5%)	262 (24.3%)	3 (0.3%)	254 (24.1%)	5 (0.5%)
Dysphagia, esophagitis, odynophagia (painful swallowing)	45 (4.3%)	2 (0.2%)	45 (4.2%)	(0.0%)	37 (3.5%)	1 (0.1%)
Flatulence	19 (1.8%)	(0.0%)	23 (2.1%)	(0.0%)	20 (1.9%)	(0.0%)
Gastritis	17 (1.6%)	(0.0%)	35 (3.2%)	1 (0.1%)	22 (2.1%)	(0.0%)
Mouth dryness	85 (8.2%)	(0.0%)	54 (5.0%)	(0.0%)	37 (3.5%)	(0.0%)
Mucositis	22 (2.1%)	1 (0.1%)	26 (2.4%)	2 (0.2%)	21 (2.0%)	1 (0.1%)
Nausea	911 (87.5%)	62 (6.0%)	946 (87.8%)	61 (5.7%)	864 (81.8%)	51 (4.8%)
Proctitis	29 (2.8%)	(0.0%)	34 (3.2%)	(0.0%)	39 (3.7%)	(0.0%)
Salivary gland changes	11 (1.1%)	(0.0%)	9 (0.8%)	(0.0%)	7 (0.7%)	(0.0%)
Sense of smell	14 (1.3%)	(0.0%)	18 (1.7%)	(0.0%)	8 (0.8%)	(0.0%)
Stomatitis/pharyngitis (oral/pharyngeal mucositis)	681 (65.4%)	37 (3.6%)	717 (66.6%)	31 (2.9%)	562 (53.2%)	15 (1.4%)
Taste disturbance (dysgeusia)	298 (28.6%)	(0.0%)	304 (28.2%)	(0.0%)	320 (30.3%)	(0.0%)
Vomiting	577 (55.4%)	65 (6.2%)	616 (57.2%)	72 (6.7%)	434 (41.1%)	37 (3.5%)
Hemorrhage						
Epistaxis	63 (6.1%)	(0.0%)	140 (13.0%)	(0.0%)	170 (16.1%)	4 (0.4%)
Rectal bleeding/ hematochezia	23 (2.2%)	(0.0%)	36 (3.3%)	1 (0.1%)	28 (2.7%)	1 (0.1%)
Vaginal bleeding	34 (3.3%)	2 (0.2%)	24 (2.2%)	2 (0.2%)	24 (2.3%)	1 (0.1%)
Endocrine						
Hot flashes/flushes	356 (34.2%)	1 (0.1%)	379 (35.2%)	2 (0.2%)	349 (33.0%)	(0.0%)
Infection/febrile neutropenia						
Catheter-related infection	18 (1.7%)	7 (0.7%)	30 (2.8%)	14 (1.3%)	26 (2.5%)	8 (0.8%)

	Any Grade	Grade 3 or 4	Any Grade	Grade 3 or 4	Any Grade	Grade 3 or 4
NCI-CTC term	AC→T (n=1041)	AC→T (n=1041)	AC→TH (n=1077)	AC-→TH (n=1077)	TCH (n=1056)	TCH (n=1056)
Febrile neutropenia (fever of unknown origin without clinically or microbiologically documented infection) (ANC < 1.0 x 109/l, fever	97 (9.3%)	96 (9.2%)	117 (10.9%)	117 (10.9%)	100 (9.5%)	100 (9.5%)
38.5°C) Infection (documented clinically or microbiologically) with grade 3 or 4 neutropenia	119 (11.4%)	116 (11.1%)	131 (12.2%)	129 (12.0%)	118 (11.2%)	118 (11.2%)
Infection with unknown ANC Infection without	122 (11.7%) 241	120 (11.5%) 33	120 (11.1%) 326	117 (10.9%) 50	87 (8.2%) 248	86 (8.1%) 37
neutropenia	(23.2%)	(3.2%)	(30.3%)	(4.6%)	(23.5%)	(3.5%)
Lymphatics	68		71	3	81	2
Lymphatics	(6.5%)	(0.0%)	(6.6%)	3 (0.3%)	(7.7%)	(0.2%)
Metabolic/laboratory						
Hyperglycemia	80 (7.7%)	18 (1.7%)	81 (7.5%)	12 (1.1%)	79 (7.5%)	20 (1.9%)
Hypokalemia	17 (1.6%)	2 (0.2%)	22 (2.0%)	4 (0.4%)	24 (2.3%)	6 (0.6%)
Hypomagnesemia	5 (0.5%)	(0.0%)	(0.0%)	(0.0%)	12 (1.1%)	1 (0.1%)
Musculoskeletal	, , , , , , , , , , , , , , , , , , ,					. , ,
Muscle weakness (not due to neuropathy)	36 (3.5%)	2 (0.2%)	36 (3.3%)	3 (0.3%)	30 (2.8%)	(0.0%)
Neurology Cognitive disturbance/ learning problems	10 (1.0%)	(0.0%)	8 (0.7%)	(0.0%)	3 (0.3%)	(0.0%)
Confusion	10 (1.0%)	(0.0%)	9 (0.8%)	2 (0.2%)	6 (0.6%)	(0.0%)
Dizziness/ lightheadedness	113 (10.9%)	6 (0.6%)	151 (14.0%)	7 (0.6%)	129 (12.2%)	4 (0.4%)
Insomnia	234 (22.5%)	1 (0.1%)	278 (25.8%)	5 (0.5%)	252 (23.9%)	3 (0.3%)
Memory loss	37 (3.6%)	(0.0%)	34 (3.2%)	1 (0.1%)	31 (2.9%)	1 (0.1%)
Mood alteration- anxiety agitation	133 (12.8%)	8 (0.8%)	126 (11.7%)	5 (0.5%)	101 (9.6%)	4 (0.4%)
Mood alteration-	108	4	135	13	122	6
depression	(10.4%)	(0.4%)	(12.5%)	(1.2%)	(11.6%)	(0.6%)
Neuropathy-motor	55 (5.3%)	4 (0.4%)	68 (6.3%)	8 (0.7%)	45 (4.3%)	3 (0.3%)
Neuropathy-sensory	511 (49.1%)	25 (2.4%)	542 (50.3%)	25 (2.3%)	384 (36.4%)	8 (0.8%)

	Any Grade	Grade 3 or 4	Any Grade	Grade 3 or 4	Any Grade	Grade 3 or 4
NCI-CTC term	AC→T (n=1041)	AC→T (n=1041)	AC-→TH (n=1077)	AC→TH (n=1077)	TCH (n=1056)	TCH (n=1056)
Syncope (fainting)	20 (1.9%)	20 (1.9%)	20 (1.9%)	20 (1.9%)	19 (1.8%)	19 (1.8%)
Vertigo	16 (1.5%)	(0.0%)	37 (3.4%)	3 (0.3%)	28 (2.7%)	6 (0.6%)
Pain			, ,		, ,	(0.070)
Abdominal pain or cramping	184 (17.7%)	7 (0.7%)	215 (20.0%)	8 (0.7%)	237 (22.4%)	8 (0.8%)
Arthralgia (joint pain)	436 (41.9%)	34 (3.3%)	497 (46.1%)	35 (3.2%)	313 (29.6%)	15 (1.4%)
Bone pain	188 (18.1%)	17 (1.6%)	224 (20.8%)	10 (0.9%)	141 (13.4%)	3 (0.3%)
Chest pain (non-cardiac and non-pleuritic)	59 (5.7%)	1 (0.1%)	79 (7.3%)	7 (0.6%)	72 (6.8%)	3 (0.3%)
Headache	307 (29.5%)	11 (1.1%)	316 (29.3%)	16 (1.5%)	304 (28.8%)	7 (0.7%)
Myalgia (muscle pain)	551 (52.9%)	54 (5.2%)	600 (55.7%)	57 (5.3%)	412 (39.0%)	19 (1.8%)
Neuropathic pain (e.g., jaw pain, neurologic pain, phantom limb pain, post- infectious neuralgia, or painful neuropathies)	18 (1.7%)	1 (0.1%)	16 (1.5%)	2 (0.2%)	10 (0.9%)	1 (0.1%)
Pulmonary						
Cough	189 (18.2%)	3 (0.3%)	204 (18.9%)	3 (0.3%)	143 (13.5%)	(0.0%)
Dyspnea (shortness of breath)	229 (22.0%)	12 (1.2%)	264 (24.5%)	30 (2.8%)	227 (21.5%)	23 (2.2%)
Voice changes /stridor/larynx (e.g., hoarseness, loss of voice, laryngitis)	10 (1.0%)	1 (0.1%)	12 (1.1%)	1 (0.1%)	11 (1.0%)	1 (0.1%)
Ocular/visual						
Conjunctivitis	94 (9.0%)	5 (0.5%)	112 (10.4%)	1 (0.1%)	43 (4.1%)	(0.0%)
Dry eye	44 (4.2%)	(0.0%)	53 (4.9%)	(0.0%)	30 (2.8%)	(0.0%)
Tearing (watery eyes)	213 (20.5%)	(0.0%)	258 (24.0%)	3 (0.3%)	124 (11.7%)	(0.0%)
Vision-blurred vision	35 (3.4%)	(0.0%)	51 (4.7%)	2 (0.2%)	55 (5.2%)	(0.0%)
Renal/genitourinary						
Dysuria (painful urination)	25 (2.4%)	(0.0%)	48 (4.5%)	(0.0%)	56 (5.3%)	1 (0.1%)
Incontinence	3 (0.3%)	(0.0%)	10 (0.9%)	1 (0.1%)	15 (1.4%)	(0.0%)
Dysuria (painful urination)	25 (2.4%)	(0.0%)	48 (4.5%)	(0.0%)	56 (5.3%)	1 (0.1%)

	Any Grade	Grade 3 or 4	Any Grade	Grade 3 or 4	Any Grade	Grade 3 or 4
NCI-CTC term	AC→T (n=1041)	AC→T (n=1041)	AC→TH (n=1077)	AC→TH (n=1077)	TCH (n=1056)	TCH (n=1056)
Incontinence	3 (0.3%)	(0.0%)	10 (0.9%)	1 (0.1%)	15 (1.4%)	(0.0%)
Urinary frequency/urgency	26 (2.5%)	(0.0%)	34 (3.2%)	(0.0%)	25 (2.4%)	(0.0%)
Vaginitis (not due to infection)	17 (1.6%)	(0.0%)	16 (1.5%)	(0.0%)	14 (1.3%)	1 (0.1%)
Sexual/reproductive functi	on					
Irregular menses (change from baseline)	372 (35.7%)	283 (27.2%)	349 (32.4%)	262 (24.3%)	383 (36.3%)	283 (26.8%)
Libido	6 (0.6%)	(0.0%)	9 (0.8%)	(0.0%)	11 (1.0%)	(0.0%)
Vaginal dryness	33 (3.2%)	(0.0%)	44 (4.1%)	(0.0%)	49 (4.6%)	(0.0%)

A=doxorubicin; C=cyclophosphamide; H=trastuzumab; T =docetaxel; C (in TCH)=carboplatin Note: In the BCIRG-006 study, all grade hematological and non-hematological AEs, and cardiac AEs were collected, as well as laboratory data.

Table 16 - Adverse Events of Any Grade with Incidence ≥ 1% in Study BCIRG-006 (5 Year Follow Up)
According to COSTART Classification

	Any	Grade	Any	Grade	Any	Grade
	Grade	3 or 4	Grade	3 or 4	Grade	3 or 4
COSTART term	AC→T	AC→T	AC→TH	AC→TH	ТСН	тсн
	(n=1041)	(n=1041)	(n=1077)	(n=1077)	(n=1056)	(n=1056)
Body as a whole						
Accidental injury	19 (1.8%)	2 (0.2%)	18 (1.7%)	1 (0.1%)	20 (1.9%)	3 (0.3%)
Back pain	83 (8.0%)	3 (0.3%)	133 (12.3%)	12 (1.1%)	97 (9.2%)	5 (0.5%)
Chest pain	13 (1.2%)	1 (0.1%)	14 (1.3%)	(0.0%)	10 (0.9%)	1 (0.1%)
Cyst	13 (1.2%)	1 (0.1%)	12 (1.1%)	1 (0.1%)	13 (1.2%)	1 (0.1%)
Face edema	12 (1.2%)	(0.0%)	16 (1.5%)	(0.0%)	12 (1.1%)	(0.0%)
Fever	32 (3.1%)	7 (0.7%)	30 (2.8%)	2 (0.2%)	22 (2.1%)	4 (0.4%)
Flu syndrome	33 (3.2%)	(0.0%)	33 (3.1%)	(0.0%)	29 (2.7%)	(0.0%)
Injection site pain	23 (2.2%)	(0.0%)	39 (3.6%)	(0.0%)	40 (3.8%)	1 (0.1%)
Neck pain	14 (1.3%)	1 (0.1%)	13 (1.2%)	(0.0%)	16 (1.5%)	(0.0%)
Pain	228 (21.9%)	5 (0.5%)	257 (23.9%)	8 (0.7%)	208 (19.7%)	3 (0.3%)
Cardiac adverse events						
(body as a whole)						
Chest pain	7 (0.7%)	(0.0%)	16 (1.5%)	(0.0%)	16 (1.5%)	(0.0%)
Cardiac adverse						
events						
(cardiovascular						
system)						
Cardiomegaly	7 (0.7%)	(0.0%)	18 (1.7%)	(0.0%)	9 (0.9%)	(0.0%)
Cardiovascular disorder	16 (1.5%)	1 (0.1%)	25 (2.3%)	(0.0%)	16 (1.5%)	1 (0.1%)
Hemorrhage	19(1.8%)	(0.0%)	11 (1.0%)	2(0.2%)	9(0.9%)	2(0.2%)
Tachycardia	7 (0.7%)	(0.0%)	18 (1.7%)	(0.0%)	14 (1.3%)	2 (0.2%)
Digestive system						
Anorexia	14 (1.3%)	(0.0%)	12 (1.1%)	(0.0%)	16 (1.5%)	(0.0%)
Dyspepsia	7 (0.7%)	(0.0%)	10 (0.9%)	(0.0%)	17 (1.6%)	(0.0%)
Esophagitis	20 (1.9%)	2 (0.2%)	8 (0.7%)	(0.0%)	12 (1.1%)	(0.0%)

	Any	Grade	Any	Grade	Any	Grade
	Grade	3 or 4	Grade	3 or 4	Grade	3 or 4
COSTART term	AC→T	AC→T	AC→TH	AC→TH	тсн	тсн
	(n=1041)	(n=1041)	(n=1077)	(n=1077)	(n=1056)	(n=1056)
Flatulence	16 (1.5%)	(0.0%)	24 (2.2%)	(0.0%)	22 (2.1%)	(0.0%)
Gum hemorrhage	1 (0.1%)	(0.0%)	14 (1.3%)	(0.0%)	5 (0.5%)	(0.0%)
Rectal disorder	17 (1.6%)	(0.0%)	23 (2.1%)	1 (0.1%)	28 (2.7%)	2 (0.2%)
Hemic and lymphatic		· · ·	, ,	, <i>i</i>	, , ,	· · ·
system						
Lymphedema	21 (2.0%)	(0.0%)	23 (2.1%)	1 (0.1%)	28 (2.7%)	(0.0%)
Metabolic and nutritional						
disorders						
Edema	4 (0.4%)	(0.0%)	6 (0.6%)	(0.0%)	13 (1.2%)	(0.0%)
Peripheral edema	349 (33.5%)	4 (0.4%)	395(36.7%)	4 (0.4%)	346 (32.8%)	2 (0.2%)
Musculoskeletal system						
Arthralgia	19 (1.8%)	(0.0%)	20 (1.9%)	(0.0%)	24 (2.3%)	1 (0.1%)
Joint disorder	9 (0.9%)	(0.0%)	7 (0.6%)	1 (0.1%)	10 (0.9%)	1 (0.1%)
Osteoporosis	6 (0.6%)	(0.0%)	11 (1.0%)	1 (0.1%)	12 (1.1%)	1 (0.1%)
Nervous system						
Hypertonia	6 (0.6%)	(0.0%)	11 (1.0%)	(0.0%)	16 (1.5%)	(0.0%)
Leg cramps	8 (0.8%)	(0.0%)	13 (1.2%)	(0.0%)	7 (0.7%)	(0.0%)
Neuropathy	8 (0.8%)	1 (0.1%)	10 (0.9%)	(0.0%)	9 (0.9%)	2 (0.2%)
Twitching	7 (0.7%)	(0.0%)	13 (1.2%)	(0.0%)	26 (2.5%)	(0.0%)
Respiratory system						
Pharyngitis	71 (6.8%)	(0.0%)	83 (7.7%)	(0.0%)	55 (5.2%)	2 (0.2%)
Rhinitis	111 (10.7%)	1 (0.1%)	142(13.2%)	1 (0.1%)	108 (10.2%)	(0.0%)
Sinusitis	18 (1.7%)	(0.0%)	21 (1.9%)	1 (0.1%)	22 (2.1%)	1 (0.1%)
Skin and appendages						
Acne	11 (1.1%)	(0.0%)	28 (2.6%)	(0.0%)	33 (3.1%)	(0.0%)
Herpes simplex	20 (1.9%)	1 (0.1%)	27 (2.5%)	4 (0.4%)	19 (1.8%)	1 (0.1%)
Nail disorder	11 (1.1%)	(0.0%)	5 (0.5%)	(0.0%)	3 (0.3%)	(0.0%)
Pruritus	10 (1.0%)	(0.0%)	16 (1.5%)	1 (0.1%)	16 (1.5%)	(0.0%)
Rash	38 (3.7%)	1 (0.1%)	55 (5.1%)	(0.0%)	42 (4.0%)	1 (0.1%)
Skin disorder	6 (0.6%)	(0.0%)	13 (1.2%)	(0.0%)	11 (1.0%)	(0.0%)
Special senses						
Abnormal vision	9 (0.9%)	(0.0%)	14 (1.3%)	(0.0%)	13 (1.2%)	(0.0%)
Conjunctivitis	17 (1.6%)	(0.0%)	10 (0.9%)	(0.0%)	2 (0.2%)	(0.0%)
Eye pain	16 (1.5%)	(0.0%)	15 (1.4%)	(0.0%)	16 (1.5%)	(0.0%)
Urogenital system						
Breast pain	53 (5.1%)	(0.0%)	57 (5.3%)	1 (0.1%)	61 (5.8%)	2 (0.2%)
Leukorrhea	16 (1.5%)	(0.0%)	26 (2.4%)	(0.0%)	19 (1.8%)	(0.0%)

The toxicity profile of trastuzumab in all four adjuvant trials appears to be similar. Cardiac dysfunction is the main concern with trastuzumab treatment (see **7 WARNINGS AND PRECAUTIONS**).

Metastatic Breast Cancer (MBC)

In clinical trials conducted prior to marketing, a total of 958 patients received trastuzumab alone or in combination with chemotherapy. Data in **Table 18** are based on the experience with the recommended dosing regimen for trastuzumab in the randomized controlled clinical trial in 234 patients who received trastuzumab in combination with chemotherapy and the open-label study of trastuzumab as a single agent in 213 patients with HER2-overexpressing MBC.

Adverse event term	Single Agent (n=213)
Body as a whole	(11-213)
Abdomen enlarged	3 (1.4%)
Abdominal pain	47 (22.1%)
Accidental injury	12 (5.6%)
Allergic reaction	4 (1.9%)
Ascites	9 (4.2%)
Asthenia	100 (46.9%)
Back pain	44 (20.7%)
Carcinoma	9 (4.2%)
Cellulitis	3 (1.4%)
Chest pain	46 (21.6%)
Chills	76 (35.7%)
Chills and fever	7 (3.3%)
Face edema	4 (1.9%)
Fever	83 (39.0%)
Flu syndrome	24 (11.3%)
Headache	56 (26.3%)
Infection	42 (19.7%)
Injection site inflammation	3 (1.4%)
Injection site pain	4 (1.9%)
Malaise	7 (3.3%)
Moniliasis	4 (1.9%)
Mucous membrane disorder	4 (1.9%)
Neck pain	11 (5.2%)
Neoplasm	4 (1.9%)
Pain	105 (49.3%)
Pelvic pain	8 (3.8%)
Procedure	4 (1.9%)
Sepsis	3 (1.4%)
Cardiovascular	
Cardiovascular disorder	3 (1.4%)
Congestive heart failure	4 (1.9%)
Heart arrest	3 (1.4%)
Hemorrhage	3 (1.4%)
Hypertension	4 (1.9%)
Hypotension	5 (2.3%)
Migraine	4 (1.9%)
Palpitation	4 (1.9%)
Tachycardia	13 (6.1%)
Vascular disorder	8 (3.8%)
Vasodilatation	16 (7.5%)
Digestive	10 (7.570)
Anorexia	28 (13.1%)
Constipation	27 (12.7%)
Diarrhea	57 (26.8%)
Dry mouth	6 (2.8%)
Dyspepsia	17 (8.0%)
Dysphagia	5 (2.3%)

Table 17 - Adverse Events Occurring in ≥ 1% of Patients in Study H0649g (up to First Disease Progression on Study)

Adverse event term	Single Agent
	(n=213)
Flatulence	10 (4.7%)
Gastroenteritis	3 (1.4%)
Gastrointestinal disorder	4 (1.9%)
Hepatic failure	4 (1.9%)
Jaundice	6 (2.8%)
Liver tenderness	7 (3.3%)
Mouth ulceration	4 (1.9%)
Nausea	79 (37.1%)
Nausea and vomiting	16 (7.5%)
Oral moniliasis	4 (1.9%)
Rectal disorder	4 (1.9%)
Stomatitis	9 (4.2%)
Vomiting	60 (28.2%)
Hemic and lymphatic	, <u>,</u>
Anemia	9 (4.2%)
Ecchymosis	7 (3.3%)
Hypochromic anemia	3 (1.4%)
Leukopenia	7 (3.3%)
Lymphadenopathy	3 (1.4%)
Lymphedema	4 (1.9%)
Metabolic and nutritional disorders	
Dehydration	5 (2.3%)
Edema	17 (8.0%)
Hypercalcemia	3 (1.4%)
Hypokalemia	8 (3.8%)
Hypomagnesemia	3 (1.4%)
Peripheral edema	21 (9.9%)
Serum glutamic pyruvic transaminase (SGPT) increased	3 (1.4%)
Weight gain	4 (1.9%)
Weight loss	7 (3.3%)
Musculoskeletal	
Arthralgia	13 (6.1%)
Bone pain	18 (8.5%)
Joint disorder	3 (1.4%)
Leg cramps	14 (6.6%)
Myalgia	16 (7.5%)
Myasthenia	6 (2.8%)
Nervous	
Abnormal gait	5 (2.3%)
Amnesia	3 (1.4%)
Anxiety	28 (13.1%)
Circumoral paresthesia	3 (1.4%)
Confusion	4 (1.9%)
Convulsion	4 (1.9%)
Depression	16 (7.5%)
Dizziness	28 (13.1%)
Hypertonia	9 (4.2%)
Insomnia	35 (16.4%)
Nervousness	6 (2.8%)
Neuropathy	4 (1.9%)
Paralysis	3 (1.4%)

Adverse event term	Single Agent
	(n=213)
Paresthesia	19 (8.9%)
Peripheral neuritis	4 (1.9%)
Somnolence	15 (7.0%)
Speech disorder	3 (1.4%)
Thinking abnormal	3 (1.4%)
Tremor	4 (1.9%)
Vertigo	3 (1.4%)
Respiratory	3 (1.470)
Asthma	13 (6.1%)
Bronchitis	7 (3.3%)
Cough increased	60 (28.2%)
Dyspnea	49 (23.0%)
Epistaxis	12 (5.6%)
Laryngitis	3 (1.4%)
Lung disorder	17 (8.0%)
	28 (13.1%)
Pharyngitis Pleural effusion	19 (8.9%)
Pneumonia	3 (1.4%)
Pneumothorax	4 (1.9%)
Rhinitis	33 (15.5%)
Sinusitis	25 (11.7%)
Voice alteration	6 (2.8%)
Skin and appendages	4 (4.00/)
Acne	4 (1.9%)
Alopecia	3 (1.4%)
Dry skin	4 (1.9%)
Herpes simplex	5 (2.3%)
Herpes zoster	4 (1.9%)
Nail disorder	4 (1.9%)
Pruritus	24 (11.3%)
Rash	30 (14.1%)
Skin benign neoplasm	3 (1.4%)
Skin ulcer	3 (1.4%)
Sweating	8 (3.8%)
Urticarial	4 (1.9%)
Special senses	
Abnormal vision	3 (1.4%)
Amblyopia	9 (4.2%)
Conjunctivitis	5 (2.3%)
Diplopia	4 (1.9%)
Ear disorder	5 (2.3%)
Ear pain	5 (2.3%)
Taste perversion	5 (2.3%)
Urogenital	
Breast carcinoma	11 (5.2%)
Breast pain	15 (7.0%)
Dysuria	8 (3.8%)
Hematuria	3 (1.4%)
Urinary frequency	7 (3.3%)
Urinary tract infection	7 (3.3%)
Vaginitis	4 (1.9%)

Adverse Event Term	H + AC (N=143)	AC Alone (N=135)	H + Paclitaxel (N=91)	Paclitaxel Alone (N=95)
Body as a whole				
Abdomen enlarged	2 (1.4%)	1 (0.7%)	1 (1.1%)	1 (1.1%)
Abdominal pain	33 (23.1%)	25 (18.5%)	31 (34.1%)	21 (22.1%)
Abscess	2 (1.4%)	1 (0.7%)	(0.0%)	(0.0%)
Accidental injury	13 (9.1%)	6 (4.4%)	12 (13.2%)	3 (3.2%)
Allergic reaction	6 (4.2%)	3 (2.2%)	7 (7.7%)	2 (2.1%)
Anaphylactoid	(0.0%)	(0.0%)	1 (1.1%)	(0.0%)
reaction	(0.070)		1 (1.170)	(0.070)
Ascites	3 (2.1%)	6 (4.4%)	(0.0%)	3 (3.2%)
Asthenia	78 (54.5%)	74 (54.8%)	56 (61.5%)	54 (56.8%)
Back pain	39 (27.3%)	21 (15.6%)	33 (36.3%)	29 (30.5%)
Carcinoma	6 (4.2%)	12 (8.9%)	7 (7.7%)	6 (6.3%)
Cellulitis	2 (1.4%)	3 (2.2%)	3 (3.3%)	5 (5.3%)
Chest pain	29 (20.3%)	28 (20.7%)	27 (29.7%)	26 (27.4%)
Chest pain substernal	3 (2.1%)	(0.0%)	(0.0%)	1 (1.1%)
Chills	50 (35.0%)	15 (11.1%)	38 (41.8%)	4 (4.2%)
Chills and fever	3 (2.1%)	1 (0.7%)	5 (5.5%)	4 (4.2%)
Cyst	2 (1.4%)	(0.0%)	1 (1.1%)	(0.0%)
Face edema	2 (1.4%)	(0.0%)	4 (4.4%)	6 (6.3%)
Facial pain	1 (0.7%)	(0.0%)	1 (1.1%)	(0.0%)
Fever	80 (55.9%)	45 (33.3%)	43 (47.3%)	22 (23.2%)
Flu syndrome	17 (11.9%)	8 (5.9%)	11 (12.1%)	5 (5.3%)
Headache	63 (44.1%)	42 (31.1%)	33 (36.3%)	27 (28.4%)
Hydrocephalus	(0.0%)	(0.0%)	(0.0%)	1 (1.1%)
Hypothermia	(0.0%)	(0.0%)	1 (1.1%)	(0.0%)
Immune system disorder	1 (0.7%)	(0.0%)	(0.0%)	(0.0%)
Infection	67 (46.9%)	41 (30.4%)	42 (46.2%)	26 (27.4%)
Infection site edema	3 (2.1%)	1 (0.7%)	2 (2.2%)	(0.0%)
Injection site hemorrhage	1 (0.7%)	1 (0.7%)	1 (1.1%)	(0.0%)
Injection site hypersensitivity	1 (0.7%)	(0.0%)	(0.0%)	1 (1.1%)
Injection site inflammation	12 (8.4%)	3 (2.2%)	3 (3.3%)	2 (2.1%)
Injection site pain	8 (5.6%)	4 (3.0%)	4 (4.4%)	5 (5.3%)
Injection site reaction	6 (4.2%)	1 (0.7%)	6 (6.6%)	1 (1.1%)
Lab test abnormal	(0.0%)	(0.0%)	(0.0%)	1 (1.1%)
Le syndrome	1 (0.7%)	(0.0%)	(0.0%)	(0.0%)
Malaise	4 (2.8%)	7 (5.2%)	3 (3.3%)	4 (4.2%)
Moniliasis	3 (2.1%)	3 (2.2%)	1 (1.1%)	1 (1.1%)
Mucous membrane disorder	31 (21.7%)	25 (18.5%)	10 (11.0%)	7 (7.4%)
Neck pain	15 (10.5%)	11 (8.1%)	8 (8.8%)	5 (5.3%)
Neck rigidity	3 (2.1%)	(0.0%)	(0.0%)	3 (3.2%)
Necrosis	1 (0.7%)	(0.0%)	(0.0%)	(0.0%)

Table 18 - Adverse Events Occurring in ≥ 1% of Patients in Study H0648g (up to First Disease Progression on Study)

Adverse Event Term	H + AC (N=143)	AC Alone (N=135)	H + Paclitaxel (N=91)	Paclitaxel Alone (N=95)
Neoplasm	5 (3.5%)	3 (2.2%)	3 (3.3%)	1 (1.1%)
Pain	82 (57.3%)	56 (41.5%)	55 (60.4%)	58 (61.1%)
Pelvic pain	1 (0.7%)	2 (1.5%)	4 (4.4%)	2 (2.1%)
Photosensitivity	2 (1.4%)	(0.0%)	(0.0%)	(0.0%)
reaction				
Procedure	11 (7.7%)	5 (3.7%)	5 (5.5%)	2 (2.1%)
Radiation injury	(0.0%)	2 (1.5%)	1 (1.1%)	2 (2.1%)
Reaction unevaluable	14 (9.8%)	9 (6.7%)	4 (4.4%)	2 (2.1%)
Sepsis	10 (7.0%)	9 (6.7%)	4 (4.4%)	1 (1.1%)
Sudden death	(0.0%)	1 (0.7%)	(0.0%)	(0.0%)
Angina pectoris	3 (2.14%)	(0.0%)	(0.0%)	(0.0%)
Arrhythmia	1 (0.7%)	2 (1.5%)	(0.0%)	2 (2.1%)
Atrial fibrillation	(0.0%)	1 (0.7%)	1 (1.1%)	2 (2.1%)
Atrial flutter	(0.0%)	1 (0.7%)	(0.0%)	(0.0%)
Bradycardia	1 ((0.7%)	1 (0.7%)	(0.0%)	(0.0%)
Cardiomegaly	2 (1.4%)	1 (0.7%)	(0.0%)	(0.0%)
Cardiomyopathy	10 (7.0%)	2 (1.5%)	1 (1.1%)	(0.0%)
Cardiovascular	3 (2.1%)	7 (5.2%)	3 (3.3%)	1 (1.1%)
disorder	. ,	. ,		. ,
Cerebrovascular	1 (0.7%)	1 (0.7%)	(0.0%)	(0.0%)
accident				
Congestive heart	17 (11.9%)	2 (1.5%)	2 (2.2%)	1 (1.1%)
failure				
Deep thrombophlebitis	4 (2.8%)	1 (0.7%)	1 (1.1%)	1 (1.1%)
Electrocardiogram	1 (0.7%)	(0.0%)	(0.0%)	(0.0%)
abnormal	= (0.770)	(01070)	(0.0,0)	(01070)
Endocarditis	(0.0%)	(0.0%)	(0.0%)	1 (1.1%)
Heart arrest	(0.0%)	1 (0.7%)	1 (1.1%)	2 (2.1%)
Heart failure	1(0.7%)	1 (0.7%)	2 (2.2%)	(0.0%)
Hemorrhage	2 (1.4%)	1 (0.7%)	3 (3.3%)	(0.0%)
Hypertension	5 (3.5%)	4 (3.0%)	5 (5.5%)	4 (4.2%)
Hypotension	10 (7.0%)	5 (3.7%)	2 (2.2%)	3 (3.2%)
Left heart failure	14 (9.8%)	7 (5.2%)	5 (5.5%)	(0.0%)
Migraine	(0.0%)	2 (1.5%)	1 (1.1%)	3 (3.2%)
Myocardial ischemia	(0.0%)	(0.0%)	1 (1.1%)	(0.0%)
Pallor	7 (4.9%)	2 (1.5%)	1 (1.1%)	2 (2.1%)
Palpitation	8 (5.6%)	5 (3.7%)	4 (4.4%)	2 (2.1%)
Pericardial effusion	1 (0.7%)	1 (0.7%)	(0.0%)	(0.0%)
Peripheral vascular	(0.0%)	(0.0%)	2 (2.2%)	3 (3.2%)
disorder	(0.070)	(0.070)	2 (2.2/0)	5 (5.270)
Phlebitis	3 (2.1%)	1 (0.7%)	1 (1.1%)	1 (1.1%)
Postural hypotension	4 (2.8%)	2 (1.5%)	1 (1.1%)	1 (1.1%)
Pulmonary embolus	(0.0%)			
	(0.0%)	(0.0%)	1 (1.1%)	(0.0%)
Shock Sinus bradycardia		(0.0%)	(0.0%)	1 (1.1%)
	(0.0%)	<u>1 (0.7%)</u>	(0.0%)	(0.0%)
Syncope Tachycardia	4 (2.8%)	3 (2.2%)	4 (4.4%)	3 (3.2%)
Tachycardia	14 (9.8%)	7 (5.2%)	11 (12.1%)	4 (4.2%)
Thrombophlebitis Thrombosis	2 (1.4%) 3 (2.1%)	<u>2 (1.5%)</u> (0.0%)	(0.0%) 2 (2.2%)	(0.0%)

Adverse Event Term	H + AC (N=143)	AC Alone (N=135)	H + Paclitaxel (N=91)	Paclitaxel Alone (N=95)
Varicose vein	(0.0%)	1 (0.7%)	(0.0%)	(0.0%)
Vascular disorder	9 (6.3%)	7 (5.2%)	2 (2.2%)	2 (2.1%)
Vasodilatation	25 (17.5%)	22 (16.3%)	20 (22.0%)	19 (20.0%)
Ventricular fibrillation	(0.0%)	1 (0.7%)	(0.0%)	(0.0%)
Ventricular tachycardia	1 (0.7%)	(0.0%)	(0.0%)	(0.0%)
Digestive				
Abnormal stools	2 (1.4%)	1 (0.7%)	2 (2.2%)	(0.0%)
Anorexia	44 (30.8%)	35 (25.9%)	22 (24.2%)	15 (15.8%)
Cheilitis	1 (0.7%)	1 (0.7%)	1 (1.1%)	(0.0%)
Cholelithiasis	1 (0.7%)	(0.0%)	(0.0%)	(0.0%)
Cirrhosis of liver	(0.0%)	1 (0.7%)	(0.0%)	(0.0%)
Colitis	3 (2.1%)	(0.0%)	(0.0%)	1 (1.1%)
Constipation	51 (35.7%)	38 (28.1%)	23 (25.3%)	26 (27.4%)
Diarrhea	64 (44.8%)	34 (25.2%)	41 (45.1%)	28 (29.5%)
Dry mouth	9 (6.3%)	12 (8.9%)	7 (7.7%)	5 (5.3%)
Dyspepsia	32 (22.4%)	27 (20.0%)	16 (17.6%)	15 (15.8%)
Dysphagia	11 (7.7%)	5 (3.7%)	3 (3.3%)	2 (2.1%)
Eructation	2 (1.4%)	(0.0%)	(0.0%)	(0.0%)
Esophageal stenosis	1 (0.7%)	(0.0%)	(0.0%)	(0.0%)
Esophageal ulcer	1 (0.7%)	(0.0%)	(0.0%)	1 (1.1%)
Esophagitis	2 (1.4%)	8 (5.9%)	(0.0%)	2 (2.1%)
Fecal impaction	(0.0%)	1 (0.7%)	(0.0%)	(0.0%)
Fecal incontinence	(0.0%)	1 (0.7%)	3 (3.3%)	(0.0%)
Flatulence	5 (3.5%)	8 (5.9%)	1 (1.1%)	5 (5.3%)
Gastritis	3 (2.1%)	4 (3.0%)	3 (3.3%)	(0.0%)
Gastroenteritis	2 (1.4%)	5 (3.7%)	2 (2.2%)	(0.0%)
Gastrointestinal carcinoma	(0.0%)	1 (0.7%)	(0.0%)	(0.0%)
Gastrointestinal disorder	7 (4.9%)	5 (3.7%)	5 (5.5%)	2 (2.1%)
Gastrointestinal hemorrhage	3 (2.1%)	2 (1.5%)	2 (2.2%)	2 (2.1%)
Gingivitis	4 (2.8%)	2 (1.5%)	2 (2.2%)	(0.0%)
Glossitis	3 (2.1%)	2 (1.5%)	(0.0%)	(0.0%)
Gum hemorrhage	3 (2.1%)	(0.0%)	(0.0%)	(0.0%)
Hematemesis	1 (0.7%)	1 (0.7%)	1 (1.1%)	1 (1.1%)
Hepatic failure	(0.0%)	1 (0.7%)	1 (1.1%)	3 (3.2%)
Hepatic neoplasia	(0.0%)	1 (0.7%)	(0.0%)	(0.0%)
Hepatitis	1 (0.7%)	(0.0%)	1 (1.1%)	(0.0%)
Hepatomegaly	2 (1.4%)	1 (0.7%)	3 (3.3%)	1 (1.1%)
Hepatosplenomegaly	(0.0%)	1 (0.7%)	(0.0%)	(0.0%)
lleus	(0.0%)	(0.0%)	(0.0%)	1 (1.1%)
Increased appetite	(0.0%)	(0.0%)	2 (2.2%)	1 (1.1%)
Increased salivation	3 (2.1%)	(0.0%)	(0.0%)	(0.0%)
Intestinal obstruction	(0.0%)	1 (0.7%)	(0.0%)	1 (1.1%)
Jaundice	(0.0%)	1 (0.7%)	1 (1.1%)	4 (4.2%)
Liver damage	(0.0%)	(0.0%)	(0.0%)	1 (1.1%)
Liver function tests abnormal	2 (1.4%)	(0.0%)	(0.0%)	1 (1.1%)
Liver tenderness	1 (0.7%)	2 (1.5%)	2 (2.2%)	1 (1.1%)

Adverse Event Term	H + AC (N=143)	AC Alone (N=135)	H + Paclitaxel (N=91)	Paclitaxel Alone (N=95)
Melena	(0.0%)	1 (0.7%)	1 (1.1%)	1 (1.1%)
Mouth ulceration	17 (11.9%)	19 (14.1%)	4 (4.4%)	1 (1.1%)
Nausea	109 (76.2%)	107 (79.3%)	46 (50.5%)	46 (48.4%)
Nausea and	26 (18.2%)	12 (8.9%)	13 (14.3%)	11 (11.6%)
vomiting	, , ,	()	, ,	, ,
Oral moniliasis	5 (3.5%)	6 (4.4%)	4 (4.4%)	6 (6.3%)
Periodontal abscess	1 (0.7%)	(0.0%)	3 (3.3%)	(0.0%)
Pseudomembranous colitis	1 (0.7%)	(0.0%)	(0.0%)	(0.0%)
Rectal disorder	10 (7.0%)	8 (5.9%)	6 (6.6%)	(0.0%)
Rectal hemorrhage	6 (4.2%)	1 (0.7%)	4 (4.4%)	1 (1.1%)
Stomach ulcer	1 (0.7%)	(0.0%)	1 (1.1%)	(0.0%)
Stomatitis	43 (30.1%)	42 (31.1%)	9 (9.9%)	7 (7.4%)
Tenesmus	4 (2.8%)	1 (0.7%)	(0.0%)	(0.0%)
Thirst	3 (2.1%)	1 (0.7%)	(0.0%)	1 (1.1%)
Tongue discoloration	1 (0.7%)	(0.0%)	(0.0%)	(0.0%
Tongue disorder	2 (1.4%)	7 (5.2%)	1 (1.1%)	(0.0%)
Tooth discoloration	(0.0%)	(0.0%)	1 (1.1%)	(0.0%)
Tooth disorder	2 (1.4%)	1 (0.7%)	1 (1.1%)	(0.0%)
Ulcerative stomatitis	1 (0.7%)	2 (1.5%)	(0.0%)	2 (2.1%)
Vomiting	76 (53.1%)	66 (48.9%)	34 (37.4%)	27 (28.4%)
Endocrine	70 (55.170)	00 (48.576)	34 (37.470)	27 (20.470)
Cushings syndrome	1 (0.7%)	4 (3.0%)	(0.0%)	1 (1.1%)
Diabetes mellitus	1 (0.7%)	1 (0.7%)	(0.0%)	(0.0%)
Goiter	1 (0.7%)	(0.0%)	(0.0%)	(0.0%)
Hyperthyroidism	1 (0.7%)	(0.0%)	(0.0%)	(0.0%)
Hypothyroidism	3 (2.1%)	1 (0.7%)	(0.0%)	(0.0%)
Thyroiditis	(0.0%)	1 (0.7%)	(0.0%)	(0.0%)
Hemic and lymphatic	(0.070)	1 (0.770)	(0.070)	(0.070)
Acute leukemia	1 (0.7%)	(0.0%)	(0.0%)	(0.0%)
Anemia	50 (35.0%)	34 (25.2%)	13 (14.3%)	9 (9.5%)
Bleeding time	(0.0%)	(0.0%)	1 (1.1%)	(0.0%)
increased	(0.070)	(0.070)	+ (+.+/0)	(0.070)
Coagulation disorder	(0.0%)	(0.0%)	1 (1.1%)	1 (1.1%)
Ecchymosis	9 (6.3%)	3 (2.2%)	7 (7.7%)	2 (2.1%)
Hemolytic anemia	(0.0%)	1 (0.7%)	(0.0%)	(0.0%)
Hypochromic	8 (5.6%)	1 (0.7%)	2 (2.2%)	2 (2.1%)
anemia				
Leukocytosis	1 (0.7%)	(0.0%)	(0.0%)	(0.0%)
Leukopenia	74 (51.7%)	45 (33.3%)	22 (24.2%)	16 (16.8%)
Lymphadenopathy	6 (4.2%)	4 (3.0%)	2 (2.2%)	1 (1.1%)
Lymphangitis	1 (0.7%)	(0.0%)	(0.0%)	1 (1.1%)
Lymphedema	8 (5.6%)	4 (3.0%)	3 (3.3%)	1 (1.1%)
Marrow depression	1 (0.7%)	(0.0%)	(0.0%)	(0.0%)
Myeloid maturation	1 (0.7%)	(0.0%)	(0.0%)	(0.0%)
arrest	. ,	. ,		
Pancytopenia	5 (3.5%)	3 (2.2%)	2 (2.2%)	1 (1.1%)
Petechia	3 (2.1%)	1 (0.7%)	1 (1.1%)	(0.0%)
Purpura	(0.0%)	1 (0.7%)	(0.0%)	(0.0%)
Thrombocythemia	1 (0.7%)	(0.0%)	(0.0%)	(0.0%)

Adverse Event Term	H + AC (N=143)	AC Alone (N=135)	H + Paclitaxel (N=91)	Paclitaxel Alone (N=95)
Thrombocytopenia	16 (11.2%)	12 (8.9%)	3 (3.3%)	3 (3.2%)
Thromboplastin	(0.0%)	(0.0%)	1 (1.1%)	(0.0%)
increased				
Metabolic and				
nutritional				
disorders				
Acidosis	(0.0%)	(0.0%)	(0.0%)	1 (1.1%)
Alkaline	1 (0.7%)	(0.0%)	(0.0%)	1 (1.1%)
phosphatase				
increased				
Bilirubinemia	(0.0%)	1 (0.7%)	1 (1.1%)	(0.0%)
Cachexia	(0.0%)	(0.0%)	1 (1.1%)	(0.0%)
Creatinine increased	1 (0.7%)	(0.0%)	1 (1.1%)	(0.0%)
Dehydration	15 (10.5%)	5 (3.7%)	8 (8.8%)	9 (9.5%)
Edema	16 (11.2%)	7 (5.2%)	9 (9.9%)	8 (8.4%)
Electrolyte	(0.0%)	2 (1.5%)	(0.0%)	(0.0%)
abnormality				
Glucose tolerance	(0.0%)	1 (0.7%)	(0.0%)	(0.0%)
decreased				
Gout	1 (0.7%)	1 (0.7%)	(0.0%)	(0.0%)
Growth retarded	(0.0%)	1 (0.7%)	(0.0%)	(0.0%)
Healing abnormal	4 (2.8%)	(0.0%)	1 (1.1%)	2 (2.1%)
Hypercalcemia	(0.0%)	1 (0.7%)	3 (3.3%)	6 (6.3%)
Hypercholesteremia	1 (0.7%)	1 (0.7%)	(0.0%)	(0.0%)
Hyperglycemia	2 (1.4%)	4 (3.0%)	2 (2.2%)	2 (2.14%)
Hyperkalemia	(0.0%)	(0.0%)	3 (3.3%)	2 (2.1%)
Hypernatremia	(0.0%)	(0.0%)	1 (1.1%)	1 (1.1%)
Hyperuricemia	1 (0.7%)	(0.0%)	(0.0%)	(0.0%)
Hypervolemia	(0.0%)	2 (1.5%)	(0.0%)	(0.0%)
Hypocalcemia	2 (1.4%)	1 (0.7%)	1 (1.1%)	(0.0%)
Hypoglycemia	1 (0.7%)	1 (0.7%)	(0.0%)	3 (3.2%)
Hypokalemia	18 (12.6%)	6 (4.4%)	2 (2.2%)	3 (3.2%)
Hypomagnesemia	3 (2.1%)	1 (0.7%)	1 (1.1%)	(0.0%)
Hyponatremia	1 (0.7%)	(0.0%)	1 (1.1%)	(0.0%)
Hypophosphatemia	(0.0%)	(0.0%)	(0.0%)	1 (1.1%)
Hypoproteinemia	1 (0.7%)	(0.0%)	1 (1.1%)	(0.0%)
Lactic	1 (0.7%)	(0.0%)	(0.0%)	(0.0%)
dehydrogenase				
increased	(0.551)	10.000	10.000	
NPN increased	(0.0%)	(0.0%)	(0.0%)	1 (1.1%)
Peripheral edema	29 (20.3%)	23 (17.0%)	20 (22.0%)	19 (20.0%)
SGOT (serum glutamic	(0.0%)	1 (0.7%)	2 (2.2%)	3 (3.2%)
oxaloacetic				
transaminase)				
increased				
serum glutamic	(0.0%)	(0.0%)	2 (2.2%)	1 (1.1%)
pyruvic				
transaminase (SGPT)				
increased				
Weight gain	4 (2.8%)	3 (2.2%)	2 (2.2%)	2 (2.1%)

Adverse Event Term	H + AC (N=143)	AC Alone (N=135)	H + Paclitaxel (N=91)	Paclitaxel Alone (N=95)
Weight loss	12 (8.4%)	8 (5.9%)	7 (7.7%)	5 (5.3%)
Musculoskeletal				
Arthralgia	12 (8.4%)	13 (9.6%)	34 (37.4%)	20 (21.1%)
Arthritis	3 (2.1%)	(0.0%)	4 (4.4%)	1 (1.1%)
Bone disorder	(0.0%)	1 (0.7%)	1 (1.1%)	(0.0%)
Bone necrosis	1 (0.7%)	(0.0%)	1 (1.1%)	(0.0%)
Bone pain	10 (7.0%)	9 (6.7%)	22 (24.2%)	17 (17.9%)
Joint disorder	5 (3.5%)	2 (1.5%)	2 (2.2%)	3 (3.2%)
Leg cramps	6 (4.2%)	3 (2.2%)	5 (5.5%)	2 (2.1%)
Myalgia	19 (13.3%)	17 (12.6%)	35 (38.5%)	34 (35.8%)
Myasthenia	4 (2.8%)	8 (5.9%)	6 (6.6%)	8 (8.4%)
Myopathy	(0.0%)	(0.0%)	(0.0%)	1 (1.1%)
Myositis	(0.0%)	(0.0%)	1 (1.1%)	(0.0%)
Osteoporosis	1 (0.7%)	(0.0%)	(0.0%)	(0.0%)
Pathological fracture	1 (0.7%)	(0.0%)	1 (1.1%)	(0.0%)
Rheumatoid arthritis	1 (0.7%)	(0.0%)	(0.0%)	(0.0%)
Tendinous	1 (0.7%)	(0.0%)	(0.0%)	(0.0%)
contracture		ζ, γ		, ,
Tenosynovitis	(0.0%)	(0.0%)	2 (2.2%)	(0.0%)
Twitching	1 (0.7%)	1 (0.7%)	(0.0%)	2 (2.1%)
Nervous				
Abnormal dreams	(0.0%)	1 (0.7%)	(0.0%)	(0.0%)
Abnormal gait	3 (2.1%)	4 (3.0%)	7 (7.7%)	4 (4.2%)
Agitation	2 (1.4%)	2 (1.5%)	(0.0%)	(0.0%)
Amnesia	3 (2.1%)	4 (3.0%)	2 (2.2%)	1 (1.1%)
Anxiety	26 (18.2%)	19 (14.1%)	17 (18.7%)	14 (14.7%)
Ataxia	2 (1.4%)	3 (2.2%)	6 (6.6%)	4 (4.2%)
Brain edema	2 (1.4%)	2 (1.5%)	1 (1.1%)	(0.0%)
Circumoral	1 (0.7%)	1 (0.7%)	2 (2.2%)	1 (1.1%)
paresthesia	· · · ·			
Coma	1 (0.7%)	(0.0%)	1 (1.1%)	(0.0%)
Confusion	8 (5.6%)	(0.0%)	3 (3.3%)	6 (6.3%)
Convulsion	1 (0.7%)	(0.0%)	2 (2.2%)	3 (3.2%)
Depression	28 (19.6%)	16 (11.9%)	11 (12.1%)	12 (12.6%)
Dizziness	34 (23.8%)	24 (17.8%)	20 (22.0%)	23 (24.2%)
Dystonia	2 (1.4%)	(0.0%)	(0.0%)	(0.0%)
Emotional lability	3 (2.1%)	1 (0.7%)	2 (2.2%)	(0.0%)
Euphoria	1 (0.7%)	(0.0%)	1 (1.1%)	(0.0%)
Extrapyramidal	1 (0.7%)	(0.0%)	(0.0%)	(0.0%)
syndrome	. ,	. ,	. ,	. ,
Foot drop	1 (0.7%)	(0.0%)	(0.0%)	(0.0%)
Guillain barre	(0.0%)	(0.0%)	(0.0%)	1 (1.1%)
syndrome	. ,	. ,	. ,	
Hallucinations	2 (1.4%)	(0.0%)	1 (1.1%)	2 (2.1%)
Hyperesthesia	3 (2.1%)	(0.0%)	2 (2.2%)	3 (3.2%)
Hyperkinesia	2 (1.4%)	(0.0%)	3 (3.3%)	2 (2.1%)
Hypertonia	11 (7.7%)	3 (2.2%)	10 (11.0%)	3 (3.2%)
Hypesthesia	1 (0.7%)	1 (0.7%)	1 (1.1%)	3 (3.2%)
Hypokinesia	(0.0%)	1 (0.7%)	2 (2.2%)	(0.0%)
Incoordination	2 (1.4%)	(0.0%)	1 (1.1%)	3 (3.2%)

Adverse Event Term	H + AC (N=143)	AC Alone (N=135)	H + Paclitaxel (N=91)	Paclitaxel Alone (N=95)
Insomnia	42 (29.4%)	21 (15.6%)	23 (25.3%)	12 (12.6%)
Meningitis	(0.0%)	(0.0%)	(0.0%)	1 (1.1%)
Movement disorder	(0.0%)	3 (2.2%)	1 (1.1%)	1 (1.1%)
Nervousness	6 (4.2%)	5 (3.7%)	4 (4.4%)	2 (2.1%)
Neuralgia	3 (2.1%)	1 (0.7%)	1 (1.1%)	2 (2.1%)
Neuropathy	5 (3.5%)	6 (4.4%)	12 (13.2%)	5 (5.3%)
Neurosis	1 (0.7%)	1 (0.7%)	(0.0%)	(0.0%)
Nystagmus	(0.0%)	(0.0%)	1 (1.1%)	(0.0%)
Paranoid reaction	1 (0.7%)	(0.0%)	(0.0%)	(0.0%)
Paraplegia	1 (0.7%)	(0.0%)	(0.0%)	(0.0%)
Paresthesia	24 (16.8%)	15 (11.1%)	43 (47.3%)	37 (38.9%)
Peripheral neuritis	3 (2.1%)	3 (2.2%)	21 (23.1%)	15 (15.8%)
Reflexes decreased	(0.0%)	1 (0.7%)	3 (3.3%)	1 (1.1%)
Reflexes increased	1 (0.7%)	(0.0%)	(0.0%)	(0.0%)
Sleep disorder	2 (1.4%)	1 (0.7%)	1 (1.1%)	(0.0%)
Somnolence	15 (10.5%)	20 (14.8%)	9 (9.9%)	9 (9.5%)
Speech disorder	3 (2.1%)	1 (0.7%)	2 (2.2%)	2 (2.1%)
Thinking abnormal	5 (3.5%)	1 (0.7%)	3 (3.3%)	1 (1.1%)
Tremor	5 (3.5%)	2 (1.5%)	4 (4.4%)	4 (4.2%)
Vertigo	4 (2.8%)	3 (2.2%)	3 (3.3%)	2 (2.1%)
Weakness	(0.0%)	2 (1.5%)	(0.0%)	1 (1.1%)
Respiratory	(0.070)	2 (1.370)	(0.070)	1 (1.170)
Apnea	1 (0.7%)	(0.0%)	1 (1.1%)	(0.0%)
Asthma	6 (4.2%)	5 (3.7%)	5 (5.5%)	2 (2.1%)
Bronchitis	2 (1.4%)	5 (3.7%)	6 (6.6%)	2 (2.1%)
Carcinoma of lung	(0.0%)	1 (0.7%)	(0.0%)	(0.0%)
Cough increased	62 (43.4%)	38 (28.1%)	38 (41.8%)	21 (22.1%)
Dry nasal	1 (0.7%)	(0.0%)	1 (1.1%)	(0.0%)
•		. ,		
Dyspnea	60 (42.0%)	33 (24.4%)	25 (27.5%)	25 (26.3%)
Epistaxis	10 (7.0%)	8 (5.9%)	16 (17.6%)	4 (4.2%)
Hemoptysis	1 (0.7%)	(0.0%)	2 (2.2%)	(0.0%)
Hiccup	4 (2.8%)	1 (0.7%)	(0.0%)	(0.0%)
Hyperventilation	3 (2.1%)	1 (0.7%)	1 (1.1%)	(0.0%)
Нурохіа	4 (2.8%)	1 (0.7%)	(0.0%)	5 (5.3%)
Laryngismus	(0.0%)	(0.0%)	1 (1.1%)	(0.0%)
Laryngitis	(0.0%)	(0.0%)	3 (3.3%)	1 (1.1%)
Larynx edema	(0.0%)	1 (0.7%)	(0.0%)	(0.0%)
Lung disorder	12 (8.4%)	4 (3.0%)	7 (7.7%)	7 (7.4%)
Lung edema	1 (0.7%)	(0.0%)	(0.0%)	(0.0%)
Pharyngitis	43 (30.1%)	25 (18.5%)	20 (22.0%)	13 (13.7%)
Pleural disorder	(0.0%)	(0.0%)	2 (2.2%)	1 (1.1%)
Pleural effusion	9 (6.3%)	4 (3.0%)	6 (6.6%)	5 (5.3%)
Pneumonia	9 (6.3%)	4 (3.0%)	2 (2.2%)	2 (2.1%)
Pneumothorax	2 (1.4%)	2 (1.5%)	(0.0%)	(0.0%)
Respiratory disorder	3 (2.1%)	(0.0%)	1 (1.1%)	(0.0%)
Rhinitis	31 (21.7%)	21 (15.6%)	20 (22.0%)	5 (5.3%)
Sinusitis	18 (12.6%)	8 (5.9%)	19 (20.9%)	7 (7.4%)
Sputum change	1 (0.7%)	(0.0%)	(0.0%)	(0.0%)
Sputum increased	1 (0.7%)	2 (1.5%)	(0.0%)	1 (1.1%)
Vocal cord paralysis	(0.0%)	(0.0%)	(0.0%)	1 (1.1%)

Adverse Event Term	H + AC (N=143)	AC Alone (N=135)	H + Paclitaxel (N=91)	Paclitaxel Alone (N=95)
Voice alteration	5 (3.5%)	(0.0%)	4 (4.4%)	3 (3.2%)
Skin and appendages				
Acne	4 (2.8%)	1 (0.7%)	10 (11.0%)	3 (3.2%)
Alopecia	83 (58.0%)	80 (59.3%)	51 (56.0%)	53 (55.8%)
Contact dermatitis	(0.0%)	(0.0%)	2 (2.2%)	1 (1.1%)
Cutaneous moniliasis	(0.0%)	1 (0.7%)	(0.0%)	(0.0%)
Dry skin	1 (0.7%)	7 (5.2%)	4 (4.4%)	4 (4.2%)
Eczema	2 (1.4%)	(0.0%)	(0.0%)	(0.0%)
Exfoliative dermatitis	2 (1.4%)	1 (0.7%)	3 (3.3%)	2 (2.1%)
Fungal dermatitis	6 (4.2%)	5 (3.7%)	3 (3.3%)	(0.0%)
Furunculosis	(0.0%)	1 (0.7%)	(0.0%)	(0.0%)
Herpes simplex	10 (7.0%)	11 (8.1%)	11 (12.1%)	3 (3.2%)
Herpes zoster	4 (2.8%)	4 (3.0%)	4 (4.4%)	2 (2.1%)
Maculopapular rash	2 (1.4%)	3 (2.2%)	3 (3.3%)	1 (1.1%)
Melanosis	1 (0.7%)	(0.0%)	(0.0%)	(0.0%)
Nail disorder	6 (4.2%)	5 (3.7%)	4 (4.4%)	1 (1.1%)
Pruritus	11 (7.7%)	8 (5.9%)	13 (14.3%)	12 (12.6%)
Psoriasis	1 (0.7%)	2 (1.5%)	(0.0%)	(0.0%)
Purpuric rash	(0.0%)	(0.0%)	1 (1.1%)	(0.0%)
Pustular rash	1 (0.7%)	(0.0%)	(0.0%)	1 (1.1%)
Rash	38 (26.6%)	23 (17.0%)	35 (38.5%)	17 (17.9%)
Seborrhea	1 (0.7%)	(0.0%)	(0.0%)	(0.0%)
Skin discoloration	7 (4.9%)	3 (2.2%)	2 (2.2%)	1 (1.1%)
Skin disorder	3 (2.1%)	1 (0.7%)	2 (2.2%)	1 (1.1%)
Skin hypertrophy	1 (0.7%)	(0.0%)	(0.0%)	(0.0%)
Skin melanoma	1 (0.7%)	(0.0%)	(0.0%)	(0.0%)
Skin nodule	(0.0%)	1 (0.7%)	(0.0%)	(0.0%)
Skin ulcer	8 (5.6%)	6 (4.4%)	3 (3.3%)	1 (1.1%)
Subcutaneous nodule	1 (0.7%)	1 (0.7%)	(0.0%)	(0.0%)
Sweating	13 (9.1%)	10 (7.4%)	7 (7.7%)	3 (3.2%)
Urticaria	2 (1.4%)	(0.0%)	1 (1.1%)	1 (1.1%)
Vesiculobullous rash	1 (0.7%)	1 (0.7%)	3 (3.3%)	1 (1.1%)
Special senses				
Abnormal vision	11 (7.7%)	3 (2.2%)	6 (6.6%)	3 (3.2%)
Amblyopia	8 (5.6%)	5 (3.7%)	5 (5.5%)	6 (6.3%)
Blepharitis	(0.0%)	2 (1.5%)	(0.0%)	(0.0%)
Blindness	1 (0.7%)	(0.0%)	(0.0%)	(0.0%)
Cataract specified	1 (0.7%)	(0.0%)	1 (1.1%)	(0.0%)
Conjunctivitis	12 (8.4%)	9 (6.7%)	6 (6.6%)	2 (2.1%)
Corneal lesion	(0.0%)	2 (1.5%)	1 (1.1%)	(0.0%)
Deafness	2 (1.4%)	3 (2.2%)	(0.0%)	2 (2.1%)
Diplopia	1 (0.7%)	2 (1.5%)	1 (1.1%)	2 (2.1%)
Dry eyes	3 (2.1%)	1 (0.7%)	1 (1.1%)	1 (1.1%)
Ear disorder	2 (1.4%)	2 (1.5%)	1 (1.1%)	1 (1.1%)
Earpain	4 (2.8%)	1 (0.7%)	3 (3.3%)	1 (1.1%)
Eye disorder	1 (0.7%)	2 (1.5%)	(0.0%)	(0.0%)
Eye hemorrhage	1 (0.7%)	1 (0.7%)	(0.0%)	1 (1.1%)
Eye pain	1 (0.7%)	2 (1.5%)	2 (2.2%)	(0.0%)
Glaucoma	(0.0%)	1 (0.7%)	1 (1.1%)	(0.0%)
Hyperacusis	(0.0%)	(0.0%)	1 (1.1%)	(0.0%)

Adverse Event Term	H + AC (N=143)	AC Alone (N=135)	H + Paclitaxel (N=91)	Paclitaxel Alone (N=95)
Keratitis	(0.0%)	(0.0%)	1 (1.1%)	(0.0%)
Lacrimation disorder	7 (4.9%)	12 (8.9%)	3 (3.3%)	(0.0%)
Otitis media	3 (2.1%)	2 (1.5%)	3 (3.3%)	(0.0%)
Parosmia	1 (0.7%)	2 (1.5%)	1 (1.1%)	(0.0%)
Photophobia	(0.0%)	2 (1.5%)	1 (1.1%)	(0.0%)
Ptosis	(0.0%)	(0.0%)	(0.0%)	1 (1.1%)
Retinal artery	1 (0.7%)	(0.0%)	(0.0%)	(0.0%)
occlusion				
Retinal disorder	1 (0.7%)	1 (0.7%)	(0.0%)	(0.0%)
Strabismus	(0.0%)	1 (0.7%)	(0.0%)	(0.0%)
Taste loss	2 (1.4%)	(0.0%)	(0.0%)	3 (3.2%)
Taste perversion	16 (11.2%)	18 (13.3%)	5 (5.5%)	3 (3.2%)
Tinnitus	2 (1.4%)	2 (1.5%)	2 (2.2%)	2 (2.1%)
Vestibular disorder	(0.0%)	1 (0.7%)	(0.0%)	(0.0%)
Visual field defect	1 (0.7%)	(0.0%)	3 (3.3%)	(0.0%)
Vitreous disorder	2 (1.4%)	(0.0%)	1 (1.1%)	(0.0%)
Urogenital	2 (1.470)	(0.070)	1 (1.170)	(0.070)
Acute kidney failure	(0.0%)	(0.0%)	1 (1.1%)	1 (1.1%)
Albuminuria	2 (1.4%)	(0.0%)	1 (1.1%)	(0.0%)
Amenorrhea	2 (1.4%)	5 (3.7%)	1 (1.1%)	(0.0%)
Breast carcinoma	6 (4.2%)	3 (2.2%)	2 (2.2%)	5 (5.3%)
Breast enlargement	1 (0.7%)	1 (0.7%)	(0.0%)	1 (1.1%)
Breast neoplasm	3 (2.14%)	2 (1.5%)	1 (1.1%)	(0.0%)
Breast pain	8 (5.6%)	7 (5.2%)	2 (2.2%)	6 (6.3%)
Cystitis	1 (0.7%)	3 (2.2%)	1 (1.1%)	1 (1.1%)
Dysmenorrhea	(0.0%)	(0.0%)	(0.0%)	2 (2.1%)
	1 (0.7%)	1 (0.7%)	(0.0%)	(0.0%)
Dyspareunia Dyspareunia	6 (4.2%)	7 (5.2%)	3 (3.3%)	
Dysuria Fibroaustia broast				3 (3.2%) (0.0%)
Fibrocystic breast	2 (1.4%)	(0.0%)	(0.0%)	
Hematuria	3 (2.1%)	2 (1.5%)	2 (2.2%)	1 (1.1%)
Hydronephrosis	2 (1.4%)	1 (0.7%)	(0.0%)	(0.0%)
Kidney failure	1 (0.7%)	(0.0%)	(0.0%)	1 (1.1%)
Kidney function	1 (0.7%)	(0.0%)	(0.0%)	(0.0%)
abnormal Kida avagin	1 (0 70/)	(0,00/)	(0,00())	(0,00()
Kidney pain	1 (0.7%)	(0.0%)	(0.0%)	(0.0%)
Leukorrhea	6 (4.2%)	1 (0.7%)	(0.0%)	1 (1.1%)
Mastitis	3 (2.1%)	1 (0.7%)	2 (2.2%)	(0.0%)
Menopause	3 (2.1%)	(0.0%)	(0.0%)	(0.0%)
Menorrhagia	(0.0%)	1 (0.7%)	1 (1.1%)	2 (2.1%)
Menstrual disorder	(0.0%)	(0.0%)	(0.0%)	1 (1.1%)
Metrorrhagia	3 (2.1%)	1 (0.7%)	2 (2.2%)	(0.0%)
Nocturia	1 (0.7%)	1 (0.7%)	(0.0%)	(0.0%)
Oliguria	1 (0.7%)	(0.0%)	(0.0%)	(0.0%)
Papanicolaou smear	(0.0%)	1 (0.7%)	(0.0%)	(0.0%)
suspicious				
Polyuria	(0.0%)	1 (0.7%)	1 (1.1%)	(0.0%)
Urinary frequency	5 (3.5%)	8 (5.9%)	1 (1.1%)	1 (1.1%)
Urinary	7 (4.9%)	1 (0.7%)	2 (2.2%)	1 (1.1%)
incontinence				
Urinary retention	2 (1.4%)	(0.0%)	(0.0%)	1 (1.1%)

Adverse Event Term	H + AC (N=143)	AC Alone (N=135)	H + Paclitaxel (N=91)	Paclitaxel Alone (N=95)
Urinary tract disorder	1 (0.7%)	1 (0.7%)	1 (1.1%)	1 (1.1%)
Urinary tract infection	19 (13.3%)	9 (6.7%)	17 (18.7%)	13 (13.7%)
Urinary urgency	1 (0.7%)	1 (0.7%)	2 (2.2%)	(0.0%)
Urination impaired	1 (0.7%)	(0.0%)	(0.0%)	(0.0%)
Urine abnormality	2 (1.4%)	1 (0.7%)	1 (1.1%)	(0.0%)
Vaginal hemorrhage	(0.0%)	2 (1.5%)	1 (1.1%)	2 (2.1%)
Vaginal moniliasis	9 (6.3%)	2 (1.5%)	2 (2.2%)	1 (1.1%)
Vaginitis	7 (4.9%)	8 (5.9%)	5 (5.5%)	1 (1.1%)

A=doxorubicin; C=cyclophosphamide; H=trastuzumab

Other Serious Adverse Events

The following other serious adverse events occurred in at least one of the 958 patients treated with trastuzumab in the MBC clinical trials conducted prior to market approval:

Body as a Whole: abdomen enlarged, allergic reaction, anaphylactoid reaction, ascites, carcinoma, cellulitis, chills and fever, death, dermatomyositis, hydrocephalus, necrosis, neoplasm, pelvic pain, radiation injury, sepsis, malaise

Cardiovascular: atrial fibrillation, cardiomyopathy, cardiovascular disorder, cerebrovascular accident, deep thrombophlebitis, heart arrest, heart failure, hemorrhage, hypotension, pericardial effusion, pulmonary embolus, thrombophlebitis, thrombosis, syncope, shock, supraventricular tachycardia, vascular disorder, ventricular arrhythmia

Digestive: colitis, dysphagia, esophageal hemorrhage, esophageal ulcer, gastritis, gastroenteritis, gastrointestinal disorder, gastrointestinal hemorrhage, hematemesis, hepatic coma, hepatic failure, hepatic neoplasia, hepatitis, hepatomegaly, ileus, intestinal obstruction, liver tenderness, pancreatitis, peptic ulcer hemorrhage, pseudomembranous colitis, rectal hemorrhage

Endocrine: hypothyroidism

Hematological: acute leukemia, coagulation disorder, lymphangitis, marrow depression, myeloid maturation arrest, pancytopenia

Metabolic: bilirubinemia, growth retardation, hypercalcemia, hyponatremia, hypoglycemia, hypomagnesemia, weight loss

Musculoskeletal: pathologic fracture, bone necrosis, myopathy

Nervous: ataxia, CNS neoplasia, confusion, convulsion, grand mal convulsion, manic reaction, thinking abnormal

Respiratory: apnea, asthma, hypoxia, laryngitis, lung disorder, lung edema, pleural effusion, pneumonia, pneumothorax, respiratory disorder

Skin: herpes zoster, skin ulceration, dry skin

Special Senses: amblyopia, deafness, retinal artery occlusion

Urogenital: breast carcinoma, breast neoplasm, cervical cancer, hematuria, hemorrhagic cystitis, hydronephrosis, kidney failure, kidney function abnormal, pyelonephritis, vaginal hemorrhage

When using in combination with Perjeta (pertuzumab) and docetaxel, consult Product Monographs for Perjeta and docetaxel for further information on these drugs.

Metastatic Gastric Cancer (MGC)

The ToGA trial (BO18255) is a randomised, open-label multicentre, phase III study of trastuzumab in combination with a fluoropyrimidine (FP) and cisplatin versus chemotherapy alone in patients with HER2 positive MGC. There were only 3.4% of patients in each treatment group with locally advanced cancer. The majority of patients had metastatic disease.

The adverse drug reactions that occurred with the incidence of at least 1% in the ToGA (BO18255) study are presented in **Table 19**.

	FP/Cisplatin	Trastuzumab/
	(FP)	FP/Cisplatin
	N = 290	(H+FP)
	No. (%)	N = 294
		No. (%)
Blood and lymphatic		
system disorders		
Neutropenia	165 (57)	157 (53)
Anemia	61 (21)	81 (28)
Thrombocytopenia	33 (11)	47 (16)
Febrile neutropenia	8 (3)	15 (5)
Leukopenia	11 (4)	11 (4)
Cardiac disorders		
Palpitations	2 (<1)	6 (2)
Ear and labyrinth disorders		
Deafness	1 (<1)	8 (3)
Eye disorders		
Lacrimation increased	2 (<1)	5 (2)
Gastrointestinal disorders		
Nausea	184 (63)	197 (67)
Vomiting	134 (46)	147 (50)
Diarrhea	80 (28)	109 (37)
Constipation	93 (32)	75 (26)
Stomatitis	43 (15)	72 (24)
Abdominal pain	42 (14)	46 (16)
Abdominal pain upper	15 (5)	27 (9)
Dyspepsia	16 (6)	18 (6)
Hemorrhoids	3 (1)	5 (2)
Abdominal discomfort	3 (1)	3 (1)
Dry mouth	2 (<1)	4 (1)
General disorders and		
administration site conditions		
Fatigue	82 (28)	102 (35)
Asthenia	53 (18)	55 (19)
Pyrexia	36 (12)	54 (18)
Mucosal inflammation	18 (6)	37 (13)
Edema	25 (9)	22 (7)
Edema peripheral	12 (4)	17 (6)
Chills	-	23 (8)

Chest pain	4 (1)	8 (3)
Malaise	6 (2)	6 (2)
Pain	4 (1)	5 (2)
Infusion related reaction	-	3 (1)
Hepatobiliary disorders		5 (1)
Hepatic function abnormal	3 (1)	3 (1)
Infections and infestations	3 (1)	5 (1)
	47.(5)	27 (12)
Nasopharyngitis	17 (6)	37 (13)
Upper respiratory tract infection	10 (3)	15 (5)
Pneumonia	2 (<1)	9 (3)
Cystitis	1 (<1)	5 (3)
Pharyngitis	2 (<1)	4 (1)
Respiratory tract infection	3 (1)	3 (1)
Infection	2 (<1)	3 (1)
Influenza	1 (<1)	4 (1)
Immune system disorders	- (-/	
Hypersensitivity	3 (1)	6 (2)
Injury, poisoning and	()	
procedural complications		
Contusion	2 (<1)	3 (1)
Investigations	= ()=)	
Weight decreased	40 (14)	69 (23)
Hemoglobin decreased	2 (<1)	7 (2)
Platelet count decreased	6 (2)	1 (<1)
Neutrophil count decreased	3 (1)	3 (1)
Metabolism and	- \-/	- \-/
nutrition disorders		
Anorexia	133 (46)	135 (46)
Hyperkalaemia	3 (1)	-
Musculoskeletal and connective	- (- <i>)</i>	
tissue disorders		
		(2/4)
Back pain	15 (5)	12 (4)
Pain in extremity	7 (2)	4 (1)
Arthralgia	2 (<1)	7 (2)
Musculoskeletal pain	4 (1)	5 (2)
Myalgia	<u>3 (1)</u> 3 (1)	4 (1)
Muscular weakness	· · ·	2 (<1)
Muscle spasms	1 (<1)	3 (1)
Musculoskeletal chest pain	3 (1)	1 (<1)
Neck pain	1 (<1)	3 (1)
Nervous system disorders	28 (10)	21 (11)
Dizziness Peripheral sensory neuropathy	<u>28 (10)</u> 24 (8)	31 (11) 23 (8)
Peripheral sensory neuropathy		
Neuropathy peripheral Dysgeusia	<u> </u>	24 (8) 28 (0)
Headache	14 (5)	14 (5)
Paraesthesia	9 (3)	9 (3)
Lethargy	8 (3)	6 (2)
Peripheral motor neuropathy	6 (2)	8 (3)
Tremor	5 (2)	3 (1)
Renal and urinary disorders	J (2)	
nenai anu urmary uisuruers		

Renal impairment	39 (13)	47 (16)
Nephropathy toxic	12 (4)	18 (6)
Renal failure acute	2 (<1)	3 (1)
Renal failure	1 (<1)	3 (1)
Respiratory, thoracic and		
mediastinal disorders		
Cough	17 (6)	19 (6)
Dyspnea	16 (6)	9 (3)
Epistaxis	9 (3)	13 (4)
Rhinorrhea	2 (<1)	6 (2)
Psychiatric disorders		
Insomnia	20 (7)	24 (8)
Depression	5 (2)	4 (1)
Anxiety	5 (2)	3 (1)
Sleep disorder	3 (1)	2 (<1)
Skin and subcutaneous		
tissue disorders		
Palmar-plantar	64 (22)	75 (26)
erythrodysaesthesia		
syndrome		
Alopecia	27 (9)	32 (11)
Rash	12 (4)	16 (5)
Nail disorder	6 (2)	13 (4)
Dry skin	4 (1)	10 (3)
Pruritus	3 (1)	8 (3)
Urticaria	3 (1)	3 (1)
Vascular disorders		
Hypertension	7 (2)	11 (4)
Hypotension	6 (2)	6 (2)

Adverse Events of Special Interest

The following subsections provide additional detail regarding adverse reactions observed in clinical trials in EBC, MBC, MGC, or post-marketing experience.

Cardiac (EBC and MBC)

For a description of cardiac toxicities see **7 WARNINGS AND PRECAUTIONS**.

Cardiac (Metastatic Gastric Cancer)

In the ToGA (BO18255) study, at screening, the median LVEF value was 64% (range 48%-90%) in the FP arm and 65% (range 50%-86%) in the FP+H arm. At baseline, a LVEF value of 50% or more (measured by ECHO or MUGA) was required at study entry.

The majority of the LVEF decreases noted in ToGA (BO18255) were asymptomatic, with the exception of one patient in the trastuzumab-containing arm whose LVEF decrease coincided with cardiac failure.

LVEF Decrease: Lowest Post-screening Value	FP/Cisplatin (N = 290) (% of patients in each treatment arm)	Trastuzumab/FP/Cisplatin (N = 294) (% of patients in each treatment arm)
*LVEF decrease of $\geq 10\%$ to a value of <50%	1.1%	4.6%
Absolute Value < 50% * LVEF decrease of $\ge 10\%$ to a value of $\ge 50\%$	1.1% 11.8%	5.9% 16.5%

*Only includes patients whose method of assessment at that visit is the same as at their initial assessments (F + C, n = 187 and H + FC, n = 237)

Table 21 - Cardiac Adverse Events ToGA (BO18255)

	FP/Cisplatin (N = 290) (% of patients in each treatment arm)	Trastuzumab/FP/ Cisplatin (N = 294) (% of patients in each treatment arm)
Total Cardiac Events	6%	6%
≥Grade 3 NCI-CTC AE V3.0	*3%	**1%

* 9 patients experienced 9 Events

** 4 patients experienced 5 Events

Infusion-Associated Symptoms

During the first infusion with trastuzumab, chills and/or fever are observed commonly in patients. Other signs and/or symptoms may include nausea, vomiting, pain, rigors, headache, cough, dizziness, rash, asthenia and hypertension. The symptoms are usually mild to moderate in severity and occur infrequently with subsequent infusions of trastuzumab. The symptoms can be treated with an analgesic/antipyretic such as meperidine or acetaminophen, or an antihistamine such as diphenhydramine (see **4 DOSAGE AND ADMINISTRATION**). Interruption of the infusion was infrequent. Some adverse reactions to infusions of trastuzumab including dyspnea, hypotension, wheezing, bronchospasm, tachycardia, reduced oxygen saturation and respiratory distress can be serious and potentially fatal (see **7 WARNINGS AND PRECAUTIONS**).

Hematological Toxicity

In a randomized controlled clinical trial in MBC (H0648g), WHO Grade 3 or 4ⁱⁱ hematological toxicity was observed in 63% of patients treated with trastuzumab and an anthracycline plus cyclophosphamide compared to an incidence of 62% in patients treated with anthracycline/cyclophosphamide combination without trastuzumab. There was an increase in WHO Grade 3 or 4 hematological toxicity in patients treated with the combination of trastuzumab and paclitaxel compared with patients receiving paclitaxel alone (34% vs. 21%).

In a randomized, controlled trial in patients with MBC conducted in the post-marketing setting, hematological toxicity was also increased in patients receiving trastuzumab and docetaxel, compared with docetaxel alone (32% grade 3/4 neutropenia versus 22%, using NCI-CTC criteria). The incidence of febrile neutropenia/neutropenic sepsis was also increased in patients treated with trastuzumab plus

docetaxel (23% versus 17% for patients treated with docetaxel alone), see **7 WARNINGS AND PRECAUTIONS**.

ⁱⁱ WHO Grade <u>3</u> Hematological Toxicity: Hemoglobin – 6.5-7.9 g/100 mL, 65-79 g/L, 4.0-4.9 mmol/L, Leukocytes (1000/mm³) – 1.0-1.9, Granulocytes (1000/mm³) – 0.5-0.9, Platelets (1000/mm³) – 25-49.

WHO Grade <u>4</u> Hematological Toxicity: Hemoglobin – <6.5 g/100 mL, <65 g/L, <4.0 mmol/L, Leukocytes $(1000/mm^3) - <0.5$, Platelets $(1000/mm^3) - <25$.

Anemia and Leukopenia

In a randomized controlled clinical trial in MBC, an increased incidence of anemia and leukopenia was observed in the treatment group receiving trastuzumab and chemotherapy (26.9% and 41%), especially in the trastuzumab and AC subgroup (35.0% and 51.7%), compared with the treatment group receiving chemotherapy alone (18.7% and 26.5%). The majority of these cytopenic events were mild or moderate in intensity, reversible, and none resulted in discontinuation of therapy with trastuzumab.

Hematologic toxicity is infrequent following the administration of trastuzumab as a single agent, with an incidence of Grade 3 toxicities for WBC, platelets, hemoglobin all < 1%. No Grade 4 toxicities were observed.

In study B-31, the incidence of grade 3 to 5 anemia was comparable between the trastuzumab + chemotherapy and the chemotherapy alone arm (3.2% versus 3.1%). The incidence of grade 3 to 5 leukopenia was lower in patients randomized to trastuzumab + chemotherapy compared with those randomized to chemotherapy alone (10.0% versus 10.7%).

In study N9831, the incidence of grade 3 to 5 anemia was comparable between the trastuzumab + chemotherapy and the chemotherapy alone arm (0.2% versus 0.0%). The incidence of grade 3 to 5 leukopenia was higher in patients randomized to trastuzumab + chemotherapy compared with those randomized to chemotherapy alone (8.5% versus 7.7%).

In study BCIRG006 the incidence of grade 3 or 4 anemia according to the NCI-CTC v 2.0 classification was comparable between the AC-T arm (4.4%) and the AC-TH arm (4.9%). The TCH arm had a higher incidence of grade 3 or 4 anemia (8.3%) as would be expected from the known toxicity profile of carboplatin. The incidence of grade 3 or 4 leukopenia according to the NCI-CTC v 2.0 classification (52.7% AC-T, 61.5% AC-TH, and 49.9% TCH) was similar in patients randomized to trastuzumab + chemotherapy compared with those randomized to chemotherapy alone.

Thrombocytopenia

In HERA study in EBC, the incidence of thrombocytopenia (0.1% vs. 0.06%) was comparable between patients randomized to trastuzumab + chemotherapy and those randomized to chemotherapy alone.

In study B-31 in EBC, the incidence of thrombocytopenia (2.2% in the AC \rightarrow TH arm vs. 2.5% in the AC \rightarrow T arm) was lower in patients randomized to trastuzumab + chemotherapy compared with those randomized to chemotherapy alone.

In study N9831 in EBC, the incidence of thrombocytopenia (0% in the AC \rightarrow TH arm vs. 0.3% in the AC \rightarrow T arm) was lower in patients randomized to trastuzumab + chemotherapy compared with those randomized to chemotherapy alone.

In study BCIRG-006 in EBC, the incidence of grade 3 or 4 thrombocytopenia (5.6% in the AC \rightarrow T arm, 6.8% in the AC \rightarrow TH arm) was higher in patients randomized to trastuzumab + chemotherapy compared with those randomized to chemotherapy alone. The incidence of grade 3 or 4 thrombocytopenia in the TCH arm (9.8%) was higher as would be expected from the known toxicity profile of carboplatin.

Neutropenia

In HERA study in EBC, the incidence of neutropenia (0.4% vs. 0.2%) was higher in patients randomized to trastuzumab + chemotherapy compared with those randomized to chemotherapy alone.

In study B-31 in EBC, the incidence of febrile neutropenia (3.8% in the AC \rightarrow TH arm vs. 4.7% in the AC \rightarrow T arm) was lower in patients randomized to trastuzumab + chemotherapy compared with those randomized to chemotherapy alone. The incidence of neutropenia (grade 3-5) (10.4% in the AC \rightarrow TH arm vs. 9.9% in the AC \rightarrow T arm) was higher in patients randomized to trastuzumab + chemotherapy compared with those randomized to chemotherapy alone.

In study N9831 in EBC, the incidence of febrile neutropenia (5.9% in the AC \rightarrow TH arm vs. 4.3% in the AC \rightarrow T arm) was higher in patients randomized to trastuzumab + chemotherapy compared with those randomized to chemotherapy alone. The incidence of neutropenia (grade 3-5) (29.5% in the AC \rightarrow TH arm vs. 27.3% in the AC \rightarrow T arm) was higher in patients randomized to trastuzumab + chemotherapy compared with those randomized to chemotherapy alone.

In study BCIRG-006, the incidence of febrile neutropenia according to NCI-CTC v 2.0 classification (10.9% in the AC \rightarrow TH arm, 9.6% in the TCH arm, and 9.3% in the AC \rightarrow T arm) was comparable between patients randomized to trastuzumab + chemotherapy and with those randomized to chemotherapy alone. The incidence of grade 3 or 4 neutropenia according to the NCI-CTC v 2.0 classification (72.5% in the AC \rightarrow TH arm, 67.0% in the TCH arm, and 64.6% in the AC \rightarrow T arm) was comparable between patients randomized to trastuzumab + chemotherapy and with those randomized to chemotherapy alone.

Infection

In three studies in EBC, the incidence of infection was higher in patients randomized to trastuzumab + chemotherapy compared with those randomized to chemotherapy alone (HERA: 29% vs. 12%; B-31: 32% AC \rightarrow TH vs. 28% AC \rightarrow T; N9831: 7.3% AC \rightarrow TH vs. 4.7% AC \rightarrow T).

In study BCIRG-006 in EBC, the overall incidence of infection (all grades) was higher with the addition of trastuzumab to AC \rightarrow T but not to TCH [44% (AC \rightarrow TH), 37% (TCH), 38% (AC \rightarrow T)]. The incidences of NCI-CTC Grade 3-4 infection were similar [25% (AC \rightarrow TH), 21% (TCH), 23% (AC \rightarrow T)] across the three arms.

In a randomized controlled clinical trial in MBC, an increased incidence of infections, primarily mild upper respiratory infections of minor clinical significance or catheter infections, was observed in patients receiving trastuzumab in combination with chemotherapy.

In the ToGA (BO18255) study in MGC, infections and infestations were reported in 20 % of patients in the FP arm vs. 32% in the FP+H arm. The major contributors to the higher incidence of infections and infestations in the trastuzumab arm were nasopharyngitis (6% in the FP arm vs. 13% in the FP+H arm) and upper respiratory tract infection (3% vs. 5%).

Hypersensitivity Reactions Including Anaphylaxis and Pulmonary Events

In HERA study, there were 4 cases of interstitial pneumonitis in trastuzumab -treated patients compared to none in the control arm.

The incidence of allergic reactions (chemotherapy alone versus trastuzumab + chemotherapy: 3.7% versus 3.4% in study B-31 and 1.2% versus 0.3% in study N9831) was comparable between the two treatment arms in both studies.

The incidence of pulmonary events in the original analysis for adjuvant studies (16.1% versus 7.8% in study B-31 and 4.1% versus 1.4% in study N9831) was higher in patients randomized to trastuzumab + chemotherapy versus chemotherapy alone. The most common pulmonary event was dyspnea. The

majority of these events were mild to moderate in intensity. Fatal pulmonary events were reported in 4 patients in the trastuzumab + chemotherapy arm. Only 1 of these patients actually received trastuzumab. The cause of death in these 4 patients was cardio-respiratory arrest, bronchopneumonia, respiratory insufficiency, and pneumonia accompanied by neutropenic fever. Pneumonitis/lung infiltrates were reported in 20 patients who participated in either adjuvant clinical trial. Twelve of these 20 patients had received trastuzumab + chemotherapy. The etiology of pneumonitis/lung infiltrates was possible hypersensitivity/inflammation reaction (n= 4), pneumonia (n=5), radiation therapy toxicity (n=1) ad unknown etiology (n= 2).

In the most recent safety update for the NSABP B-31 and NCCTG N9831 Joint Analysis report (median follow-up of 8.1 years for the AC \rightarrow TH group and 8.5 years for the AC \rightarrow T group), the incidences of pulmonary adverse events reported in study B-31 were 17.5% in the AC \rightarrow T + H group and 8.5% in the AC \rightarrow T group. Likewise, the incidences of pulmonary adverse events reported in study N9831 were 4.0% in the AC \rightarrow T + H group and 1.7% in the AC \rightarrow T group. These results confirm the results from the original analysis, which showed a higher rate of pulmonary events in the trastuzumab patients. Dyspnea remained the most common pulmonary adverse event reported in both studies. Dyspnea can be a result of cardiac left ventricular dysfunction.

Pneumonitis/pulmonary infiltrates were reported in 26 patients in both studies (7 in study B-31, 18 in study N9831) and 17 of these patients were in the AC \rightarrow T + H group. All 7 patients in study B-31 were in the AC \rightarrow T + H group, and 10 of the patients in study N9831 were in the AC \rightarrow T + H group. There were 8 patients with this adverse event in study N9831 in the AC \rightarrow T group. In study BCIRG006, the incidence of allergic reactions according to the NCI-CTC v 2.0 classification was 9.4%, 12.3% and 14.9% in AC \rightarrow T, AC \rightarrow TH and TCH arms, respectively.

Among women receiving trastuzumab for treatment of MBC in a randomized controlled clinical trial, the incidence of pulmonary toxicity was also increased in patients randomized to trastuzumab + chemotherapy compared with those randomized to chemotherapy alone (e.g. dyspnea 36.3% vs. 25.2%, lung disorder 8.1% vs. 4.8%, lung edema 0.4% vs. 0%, pleural effusion 6.4% vs. 3.9%).

In the post-marketing setting, severe hypersensitivity reactions (including anaphylaxis), infusion reactions, and pulmonary adverse events have been reported. These events include anaphylaxis, angioedema, bronchospasm, hypotension, hypoxia, dyspnea, lung infiltrates, pleural effusions, non-cardiogenic pulmonary edema, and acute respiratory distress syndrome (see **7 WARNINGS AND PRECAUTIONS**).

Thrombosis/Embolism

In study BCIRG-006, the incidence of all grades thrombosis/embolism according to the NCI- CTC v 2.0 classification was higher in patients receiving trastuzumab in combination with docetaxel and carboplatin (TCH) (3.2%) compared to the AC \rightarrow TH group (2.0%) and AC \rightarrow T group (1.7%). The incidence of thrombosis/embolism, grade 3 (deep vein thrombosis, requiring anticoagulant) and grade 4 (embolic event including pulmonary embolism) combined, was higher in patients receiving trastuzumab in combination with docetaxel and carboplatin (TCH) (2.7%) compared to the AC \rightarrow TH group (1.8%) and AC \rightarrow T group (1.5%).

In study B-31, thrombosis/embolism (all grades) was reported in 3.8% of patients randomized to trastuzumab + chemotherapy versus 2.7% of patients randomized to the chemotherapy alone arm. In study N9831, thrombosis/embolism (all grades) was reported in 1.9% of patients randomized to trastuzumab + chemotherapy versus 2.9% of patients randomized to chemotherapy alone.

The incidence of thrombotic adverse events was also higher in patients receiving trastuzumab and chemotherapy compared to chemotherapy alone in a randomized clinical trial in MBC setting (2.1% vs. 0%).

Diarrhea

Among women receiving adjuvant therapy for breast cancer, the incidence of NCI-CTC (v 2.0) Grade 3-5 diarrhea (2.5% vs. 2.6% [B-31]) and of NCI-CTC Grade 3-5 diarrhea (3.4% vs. 0.7% [N9831]), and of Grade 1-4 diarrhea (7% vs. 1% [HERA]) were commonly higher in patients receiving trastuzumab as compared to controls. In BCIRG006 study, the incidence of Grade 3-4 diarrhea was higher [5.6% AC-TH, 5.4% TCH vs. 3.1% AC-T] and of Grade 1-4 was higher [51% AC-TH, 63% TCH vs. 43% AC-T] among women receiving trastuzumab.

Of patients treated with trastuzumab as a single agent for the treatment of MBC, 25% experienced diarrhea. An increased incidence of diarrhea, primarily mild to moderate in severity, was observed in patients receiving trastuzumab in combination with chemotherapy.

In the ToGA (BO18255) study in MGC, 109 patients (37%) participating in the trastuzumab - containing treatment arm versus 80 patients (28%) in the comparator arm experienced any grade diarrhea. Using NCI-CTCAE v3.0 severity criteria, the percentage of patients experiencing grade \geq 3 diarrhea was 4% in the FP arm vs. 9% in the FP+H arm.

Hepatic and Renal Toxicity

In a randomized controlled clinical trial in MBC, WHO Grade 3 or 4ⁱⁱⁱ hepatic toxicity was observed in 6% of patients treated with trastuzumab and an anthracycline plus cyclophosphamide compared with an incidence of 8% in patients treated with anthracycline/cyclophosphamide combination without trastuzumab. Hepatic toxicity was less frequently observed among patients receiving trastuzumab and paclitaxel than among patients receiving paclitaxel (7% vs. 15%).

ⁱⁱⁱ WHO Grade 3 Hepatic Toxicity: Bilirubin – 5.1-10 x N, Transaminases (ASAT/ALAT) – 5.1-10 x N, Alkaline Phosphatase – 5.1-10 x N, where N is the upper limit of normal of population under study.

WHO Grade 4 Hepatic Toxicity: Bilirubin $->10 \times N$, Transaminases (ASAT/ALAT) $->10 \times N$, Alkaline Phosphatase $->10 \times N$, where N is the upper limit of normal of population under study.

WHO Grade 3 or 4 hepatic toxicity was observed in 12% of patients following administration of trastuzumab as a single agent. This toxicity was associated with progression of disease in the liver in 60% of these patients.

The toxicity grading scale used for HERA, NSABP B-31, NCCTG N9831, and BCIRG-006 studies in the adjuvant treatment of EBC was the NCI-CTC v 2.0. The definitions for grade 3 and 4 elevations of serum creatinine were: grade 3 (> 3.0 to 6.0 X ULN) and grade 4 (> 6.0 X ULN).

The frequencies of grade 3-4 elevated serum creatinine reported in each study are shown, by treatment arm in **Table 22**.

Table 22 - Frequencies of Grade 3-4 Elevated Serum Creatinine in Studies of the Adjuvant Treatment	
of Early Breast Cancer	

Study	Treatment Arm		Grade 3-4 Seru	um Creatinine Elevation
	Regimen	Ν	N	%
HERA	observation only	1708	0	0.0
	1-year trastuzumab	1678	0	0.0

Study	Treatment Arm		Grade 3-4 Serum Creatinine Elevation	
	Regimen	N	N	%
NSABP B-31	AC→T	885	1	0.1
	AC→TH	1030	0	0.0
NCCTG N9831	AC→T	766	0	0.0
	AC→TH	969	0	0.0
BCIRG-006	AC→T	1041	6	0.6
	AC→TH	1077	3	0.3
	ТСН	1056	1	0.1

A higher incidence of renal impairment (13% in the FP arm vs. 16% in the FP+H arm) and toxic nephropathy (4% in the FP arm vs. 6% in the FP+H arm) was reported in the ToGA (BO18255) trial in MGC using NCI-CTCAE (v 3.0) criteria. Grade \geq 3 renal toxicity was higher in patients receiving trastuzumab than those in the chemotherapy alone arm (3% and 2% respectively).

NCI-CTCAE (v 3.0) grade \geq 3 adverse events in the Hepatobiliary Disorders SOC: Hyperbilirubinaemia was reported in 1% of patients receiving trastuzumab compared to < 1% in patients in the chemotherapy alone arm.

Blood and Lymphatic System Disorders

In the ToGA (BO18255) study in MGC, the total percentages of patients who experienced an AE of \geq grade 3 NCI-CTC AE v3.0 categorised under the SOC of Blood and Lymphatic System Disorders were 38% in the FP arm and 40% in the FP + H arm.

Table 23 - Blood and Lymphatic System Disorders SOC:The Most Frequently Reported AEs of Grade \geq 3 with Incidence Rate \geq 1%

	FP/Cisplatin (N = 290) (% of patients in each treatment arm)	Trastuzumab/FP/Cisplatin (N = 294) (% of patients in each treatment arm)
Neutropenia	30%	27%
Anaemia	10%	12%
Febrile Neutropenia	3%	5%
Thrombocytopenia	3%	5%
Leukopenia	<1%	2%

8.3 Less Common Clinical Trial Adverse Reactions

Early Breast Cancer (EBC)

Listing of Adverse Events with Incidence Rate of <1% in Study B-31 (Final analysis after median follow-up of 8.1 years in the AC – T+H group)

Allergy/immunology: allergy-other, autoimmune reaction

Auditory/hearing: hearing-other, inner ear/hearing, middle ear/hearing

Blood/bone marrow: hematologic-other, hemolysis, transfusion: platelets, transfusion: pRBC (packed red blood cells)

Cardiovascular (arrhythmia): arrythmia-other, nodal/junctional arrythmia/dysrhythmia, palpitations, sinus tachycardia, supraventricular arrhythmias*, vasovagal episode, ventricular arrhythmia,

Cardiovascular (general): cardiac troponin I (cTnI), cardiac-ischemia/infarction*, circulatory or cardiac-other, hypotension, pericardial effusion/pericarditis, peripheral arterial ischemia, phlebitis (superficial), visceral arterial ischemia (non-myocardial),

Coagulation: coagulation-other, prothrombin time (PT)

Constitutional symptoms: constitutional symptoms-other, rigors/chills*, weight loss **Dermatology/skin:** bruising (in absence of thrombocytopenia), dermatitis, dry skin, erythema multiforme, flushing, hand-foot skin reaction, injection site reaction, pigmentation changes, urticaria (hives, welts, wheals), wound non-infectious

Endocrine: endocrine-other, feminization of male, hypothyroidism, syndrome of inappropriate anti-diuretic hormone (SIADH)

Gastrointestinal: colitis, duodenal ulcer, dysphagia, dysphagia-esophageal, flatulence, gastric ulcer, gastritis, mouth dryness, mucositis due to radiation, pancreatitis, proctitis, salivary gland changes, sense of smell

Hemorrhage: CNS hemorrhage/bleeding, epistaxis, hematuria*, hemorrhage/bleeding without thrombocytopenia, melena/GI bleeding, petechiae/purpura, rectal bleeding/hematochezia, **Hepatic:** alkaline phosphatase*, bilirubin*, GGT (gamma-glutamyl transpeptidase), hepatic

enlargement, hepatic- other, hypoalbuminemia

Infection/febrile neutropenia: catheter-related infection

Lymphatics: lymphatics-other

Metabolic/laboratory: amylase, CPK (creatinine phosphokinase), hypocalcemia, hypokalemia, hypercholesterolemia, hyperkalemia, hypertriglyceridemia, hypomagnesemia, hyponatremia, hypophosphatemia,lipase, metabolic-other

Musculoskeletal: arthritis, muscle weakness, osteonecrosis

Neurology: arachnoiditis/meningismus/radiculitis, CNS cerebrovascular ischemia*, confusion, cognitive disturbance/learning problems, delusions, depressed level of consciousness,

extrapyramidal/involuntary movement/, restlessness, leukoencephalopathy, memory loss, neurologic-other, neuropathy-cranial, personality/behavioral, seizure(s), speech impairment, tremor, vertigo

Not coded: raw term unknown

Ocular/visual: cataract, glaucoma, conjunctivitis, ocular-other, vision-double vision (diplopia), vision-flashing lights/floaters, vision-photophobia

Pain: dysmenorrhea, dyspareunia, earache (otalgia), pain due to radiation, pelvic pain, pleuritic pain, rectal or perirectal pain (proctalgia), tumour pain

Pulmonary: acute respiratory distress syndrome (ARDS), hypoxia, pleural effusion (nonmalignant), pneumonitis/pulmonary infiltrates, pneumothorax, pulmonary fibrosis, voice changes/stridor/larynx

Radiation morbidity: radiation-other

Renal/genitourinary: bladder spasms, creatinine, incontinence, proteinuria, renal failure, renal/genitourinary-other, ureteral obstruction

Sexual/reproductive function: libido, sexual/reproductive function-other *AE term is itemized on the AE CRF.

Listing of Adverse Events with Incidence Rate of <1% in Study N9831 (Final analysis after median follow-up of 8.1 years in the AC – T+H group)

Auditory/hearing: inner ear/hearing

Blood/bone marrow: bone marrow cellularity, hemoglobin (HGB)*, platelets*, transfusion: platelets, transfusion: pRBCS (packed red blood cells)

Cardiovascular (arrhythmia): arrythmia-other, sinus bradycardia, sinus tachycardia, supraventricular arrhythmias, vasovagal episode, ventricular arrhythmia

Cardiovascular (general): circulatory or cardiac-other, hypotension, pericardial effusion/pericarditis, phlebitis (superficial), visceral arterial ischemia (non-myocardial)

Constitutional symptoms: fever (in the absence of neutropenia), rigors/chills, weight gain, weight loss **Dermatology/skin:** dermatitis, erythema multiforme, hand-foot skin reaction, injection site reaction, photosensitivity, radiation dermatitis, rash/desquamation, skin other, wound-infectious

Endocrine: endocrine-other, hypothyroidism, syndrome of inappropriate anti-diuretic hormone (SIADH) **Gastrointestinal:** anorexia, colitis, constipation, dehydration, diarrhea with prior colostomy*, dyspepsia, GI-other, ileus, stomatitis/pharyngitis*

Hemorrhage: CNS hemorrhage/bleeding, hemorrhage/bleeding with thrombocytopenia

Hepatic: SGOT (AST) (serum glutamic oxaloacetic transaminase), SGPT (ALT) serum glutamic pyruvic transaminase

Lymphatics: lymphatics*

Metabolic/laboratory: hypoglycemia, hypokalemia, hyponatremia

Musculoskeletal: arthritis

Neurology: ataxia (incoordination), CNS cerebrovascular ischemia, confusion, dizziness/lightheadedness, hallucinations, insomnia, memory loss, mood alteration-anxiety/agitation, mood alteration-depression, speech impairment, syncope (fainting)

Ocular/visual: conjunctivitis

Pain: abdominal pain or cramping, bone pain, dyspareunia, headache, neuropathic pain, pain-other, pleuritic pain

Pulmonary: acute respiratory distress syndrome (ARDS), apnea, cough, FEV1, hypoxia, pleural effusion (non- malignant), pulmonary fibrosis, pulmonary-other

Renal/genitourinary: dysuria (painful urination), fistula or genitourinary fistula, renal failure,

renal/genitourinary- other, urinary frequency/urgency

Sexual/reproductive function: irregular menses (change from baseline)

*AE term is itemized on the AE CRF.

Listing of Adverse Events with Incidence Rate of <1% in Study BCIRG-006 (5 Year Follow UP) According to NCI-CTC Classification v 2.0

Allergy/immunology: vasculitis

Auditory/hearing: external auditory canal

Blood/bone marrow: leukocytes (total WBC), platelets, transfusion: platelets, transfusion: pRBCS (packed red blood cells)

Cardiovascular (general): CNS cerebrovascular ischemia, hypertension, hypotension, phlebitis (superficial), thrombosis/embolism, cardiac- ischemia/infarction, edema, myocarditis

Cardiovascular (arrhythmia): sinus tachycardia, vasovagal episode, conduction abnormality/

atrioventricular heart block, sinus bradycardia, ventricular arrhythmia

(PVCs/bigeminy/trigeminy/ventricular tachycardia)

Dermatology/skin: photosensitivity, radiation recall reaction (reaction following chemotherapy in the absence of additional radiation therapy that occurs in a previous radiation port), urticaria (hives, welts, wheals).

Gastrointestinal: colitis, duodenal ulcer (requires radiographic or endoscopic documentation), dysphagia- esophageal related to radiation, gastric ulcer (requires radiographic or endoscopic documentation), dyspepsia/heartburn

Hemorrhage: hematemesis, hematuria (in the absence of vaginal bleeding), hemoptysis, hemorrhage/bleeding without grade 3 or 4 thrombocytopenia, melena/GI bleeding, petechiae/purpura (hemorrhage/bleeding into skin or mucosa)

Hepatic: alkaline phosphatase, bilirubin, GGT (gamma - glutamyl transpeptidase), hepatic pain, hypoalbuminemia, SGOT (AST) (serum glutamic oxaloacetic transaminase), SGPT (ALT) (serum glutamic pyruvic transaminase)

Endocrine: cushingoid appearance (e.g., moon face with or without buffalo hump, centripetal obesity, cutaneous striae), hypothyroidism

Metabolic/laboratory: hypercalcemia, hypercholesterolemia, hyperkalemia, hypernatremia, hypertriglyceridemia, hyperuricemia, hypocalcemia, hypoglycemia, hyponatremia

Musculoskeletal: arthritis, myositis (inflammation/damage of muscle)

Neurology: arachnoiditis/meningismus/radiculitis, ataxia (incoordination), depressed level of consciousness, extrapyramidal/involuntary movement/ restlessness, hallucinations, mood alteration-euphoria, neuropathy-cranial, personality/behavioral, seizure(s), speech impairment (e.g., dysphasia or aphasia)

Ocular/visual: cataract, glaucoma, middle ear/hearing, vision- double vision (diplopia), vision- flashing lights/floaters, vision- night blindness (nyctalopia), vision-photophobia

Pain: dysmenorrhea, dyspareunia, pain due to radiation, pelvic pain, pleuritic pain, pain due to radiation, rectal or perirectal pain (proctalgia), chest pain (non-cardiac and non-pleuritic)
Pulmonary: apnea, FEV1, hiccoughs (hiccups, singultus), pleural effusion (non-malignant), pulmonary fibrosis, pneumonitis/pulmonary infiltrates, pneumothorax, dyspnea (shortness of breath)
Renal/genitourinary: bladder spasms, creatinine, proteinuria, renal failure, urinary retention, urine color change (not related to other dietary or physiologic cause e.g., bilirubin, concentrated urine, hematuria)

Listing of Adverse Event with Incidence Rate of <1% in Study BCIRG-006 (5 Year Follow Up) According to COSTART Classification

Body as a whole: abdomen enlarged, abdominal pain, abscess, aggravation reaction, allergic reaction, ascites, asthenia, body odor, cellulitis, chest pain substernal, chills, collagen disorder, granuloma, halitosis, headache, hernia, hormone level altered, hydrocephalus, hypothermia, immune system disorder, infection, infection fungal, infection parasitic, injection site edema, injection site hemorrhage, injection site inflammation, injection site reaction, lab test abnormal, malaise, mucous membrane disorder, neck rigidity, necrosis, neoplasm, pelvic pain, peritonitis, photosensitivity reaction, radiation injury, rheumatoid arthritis, scleroderma, viral infection

Cardiac adverse events (body as a whole): chest pain substernal, face edema, pain, angina pectoris **Cardiovascular system:** aortic stenosis, aphthous stomatitis, arrhythmia, arteriosclerosis, bigeminy, bradycardia, bundle branch block, cardiomyopathy, cardiospasm, cardiovascular disorder, carotid occlusion, cerebrovascular accident, cheilitis, congestive heart failure, coronary artery disorder, coronary occlusion, dyspnea, electrocardiogram abnormal, endocarditis, extrasystoles, heart arrest, heart failure, heart malformation, hyperkinesia, hyperlipemia, hypokinesia, hypotension, hypertonia, left heart failure, myocardial ischemia, pallor, palpitation, pericarditis, peripheral vascular disorder, spider angioma, supraventricular extrasystoles, supraventricular tachycardia, syncope, T inverted, tachycardia, thrombophlebitis, varicose vein, vascular anomaly, vascular disorder, venous pressure increased, ventricular extrasystoles, peripheral edema

Digestive system: cholecystitis, cholelithiasis, cirrhosis of liver, colitis, constipation, diarrhea, dysphagia, eructation, esophageal hemorrhage, fecal incontinence, gamma glutamyl transpeptidase increased, gastritis, gastroenteritis, gastrointestinal disorder, gastrointestinal hemorrhage, gingivitis, glossitis, hepatitis, hepatomegaly, increased appetite, jaundice, liver function tests abnormal, liver necrosis, liver

tenderness, melena, mouth ulceration, nausea, oral moniliasis, perforated stomach ulcer, periodontal abscess, proctitis, rectal hemorrhage, sialadenitis, stomach atony, stomatitis, tongue discoloration, tongue disorder, tongue edema, tooth disorder, tooth malformation, vomiting

Endocrine system: diabetes mellitus, endocrine disorder, goiter, hyperthyroidism, thyroid disorder **Hemic and lymphatic system:** aplastic anemia, ecchymosis, hemolysis, hypochromic anemia, leukopenia, lymphadenopathy, macrocytic anemia, myeloproliferative disorder, pancytopenia, petechia, purpura, thrombocytopenia

Metabolic and nutritional disorders: acidosis, albuminuria, bun increased, electrolyte abnormality, enzymatic abnormality, generalized edema, healing abnormal, hypercalcemia, hypercholesteremia, hyperlipemia, hypoglycemia, hypophosphatemia, hypoproteinemia, hypovolemia, lactic dehydrogenase increased, liver fatty deposit, respiratory alkalosis, thirst, uremia, weight loss

Musculoskeletal system: arthritis, arthrosis, bone disorder, bone pain, bursitis, generalized spasm, myalgia, myasthenia, myositis, osteomyelitis, tendinous contracture, tenosynovitis

Nervous system: abnormal dreams, abnormal gait, agitation, amnesia, anxiety, ataxia, CNS stimulation, coma, delirium, depression, dizziness, dry mouth, dysautonomia, emotional liability, facial paralysis, grand mal convulsion, hyperesthesia, hyperkinesia, hypesthesia, hypokinesia, ileus, incoordination, increased salivation, myelitis, myoclonus, nervousness, neuralgia, nystagmus, paresthesia, peripheral neuritis, reflexes decreased, somnolence, thinking abnormal, tremor, trismus, vasodilatation, apnea **Respiratory system:** asthma, atelectasis, bronchitis, cough increased, dyspnea, hemoptysis, hiccup, hyperventilation, hypoxia, laryngismus, laryngitis, larynx edema, lung disorder, lung edema, lung fibrosis, pleural disorder, pneumonia, pneumothorax, respiratory disorder, sputum increased, application site reaction

Skin and appendages: dry skin, eczema, erythema multiforme, exfoliative dermatitis, fungal dermatitis, furunculosis, hair disorder, herpes zoster, hirsutism, ichthyosis, maculopapular rash, psoriasis, pustular rash, skin benign neoplasm, skin carcinoma, skin discoloration, skin granuloma, skin hypertrophy, skin nodule, skin ulcer, sweating, vesiculobullous rash

Special senses: abnormality of accommodation, blepharitis, blindness, conjunctival edema, corneal lesion, deafness, ear disorder, extraocular palsy, eye disorder, eye hemorrhage, glaucoma, keratitis, lacrimation disorder, mydriasis, ophthalmitis, otitis media, parosmia, ptosis, pupillary disorder, refraction disorder, retinal vascular disorder, taste loss, taste perversion, tinnitus, vestibular disorder, vitreous disorder

Urogenital system: amenorrhea, breast carcinoma, breast enlargement, breast neoplasm, cervix disorder, cervix neoplasm, cystitis, dysmenorrhea, dyspareunia, dysuria, endometrial disorder, endometrial hyperplasia, female lactation, genital edema, kidney function abnormal, kidney pain, mastitis, menopause, menorrhagia, menstrual disorder, metrorrhagia, nocturia, oliguria, ovarian disorder, polyuria, ruptured uterus, toxic nephropathy, unintended pregnancy, urethritis, urinary frequency, urinary incontinence, urinary tract disorder, urinary tract infection, urine abnormality, uterine disorder, uterine fibroids enlarged, uterine hemorrhage, uterine neoplasm, vaginal hemorrhage, vaginal moniliasis, vaginitis, vulvovaginal disorder, vulvovaginitis

Metastatic Gastric Cancer (MGC)

Listing of Adverse Drug Reactions with Incidence Rate <1% in ToGA (BO18255)

Cardiac disorders: arrhythmia, atrial fibrillation, atrial flutter, bradycardia, cardiac failure, left ventricular dysfunction

Eye disorders: dry eye

Gastrointestinal disorders: abdominal pain lower, haemorrhoidal haemorrhage, lip swelling, pancreatitis acute

General disorders and administration site conditions: influenza like illness, mucous **membrane disorder Hepatobiliary disorders:** hepatic failure, hepatitis toxic, hepatotoxicity, jaundice

Infections and infestations: bronchitis, cellulitis, herpes zoster, lower respiratory tract infection, lung infection, neutropenic sepsis, paronychia, rhinitis, sepsis, sinusitis, urinary tract infection **Investigations:** alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood lactate dehydrogenase increased,

Blood potassium increased, blood pressure decreased, ejection fraction decreased, gammaglutamyltransferase increased, transaminases increased, white blood cell count decreased

Metabolism and nutrition disorders: decreased appetite, fluid retention

Musculoskeletal and connective tissue disorders: arthritis, joint swelling

Nervous system disorders: neurotoxicity, paresis, somnolence, toxic neuropathy **Renal and urinary disorders:** renal disorder

Respiratory, thoracic and mediastinal disorders: acute respiratory distress syndrome, hypoxia, pharyngeal edema, pleural effusion, pneumonitis

Skin and subcutaneous tissue disorders: acne, dermatitis, erythema, hyperhidrosis, rash macular, rash papular, rash pruritic

8.5 Post-Market Adverse Reactions

	Adverse reaction
nfections and infestations	Cystitis
	Neutropenic sepsis
Blood and lymphatic system disorders	Hypoprothrombinemia
	Immune thrombocytopenia
Immune system disorders	Anaphylactoid reaction
	Anaphylactic reaction
	Anaphylactic shock
Metabolism and nutrition disorders	Tumour lysis syndrome
Eye disorders	Madarosis
Cardiac disorders	Cardiogenic shock
	Tachycardia
	Pericardial effusion
Respiratory, thoracic and mediastinal disorders	Bronchospasm
	Oxygen saturation decreased
	Respiratory failure
	Interstitial lung disease
	Lung infiltration
	Acute respiratory distress syndrome
	Respiratory distress
	Pulmonary fibrosis
	Нурохіа
	Laryngeal oedema
Hepatobiliary disorders	Hepatocellular injury
Renal and urinary disorders	Glomerulonephropathy

Table 24 - Adverse Reactions Reported in the Post-Marketing Setting

System organ class	Adverse reaction
	Renal failure
Pregnancy, puerperium and perinatal	Pulmonary hypoplasia
conditions	Renal hypoplasia
	Oligohydramnios

Adverse Events

Table 25 below indicates adverse events that have been reported in patients who have received trastuzumab.

Table 25 - Adverse Events

System organ class	Adverse Event
Infections and infestations	Meningitis
	Bronchitis
Blood and lymphatic system disorders	Leukaemia
Nervous system disorders	Cerebrovascular disorder
	Lethargy
	Coma
Ear and labyrinth disorders	Vertigo
Respiratory, Thoracic and Mediastinal system	Hiccups
disorders	Dyspnoea exertional
Gastrointestinal system disorders	Gastritis
	Pancreatitis
Musculoskeletal and connective tissue disorders	Musculoskeletal pain
Renal and urinary disorders	Dysuria
Reproductive system and breast disorders	Breast pain
General disorders and administration site conditions	Chest discomfort

9 DRUG INTERACTIONS

9.2 Drug Interactions Overview

There have been no formal drug interaction studies performed with trastuzumab in humans. Strong evidence for clinically significant interactions with concomitant medications used in trastuzumab clinical studies has not been observed.

9.4 Drug-Drug Interactions

However, administration of paclitaxel in combination with trastuzumab resulted in a two-fold decrease in clearance of trastuzumab in a non-human primate study. In one trastuzumab clinical study, an apparent 1.5-fold increase in serum levels of trastuzumab was seen when trastuzumab was administered with paclitaxel. However, this observation could not be confirmed using a population pharmacokinetic approach (see **10 CLINICAL PHARMACOLOGY**: **10.3 Pharmacokinetics**).

A population pharmacokinetic method using data from phase I, phase II and pivotal phase III studies, was used to estimate the steady state pharmacokinetics in patients administered trastuzumab at a loading dose of 4 mg/kg followed by a 2 mg/kg maintenance dose administered weekly. The administration of concomitant chemotherapy (either anthracycline/ cyclophosphamide or paclitaxel) did not appear to influence the pharmacokinetics of trastuzumab. Experience from phase III clinical trials suggests that there is a potential drug interaction between trastuzumab and anthracycline chemotherapy. However, the clinical pharmacokinetic profile of doxorubicin or epirubicin in the presence of trastuzumab has not been described to date, and the exact nature of this potential interaction has yet to be described.

When using in combination with Perjeta (pertuzumab) and docetaxel, consult Product Monographs for Perjeta and docetaxel for further information on these drugs.

9.5 Drug-Food Interactions

Interactions with food have not been established.

9.6 Drug-Herb Interactions

Interactions with herbal products have not been established.

9.7 Drug-Laboratory Test Interactions

Interactions with laboratory tests have not been established.

10 CLINICAL PHARMACOLOGY

10.1 Mechanism of Action

Trastuzumab is a recombinant DNA-derived humanized monoclonal antibody that selectively targets the extracellular domain of the human epidermal growth factor receptor 2 protein (HER2). The antibody is an IgG1 isotype that contains human framework regions with complementarity-determining regions of a murine anti-p185 HER2 antibody that binds to human HER2.

The HER2 (or c-erbB2) proto-oncogene or c-erbB2 encodes for a single transmembrane spanning, receptor-like protein of 185 kDa, which is structurally related to the epidermal growth factor receptor. HER2 protein overexpression is observed in 25%-30% of primary breast cancers. Studies of HER2-positivity rates in gastric cancer (GC) using immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) or chromogenic in situ hybridization (CISH) have shown that there is a broad variation of HER2-positivity ranging from 6.8% to 34.0% for IHC and 7.1% to 42.6% for FISH A consequence of HER2 gene amplification is an increase in HER2 protein expression on the surface of these tumour cells, which results in a constitutively- activated HER2 protein. Studies indicate that patients whose tumours overexpress HER2 have a shortened disease-free survival compared to patients whose tumours do not overexpress HER2. HER2 protein overexpression can be determined using an immunohistochemistry-based assessment of fixed tumour blocks, ELISA techniques on tissue or serum samples or Fluorescence In Situ Hybridisation (FISH) technology. N.B., to date, only data derived from immunohistochemistry staining is relevant to treatment with trastuzumab (see **7 WARNINGS AND PRECAUTIONS**: <u>Selection of Patients / Diagnostic Tests</u>).

Trastuzumab has been shown, in both in vitro assays and in animals, to inhibit the proliferation of human tumour cells that overexpress HER2.

Trastuzumab is a mediator of antibody-dependent cell-mediated cytotoxicity (ADCC). In vitro, ADCC mediated by trastuzumab has been shown to be preferentially exerted on HER2 overexpressing cancer cells compared with cancer cells that do not overexpress HER2.

10.3 Pharmacokinetics

The pharmacokinetics of trastuzumab have been studied in breast cancer patients with metastatic disease. In phase I studies, short duration intravenous infusions of 10, 50, 100, 250 and 500 mg once weekly in patients demonstrated dose-dependent pharmacokinetics at doses below 100 mg. Mean half-lives increased and clearance decreased with increasing dose level. The half-life of trastuzumab averaged 1.7 and 12 days at the 10 and 500 mg dose levels, respectively.

Early Breast Cancer (EBC)/Metastatic Breast Cancer (MBC)

A population pharmacokinetic method, using data from phase I, phase II and pivotal phase III studies, was used to estimate the steady state pharmacokinetics in patients administered trastuzumab at a loading dose of 4 mg/kg followed by a weekly maintenance dose of 2 mg/kg. In this assessment, the typical clearance of trastuzumab was 0.225 L/day and the typical volume of distribution was 2.95 L, with a corresponding terminal half-life of 28.5 days (95% confidence interval, 25.5 - 32.8 days). The inter-patient variability in clearance and volume of distribution was 43% and 29% (co-efficient of variation), respectively. These values are lower than those estimated from the base model. Steady state weekly AUC of 578 mg•day/L, peak concentrations of 110 mg/L and trough concentrations of 66 mg/L should be reached by 143 days, or approximately 20 weeks. It should be noted that these values represent free and dimer complexes of trastuzumab as the assay utilized was unable to detect the trimer complex. Trastuzumab may persist in the circulation for approximately 24 weeks (range: 22-28 weeks, based on a 6-fold terminal elimination half-life value) (see **7 WARNINGS AND PRECAUTIONS**: **Cardiovascular, Cardiotoxicity**).

EBC patients administered an initial loading dose of 8 mg/kg followed by a three weekly maintenance dose of 6 mg/kg achieved steady state (see **Table 26** below). These concentrations were comparable to those reported previously in patients with MBC.

PK Parameter	Cycle 18 (trastuzumab 1-year arm)
	Mean ± SD (n)
Cmax (μg/mL)	225 ± 30 (30)
Concentration – Day 21* (µg/mL)	68.9 ± 14 (28)
Concentration – Day 42 (µg/mL)	30.7 ± 14 (28)
AUC0-21d (day•µg/mL)	2260 ± 340 (28)
AUC0-42d (day•µg/mL)	3270 ± 560 (28)
Half-life (day)	18.8 ± 7.2 (29)

Table 26 - Summary of Trastuzumab Pharmacokinetic Parameters for Patients Enrolled into the Trastuzumab 1-Year Treatment Group (Sampled PK Population)

*Day 21 concentration was calculated by linear interpolation from concentrations observed in patients on Days 14 and 28.

Detectable concentrations of the circulating extracellular domain of the HER2 receptor (shed antigen) are found in the serum of some patients with HER2- overexpressing tumours. Patients with higher baseline

shed antigen levels were more likely to have lower serum trough concentrations of trastuzumab, however, with weekly dosing, most patients with elevated shed antigen levels achieved target serum concentrations by week 6. Levels of shed antigen were only determined at baseline in the clinical trials. As a result, the available data are too limited to adequately characterize the interrelationship of HER2 overexpression and serum shed antigen concentrations.

Data suggest that the disposition of trastuzumab is not altered based on age or serum creatinine (up to 2.0 mg/dL or 176.8 μ mol/L). No formal interaction studies have been performed.

Metastatic Gastric Cancer (MGC)

A population pharmacokinetic method, using data from the Phase III study ToGA (BO18255), was used to estimate the steady state pharmacokinetics in patients with MGC administered trastuzumab 3-weekly at a loading dose of 8 mg/kg followed by a 3-weekly maintenance dose of 6 mg/kg. In this assessment, the typical clearance of trastuzumab was 0.378 L/day and the typical volume of distribution was 3.91 L, with a corresponding equilibrium half-life of 12.2 days. The median predicted steady-state AUC values (over a period of 3 weeks at steady state) is equal to 1030 mg•day/L, the median steady-state C_{max} is equal to 128 mg/L and the median steady-state C_{min} values is equal to 23 mg/L. Steady state concentrations should be reached by 49 days, (four equilibrium half-lives) or approximately 7 weeks.

Trastuzumab clearance in MGC patients is higher than that in MBC patients, leading to lower AUC, C_{max} and C_{min} at steady-state.

The estimated equilibrium half-life of trastuzumab was 12.2 days in the ToGA (BO18255) trial and 26.3 days for studies BO15935 and WO16229 (in MBC). The lower value in the ToGA (BO18255) trial was due to the increase in clearance in the MGC patients.

Special Populations and Conditions

Detailed pharmacokinetic studies in the elderly and those with renal or hepatic impairment have not been carried out.

11 STORAGE, STABILITY AND DISPOSAL

Unopened vials of Trazimera should be stored under refrigeration (2°C - 8°C) until expiry shown on the vial. Trazimera should be stored in the original package prior to use.

Unopened vials of Trazimera may be removed from refrigeration and stored up to 30°C for a single period of up to 3 months. Once removed from refrigeration and stored under these conditions, discard after 3 months. A date field is provided on the carton to record the discard date.

Store reconstituted Trazimera at 2°C - 8°C.

- If Trazimera is reconstituted with BWFI, discard unused Trazimera after 28 days.
- If Trazimera is reconstituted with SWFI, discard unused Trazimera after 48 hours.

The reconstituted solution should not be frozen.

Solutions for intravenous infusion are physicochemically compatible with polyvinylchloride, polyethylene, polypropylene, or ethylene vinyl acetate bags or glass IV bottles containing sodium chloride 9 mg/mL (0.9%) solution for injection. If reconstituted with BWFI, the solutions for intravenous infusion are stable for 24 hours at temperatures not exceeding 30°C; if reconstituted with SWFI, the infusion solutions are stable for 30 days at 2°C - 8°C and 24 hours at temperatures not exceeding 30°C.

From a microbiological point of view, the reconstituted solution (if SWFI is used) and infusion solution should be used immediately. The product is not intended to be stored after dilution unless this has taken place under controlled and validated aseptic conditions. If not used immediately, in-use storage times and conditions are the responsibility of the user.

12 SPECIAL HANDLING INSTRUCTIONS

Disposal of syringes/sharps

The following procedures should be strictly adhered to regarding the use and disposal of syringes and other medicinal sharps:

- Needles and syringes should never be reused.
- Place all used needles and syringes into a sharps container (puncture-proof disposable container).
- Dispose of the full container according to local requirements.

Disposal of unused/expired medicines

The release of pharmaceuticals in the environment should be minimized. Medicines should not be disposed of via wastewater and disposal through household waste should be avoided. Use established "collection systems", if available in your location. Local requirements should be followed for the disposal process of unused/expired medicines.

PART II: SCIENTIFIC INFORMATION

13 PHARMACEUTICAL INFORMATION

Drug Substance

Proper name: trastuzumab

Chemical name: humanized anti-HER2 monoclonal antibody

Molecular formula and molecular mass:

Trastuzumab is a humanized monoclonal antibody (mAB) directed against the human epidermal growth factor receptor 2 (HER2/neu receptor). Trastuzumab is a recombinant humanized IgG1 mAB that contains 2 heavy (H) chains, comprising 449 amino acids each (without the COOH-terminal lysine), and 2 kappa light (L) chains, each comprising 214 amino acids, which are disulfide-bonded to form a 4-chain molecule (H2L2) with a molecular weight of approximately 148 Kilodaltons (kDa).

Structural formula:

Light (L) Chain

1 DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPS	60
61 rfsgsrsgtdftltisslqpedfatyyC QQ HYTTPPT FGQGTKVEIKRTVAAPSVFIFPP	120
121 SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT	180
181 LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC H Chain	214
Heavy (H) Chain	
1 EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRY	60
$61 \underline{ADSVKG}$ RFTISADTSKNTAYLQMNSLRAEDTAVYYĊSRWGGDGFYAMDYWGQGTLVTVSS	120
121 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS	180
181 GLYSLSSVVTVPSSSLGTQTYIĊNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG L chain \leftarrow	240 C hain
241 PSVFLFP3KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY N	300
301 st yrvvsvltvlhodwlngkeykčkvsnkalpapiektiskakg oprepovytlppsree	360
361 MTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW	420
421 QQGNVFSCSVMHEALHNHYTQKSLSLSPG(K)	450

Product Characteristics:

Trazimera is humanized immunoglobulin G1 (IgG1) kappa monoclonal antibody (mAb) with two identical heavy (H) chains and two identical light (L) chains covalently linked with four inter-chain disulfide bonds. The humanized antibody against HER2 is produced by a recombinant mammalian cell (Chinese Hamster Ovary, CHO) cell culture process. Trazimera (trastuzumab) selectively binds with high affinity to extra cellular domain (ECD) of the human epidermal growth factor receptor 2 (HER2).

14 CLINICAL TRIALS

14.1 Efficacy and safety studies

Trial Design and Study Demographics

Clinical studies conducted to support similarity between Trazimera and the reference biologic drug Herceptin included the following:

- Study B3271001, a randomized, double-blind, parallel-group, single-dose study to compare the PK, safety and immunogenicity of Trazimera and Herceptin in healthy male subjects.
- Study B3271002, a randomized, double-blind, parallel-group, active-controlled study to compare the efficacy and safety of Trazimera and Herceptin in combination with paclitaxel in first-line treatment of patients with HER-2 positive metastatic breast cancer.
- Study B3271004, a supportive study to compare PK and safety (efficacy as secondary endpoints) of Trazimera and Herceptin in, combination with docetaxel and carboplatin, as neoadjuvant treatment in patients with HER2-positive early breast cancer.

An overview of the study designs and demographic characteristics of patients enrolled in each clinical study is presented in **Table 27**.

Table 27	- Summary	of trial	designs and	patient	demographics
----------	-----------	----------	-------------	---------	--------------

Study design	Dosage, route of administration and duration	Study subjects (n)	Mean age (Range)	Sex
Double blind, randomized, parallel-group, single-dose, 3- arm, comparative PK study of Trazimera and trastuzumab-US and trastuzumab-EU administered to healthy male volunteers	Trazimera: 6 mg/kg as a 90-minute IV infusion.	105	Trazimera Ma 34.5 (18-55)	Male
	Trastuzumab-EU: 6 mg/kg as a 90-minute IV infusion.	-	Trastuzumab-EU 36.1 (21-55)	-
	Trastuzumab-US: 6 mg/kg as a 90-minute IV infusion.	-	Trastuzumab-US 35.3 (21-53)	-
Randomized, double-blind study of Trazimera plus paclitaxel versus trastuzumab-EU plus paclitaxel for the first-line treatment of patients with HER2-positive metastatic breast cancer.	Trazimera: Route: IV; Dose Regimen: loading dose: 4 mg/kg; subsequent weekly dose: 2 mg/kg until Week 33, then dosage may have changed to 6 mg/kg every 3 weeks after paclitaxel discontinuation.	707	Trazimera 54.0 (19 - 80)	Female
	Trastuzumab-EU Route: IV; Dose Regimen: loading dose: 4 mg/kg; subsequent weekly dose: 2 mg/kg until Week 33, then dosage may have changed to 6 mg/kg every 3 weeks after		Trastuzumab-EU 54.1 (25-85)	
	Double blind, randomized, parallel-group, single-dose, 3- arm, comparative PK study of Trazimera and trastuzumab-US and trastuzumab-EU administered to healthy male volunteers. Randomized, double-blind study of Trazimera plus paclitaxel versus trastuzumab-EU plus paclitaxel for the first-line treatment of patients with HER2-positive	Study designadministration and durationDouble blind, randomized, parallel-group, single-dose, 3- arm, comparative PK study of Trazimera and trastuzumab-US and trastuzumab-EU administered to healthy male volunteers.Trazimera: 6 mg/kg as a 90-minute IV infusion.Randomized, double-blind study of Trazimera plus paclitaxel versus trastuzumab-EU plus paclitaxel for the first-line treatment of patients with HER2-positive metastatic breast cancer.Trazimera: Route: IV; Dose Regimen: loading dose: 4 mg/kg; subsequent weekly dose: 2 mg/kg until Week 33, then dosage may have changed to 6 mg/kg subsequent weekly dose: 2 mg/kg until Week 33, then dosage may have changed to 6 mg/kg subsequent weekly dose: 2 mg/kg until Week 33, then dosage may have changed to 6 mg/kg subsequent weekly dose: 2 mg/kg until Week 33, then dosage may have changed to 6 mg/kg subsequent weekly dose: 2 mg/kg until Week 33, then dosage may have changed to 6 mg/kg subsequent weekly dose: 2 mg/kg until Week 33, then dosage may have changed to 6 mg/kg subsequent weekly dose: 2 mg/kg until Week 33, then dosage may have changed to	Study designadministration and durationsubjects (n)Double blind, randomized, parallel-group, single-dose, 3 arm, comparative PK study of Trazimera and trastuzumab-US and trastuzumab-EU administered to healthy male volunteers.Trazimera: 6 mg/kg as a 90-minute IV infusion.105Trastuzumab-EU: 6 mg/kg as a 90-minute IV infusion.Trastuzumab-EU: 6 mg/kg as a 90-minute IV infusion.105Randomized, double-blind study of Trazimera plus paclitaxel versus trastuzumab-EU plus paclitaxel for the first-line treatment of patients with HER2-positive metastatic breast cancer.Trazimera: Route: IV; Dose Regimen: loading dose: 4 mg/kg; subsequent weekly dose: 2 mg/kg until Week 33, then dosage may have changed to 6 mg/kg use: 4 mg/kg; subsequent weekly dose: 2 mg/kg until Week 33, then loading dose: 4 mg/kg; subsequent weekly dose: 2 mg/kg until Week 33, then 	Joury designadministration and durationsubjects (n)(Range)Double blind, randomized, parallel-group, single-dose, a arm, comparative PK study of Trazimera and trastuzumab-US and trastuzumab-EU administered to healthy male volunteers.Trazimera: 6 mg/kg as a 90-minute IV infusion.105Trazimera 34.5 (18-55)Trastuzumab-EU: 6 mg/kg as a 90-minute IV infusion.Trastuzumab-EU: 6 mg/kg as a 90-minute IV infusion.Trastuzumab-EU 36.1 (21-55)Randomized, double-blind study of Trazimera plus pacitazel versus trastuzumab-EU plus pacitazel for the first-line treatment of patients with HER2-positive metastatic breast cancer.Trazimera: Route: IV; Dose Regimen: loading dose: 4 mg/kg; subsequent weekly dose: 2 mg/kg until Week 33, then dosage may have changed to 6 mg/kg sos 33, then dosage may have changed to 6 mg/kg subsequent weekly dose: 2 mg/kg until Week 33, then dosage may have changed toTrasturamab-EU S4.1 (25-85)

B3271004	A double-blind, randomized, clinical trial evaluating the	Trazimera	226	Trazimera	Female
	PK, efficacy, safety, and immunogenicity of Trazimera in	Route: IV;		54.0	
	combination with docetaxel and carboplatin versus	Dose Regimen:		(26-77)	
	trastuzumab-EU in combination with docetaxel and	loading dose:			
	carboplatin in patients with operable HER2-positive	8 mg/kg; subsequent dosing			
	breast cancer in the neoadjuvant setting.	[every 3 weeks]: 6 mg/kg).			
		docetaxel and carboplatin			
		were administered every 3			
		weeks (ie, cycled every 21			
		days) for a total of 6			
		treatment cycles			
		Trastuzumab-EU		Trastuzumab-EU	_
		Route: IV;		51.2	
		Dose Regimen:		(24-79)	
		loading dose:			
		8 mg/kg; subsequent			
		dosing [every 3			
		weeks]: 6 mg/kg.			
		docetaxel and			
		carboplatin were			
		administered every 3			
		weeks (ie, cycled			
		every 21 days) for a			
		total of 6 treatment			
		cycles.			

The comparative clinical efficacy and safety study B3271002 was designed to rule out any clinically meaningful differences between Trazimera and trastuzumab-EU. The study included female patients with histologically confirmed diagnosis of metastatic breast cancer, who had not received prior systemic therapy in the metastatic disease setting, and who had HER2 gene amplification as confirmed by fluorescent in situ hybridization (FISH), or HER2-overexpression by immunohistochemistry (defined as IHC3+, or IHC2+ with FISH confirmation). Demographics were comparable in the Trazimera and trastuzumab-EU groups. The primary endpoint for this study was the Objective Response Rate (ORR) defined as the percentage of patients within each treatment group that achieved response, either complete response (CR) or partial response (PR), by Week 25 of the study (window ±14 days) and subsequently confirmed by Week 33.

14.2 Study Results

See 14.3 Comparative Bioavailability Studies.

Comparative Safety and Efficacy

Efficacy

Study B3271002

Results for the primary endpoint are shown in Table 28.

Table 28 - Analysis of Objective Response Rate Derived from Central Radiology Assessments - ITT Population (Study B3271002)

	Trazimera (N=352)	Trastuzumab-EU (N=355)	Risk Ratio ^a Estimate (95% Cl)
Objective Response Rate			
n (%)	220 (62.5)	236 (66.5)	0.940
(95% CI)	(57.2, 67.6)	(61.3, 71.4)	(0.842, 1.049) ^b

Abbreviations: CI = confidence interval; EU = European Union; ITT = intent-to-treat; n/N = number of patients with an objective response/total number of patients.

a. Risk Ratio and associated 95% CI were based on the Miettinen and Nurminen method.

b. The pre-defined equivalence interval was (0.80, 1.25).

Safety

The types, frequency and severity of adverse events were comparable between the biosimilar and the reference biologic drug.

14.3 Comparative Bioavailability Studies

14.3.1 Pharmacokinetics

Study B3271001

When comparing PK parameters of Trazimera versus trastuzumab (EU), comparability criteria were met for the PK parameters C_{max} and AUC_T as the point estimate for the C_{max} was 91.5%, and the 90% confidence intervals (CIs) for the geometric means for AUC_T were fully contained within the pre-defined bounds of 80.0% to 125.0% (See **Table 29**).

Trastuzumab From measured data Adjusted Geometric Mean							
Arithmetic Mean (CV %)* Parameter Test Reference % Ratio (Test/Reference) of Adjusted Geometric 90% Confidence Means Interval for Ratio							
	Trazimera	Trastuzumab-EU					
AUC⊤(µg•hr/mL)	35210	38000	92.66	(86.44, 99.34)			
AUC _{inf} (µg∙hr/mL)	36650	39770	92.15	(86.03, 98.69)			
С _{мах} (µg/mL)	157	171	91.49	(85.32, 98.09)			
AUC⊤ (µg∙hr/mL) *	35700 (18%)	38510 (17%)					
AUC _{inf} (µg•hr/mL) *	37130 (17%)	40330 (17%)					
C _{MAX} (µg/mL) *	158.8 (16%)	174.0 (18%)					
t _{1/2} (hr) *	213.1 (20%)	219.6 (19%)					
T _{max}	NA	NA	NA				

Table 29 - Analyses of PK Parameters (from measured data) in Study B3271001

Abbreviations: AUCinf = area under the concentration-time curve from time zero to infinity; AUCt = area under the concentration-time curve from time zero to time t; C_{MAX} = maximum observed concentration; CI = confidence interval; $t_{1/2}$ = half-life; T_{MAX} = time at which C_{MAX} is attained; EU = European Union

^aThe ratios (and 90% CIs) are expressed as percentages

14.4 Immunogenicity

Study B3271002

In Study B3271002, the immunogenicity of Trazimera and trastuzumab-EU was assessed in that serum samples collected for immunogenicity assessment (at baseline and at Day 1 of Cycles 3, 5, 8, every 3 cycles thereafter, and at the end of the treatment visit) were first tested for ADA against randomized drug. Samples reported positive for ADA were subsequently analyzed for ADA cross-reactivity and NAb, whereas samples reported negative for ADA were assigned to be negative for ADA cross-reactivity and NAb.

Among all patients who tested positive for ADAs at least once at any timepoint post-baseline regardless of the ADA result at baseline, 2 patients (1 each in the Trazimera group and the trastuzumab-EU group) were tested positive for ADA while on treatment; the overall ADA rate was 0.3% (1/349) in the Trazimera arm and 0.3% (1/353) in the trastuzumab-EU arm. Titers were low in both arms across all time points. However, at baseline, 44 metastatic breast cancer patients (30 in the Trazimera group and 14 in the trastuzumab-EU group) were tested positive for ADA. Of the 44 ADA-positive patients at Baseline, 20 patients in the Trazimera group and 9 patients in the trastuzumab-EU group were tested positive for NAb at baseline. Furthermore, 41 of the Baseline ADA-positive patients had post-treatment ADA samples tested. Of these, 1 patient in the Trazimera group had a positive post-treatment ADA and NAb tests at the end of treatment (EOT) visit. The baseline observation prior to study treatment may be related to a false positive rate of approximately 1% for the ADA assay.

The results demonstrate a low incidence of immunogenicity for Trazimera, which was comparable to that of trastuzumab-EU.

As with all therapeutic proteins, there is a potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay.

14.5 Clinical Trials - Reference Biologic Drug

The following descriptions are about the clinical trials conducted with HERCEPTIN, the reference biologic drug of TRAZIMERA:

Early Breast Cancer (EBC)

In the adjuvant treatment setting, trastuzumab was investigated in 4 large multicenter, randomised, trials:

- The HERA study was designed to compare one year of three-weekly trastuzumab treatment versus observation in patients with HER2 positive EBC following surgery, established chemotherapy and radiotherapy (if applicable).
- The NSAPB B31 and NCCTG N9831 studies that comprise the Joint Analysis were designed to investigate the clinical utility of combining trastuzumab treatment with paclitaxel following AC chemotherapy in HER2 positive EBC following surgery. Additionally, the NCCTG N9831 study investigated adding trastuzumab sequentially after AC-paclitaxel chemotherapy in patients with HER2 positive EBC following surgery.
- The BCIRG-006 study was designed to investigate combining trastuzumab treatment with docetaxel either following AC chemotherapy, or in combination with docetaxel and carboplatin in patients with HER2 positive EBC following surgery.

The comparative efficacy and safety between different chemotherapy regimens (i.e. concurrent versus sequential, anthracycline containing versus non-anthracycline containing) was not studied.

Eligible patients in the four studies included women with operable, non-metastatic adenocarcinoma of the breast whose tumours overexpressed HER2 and who had either node-positive or high-risk node-negative disease. Definitions used in each protocol are shown in **Table 30**.

STUDY	AJCC TNM Version	Т	Ν	Μ	Comment
HERA	Staging Manual 5 th edition (1997)	≥T1c, T2, T3, pT4	N0, N1, N2, N3	MO	Prior (neo)adjuvant chemotherapy required. Prior radiotherapy required for nodal (axillary, internal mammary) or pT4 disease.
NSABP B-31	Staging Manual 5 th edition (1997) <u>updated</u> <u>May 2003 to:</u> Staging Manual 6 th edition (2002)	clinical T1, T2, T3 <u>updated May 2003</u> <u>to:</u> T1, T2, T3 (clinical <u>and</u> pathologic)	cN0, cN1 <u>updated May 2003</u> <u>to</u> : cN0, cN1 <u>and</u> pN1, pN2a, pN3a	M0	No prior chemotherapy or radiotherapy permitted. Whole breast irradiation required during study; partial breast or internal mammary radiation prohibited.
NCCTG N9831	Staging Manual 5 th edition (1997)	T1, T2, T3 T1c (ER-/PR- only) T2, T3	pN1, pN2 (minimum 1/6 nodes) pN0 (minimum sentinel node or 1/6 nodes)	M0	No prior chemotherapy or radiotherapy permitted. Breast + regional lymphatic irradiation during study, per radiotherapist.
BCIRG-006	Staging Manual 5 th edition (1997) [not specified in protocol]	T1, T2, T3 ≥T2, or ER-/PR-, or nuclear Grade 2-3, or age <35 yrs	pN1, pN2 (minimum 1/6 nodes) pN0 (minimum sentinel node or 1/6 nodes)	M0	No prior chemotherapy or radiotherapy permitted. Breast + regional lymphatic irradiation during study, per radiotherapist.

Table 30 - Eligible Populations in EBC Studies, by TNM Categories^a

^a Required for all studies: (1) invasive adenocarcinoma on histologic examination; (2) complete excision of primary tumour with tumour-free margins on histologic examination of specimens from definitive surgery; and (3) HER2 positive tumour

<u>HERA</u>

In the adjuvant setting, trastuzumab was investigated in HERA, a multicentre, randomised, trial designed to compare one and two years of three-weekly Herceptin treatment versus observation in patients with HER2 positive EBC following surgery, established chemotherapy and radiotherapy (if applicable). In addition, a comparison of two years trastuzumab treatment versus one year trastuzumab treatment was performed, with the objective to assess the superiority of two years of trastuzumab treatment relative to one year of trastuzumab treatment. Breast tumour specimens were required to show HER2 overexpression (3+ by IHC) or gene amplification (by FISH) as determined at a central laboratory.

Patients assigned to receive trastuzumab were given an initial loading dose of 8 mg/kg, followed by 6 mg/kg every three weeks for either one or two years. One year of trastuzumab treatment was defined as 12 calendar months of treatment from day 1 of first administration and 18 infusions maximum. Two years of trastuzumab treatment were defined as 24 calendar months of treatment from day 1 of first administration and 35 infusions maximum.

The efficacy results from the HERA trial are summarized in **Table 31**. Please see **8 ADVERSE REACTIONS** and **7 WARNINGS AND PRECAUTIONS**: **Cardiovascular/Cardiotoxicity/Early Breast Cancer** for a summary of the HERA safety information.

	Median follow-up 12 months		Median f yea	ollow-up 8 rs
Parameter	Observation N=1693	Trastuzumab 1 Year N = 1693	Observation N=1697***	Trastuzumab 1 Year N=1702***
Disease-free survival (DFS)				
- No. patients with event	219 (12.9%)	127 (7.5%)	570 (33.6%)	471 (27.7%)
- No. patients without event P-	1474 (87.1%)	1566 (92.5%)	1127 (66.4%)	1231 (72.3%)
value versus Observation	<0	.0001		-
Hazard Ratio versus Observation	0).54	0.	76
Adjusted (99.9%) Confidence Interval****	(0.3	8, 0.78)		
Recurrence-free survival				
- No. patients with event	208 (12.3%)	113 (6.7%)	506 (29.8%)	399 (23.4%)
- No. patients without event	1485 (87.7%)	1580 (93.3%)	1191 (70.2%)	1303 (76.6%)
Hazard Ratio versus Observation		0.51	0.	73
Distant disease-free survival	104 (10 00()	00 (5.0%)	400 (20.0%)	200 (22 40/)
- No. patients with event	184 (10.9%)	99 (5.8%)	488 (28.8%)	399 (23.4%)
- No. patients without event	1508 (89.1%)	1594 (94.6%)	1209 (71.2%)	1303 (76.6%)
Hazard Ratio versus Observation	0.50 0.76		/6	
Overall survival (death)				
- No. patients with event	40 (2.4%)	31 (1.8%)	350 (20.6%)	278 (16.3%)
- No. patients without event	1653 (97.6%)	1662 (98.2%)	1347 (79.4%)	1424 (83.7%)
Hazard Ratio versus Observation).75	0.	76

Table	e 31 - Efficacy Results from the HERA Trial: Results at 12 months* an	nd 8 years** of median
	follow-up	

*Co-primary endpoint of DFS of 1 year vs observation met the pre-defined statistical boundary of 0.0010.

**Final analysis (including crossover of 52% of patients from the observation arm to trastuzumab).


***There is a discrepancy in the overall sample size due to a small number of patients who were randomized after the cut-off date for the 12-month median follow-up analysis.


**** Adjusted (both for the interim analysis and the 2 comparisons of each trastuzumab arm (1 year and 2 years) vs. observation) confidence interval presented, to reflect the stopping boundary of p≤ 0.0010 of the comparison Herceptin 1 year vs. observation. The interval represents the 99.9% confidence interval.

The efficacy results from the interim efficacy analysis crossed the protocol pre-specified statistical boundary of 0.0010 for the comparison of 1-year of trastuzumab vs. observation. After a median follow-up of 12 months, the hazard ratio (HR) for disease free survival (DFS) was 0.54 (adjusted 99.9% CI: 0.38, 0.78) which translates into an absolute benefit, in terms of a 2-year disease-free survival rate, of 7.6 percentage points (85.8% vs. 78.2%) in favour of the trastuzumab arm. Please see Figure 1.

A final analysis was performed after a median follow-up of 8 years, which showed that 1 year trastuzumab treatment is associated with a 24% risk reduction compared to observation only (HR = 0.76, unadjusted 95% CI: 0.67, 0.86). This translates into an absolute benefit in terms of an 8 year disease free survival rate of 6.4% in favour of 1 year trastuzumab treatment.

In this final analysis, superiority of 2 years trastuzumab treatment over 1 year trastuzumab treatment could not be demonstrated (DFS HR in the intent to treat (ITT) population of 2 years vs 1 year = 0.99 (unadjusted 95% CI: 0.87, 1.13), p-value = 0.90 and OS HR = 0.98 (unadjusted 95% CI: 0.83, 1.15); p-value = 0.78). The rate of secondary cardiac endpoints was increased in the 2-year treatment arm (8.1% vs 4.6% in the 1-year treatment arm). More patients experienced at least one grade 3 or 4 adverse event in the 2-year treatment arm (20.4%) compared with the 1- year treatment arm (16.3%).






*Adjusted (both for the interim analysis and the 2 comparisons of each trastuzumab arm (1 year and 2 years) vs. observation) confidence interval presented, to reflect the stopping boundary of $p \le 0.0010$ of the comparison trastuzumab 1 year vs. observation. The interval represents the 99.9% confidence interval.

The benefit in disease-free survival was seen in all subgroups analyzed (Please see Figure 2).


Figure 2 Risk Ratios and 95% Confidence Intervals for Disease-Free Survival (DFS) by Subgroup (After a Median Follow-up of 12 Months)




Note: 95%-Cls are not adjusted for multiple testing.

Twenty one (1.2%) patients in the trastuzumab arm and 16 (0.9) patients in the observation had CNS metastases as first site of relapse.





Note: 95%-Cl is not adjusted for multiple testing.



Note: 95%-Cl is not adjusted for multiple testing.

Joint Analysis: NSABP B-31 and NCCTG N9831

Two cooperative group trials, NSABP B-31 and NCCTG N9831, evaluated the efficacy of incorporating trastuzumab into standard adjuvant systemic therapy in women with early stage, HER2 positive breast cancer. Breast tumour specimens were required to show HER2 overexpression (3+ by IHC) or gene amplification (by FISH). HER2 testing was verified by a central laboratory prior to randomization (N9831) or was required to be performed at a reference laboratory (B-31). Patients were randomized to receive doxorubicin and cyclophosphamide followed by paclitaxel (AC \rightarrow T) or doxorubicin and cyclophosphamide followed by paclitaxel plus trastuzumab (AC \rightarrow T + H). In both trials patients received four cycles (3 weeks per cycle) of doxorubicin, at 60 mg/m2 IV push, concurrently with IV cyclophosphamide at 600 mg/m2 over 20–30 minutes. Paclitaxel was administered weekly (80 mg/m2) for a total of 12 weeks in NSABP B-31; paclitaxel was administered weekly (80 mg/m2) for 12 weeks in NCCTG N9831. Trastuzumab was administered at a loading dose of 4 mg/kg load followed by 2 mg/kg IV weekly. Trastuzumab commenced with paclitaxel and continued for a total of 52 weeks in both trials. Disease-free survival was the pre-specified primary endpoint of the combined efficacy analysis of these studies.

A total of 3752 patients were evaluable for analysis of efficacy at the time of the definitive disease-free survival analysis. Median follow-up from the time of randomization was 1.8 years for the chemotherapy alone arm and 2.0 years for the trastuzumab + chemotherapy arm for both studies combined. Efficacy results are presented in **Table 32** and **Figure 5**. For the primary endpoint, disease-free survival, addition of trastuzumab to chemotherapy reduced the risk of a first event by 52%. Please see **8 ADVERSE REACTIONS** and **7 WARNINGS AND PRECAUTIONS**:

Cardiovascular/Cardiotoxicity/Early Breast Cancer for a summary of the Joint Analysis safety information.

Table 32 - Joint Analysis: NSABP B-31 and NCCTG N9831 Efficacy Results at the Time of the Definitive Disease-Free Survival Analysis* (ITT population)

	AC→Tª n=1880	AC→T+Herceptin ^a n=1872		
	No. with Event	No. with Event	Hazard Ratio ^b (95% CI)	p-value ^c
Disease-free survival (DFS)	261	133	0.48 (0.39–0.59)	< 0.0001
Overall survival (OS)	92	62	0.67	NS ^d

CI = confidence interval.


Disease-free survival was defined as the time from randomization to recurrence, contralateral breast cancer or other second primary cancer, or death, whichever occurred first. Overall survival was defined as the time from randomization to death.

- * at median duration of follow up of 1.8 years for the patients in the AC→T arm and 2.0 years for patients in the AC→TH arm
- ^a NSABP B-31 and NCCTG N9831 regimens: doxorubicin and cyclophosphamide followed by paclitaxel (AC→T) or paclitaxel plus Herceptin (AC→TH).
- ^b Hazard ratio estimated by Cox regression stratified by clinical trial, intended paclitaxel schedule, number of positive nodes, and hormone receptor status.

^c stratified log-rank test.

^d NS=non-significant.

Figure 5 - Duration of Disease-Free Survival in Patients from the Joint Analysis: NSABP B-31 and NCCTG N9831



There were insufficient numbers of patients within each of the following subgroups to determine if the treatment effect was different from that of the overall patient population: Black, Hispanic, Asian/Pacific Islander patients, node-negative high-risk patients, and patients > 65 years of age.


The pre-planned final analysis of overall survival (OS) from the joint analysis of studies NSABP B-31 and NCCTG N9831 was performed when 707 deaths had occurred (median follow-up 8.3 years in the AC \rightarrow T+H group). Treatment with AC \rightarrow T+H resulted in a statistically significant improvement in OS compared with AC \rightarrow T (stratified HR=0.64; 95.1% CI [0.55, 0.74]; log-rank p-value < 0.0001); formal boundary for statistical significance p-value=0.0245). At 8 years, the survival rate was estimated to be 86.9% in the AC \rightarrow T+H arm and 79.4% in the AC \rightarrow T arm, an absolute benefit of 7.4% (refer to Figure 6).


The final OS results from the joint analysis of studies NSABP B-31 and NCCTG N9831 are summarized in **Table 33**.

Table 33 - Final Overall Survival Analysis from the Joint Analysis: NSABP B-31 and	NCCTG N9831

	AC→Tª	AC→T+Hª		
	n=2032	n=2031		
	No. with Event	No. with Event	Hazard Ratio (95.1% Cl)	p-value
Overall Survival	418 (20.6%)	289 (14.2%)	0.64 (0.55–0.74)	< 0.0001

^aNSABP B-31 and NCCTG N9831 regimens: doxorubicin and cyclophosphamide followed by paclitaxel (AC \rightarrow T) or paclitaxel plus trastuzumab (AC \rightarrow TH).





. .

Disease-Free Survival (DFS) analysis was also performed at the final analysis of OS from the joint analysis of studies NSABP B-31 and NCCTG N9831. The updated DFS analysis results showed a similar DFS benefit compared to the definitive primary DFS analysis.

BCIRG-006

In the BCIRG006 study, patients were randomized (1:1:1) to receive doxorubicin and cyclophosphamide followed by docetaxel (AC \rightarrow T), doxorubicin and cyclophosphamide followed by docetaxel plus trastuzumab (AC \rightarrow TH), or docetaxel and carboplatin plus trastuzumab (TCH). Trastuzumab was administered weekly (initial dose of 4 mg/kg followed by weekly dose of 2 mg/kg) concurrently with either T or TC, and then every 3 weeks (6 mg/kg) as monotherapy for a total of 52 weeks.

In the AC \rightarrow T arm, doxorubicin 60 mg/m2 IV was administered in combination with cyclophosphamide 600 mg/m2 IV on an every 3 week basis for 4 cycles followed by docetaxel 100 mg/m2 as 1 hour IV infusion on an every 3 week basis for 4 cycles.

In the AC→TH arm, every 3 weeks for four cycles, patients in the AC→TH arm received 60 mg/m2 doxorubicin as a 5- to 15-minute intravenous (IV) bolus injection followed by 600 mg/m2 IV cyclophosphamide as a 5- to 60-minute IV bolus injection. Three weeks after the last treatment with AC (i.e., on Day 1 of Cycle 5), a 4-mg/kg trastuzumab loading dose was administered as a 90-minute IV infusion. Beginning on Day 8 of Cycle 5, 2 mg/kg trastuzumab was administered as a 30-minute IV infusion every week. Docetaxel 100 mg/m² was administered as a 1-hour IV infusion every 3 weeks for four cycles, beginning on Day 2 of Cycle 5 and then on Day 1 of all subsequent cycles. Beginning 3 weeks after the last treatment with docetaxel, 6 mg/kg trastuzumab was administered as a 30-minute IV infusion every 3 weeks.

In the TCH arm, patients received a 4-mg/kg trastuzumab loading dose as a 90-minute IV infusion on Day 1 of Cycle 1. Beginning on Day 8 of Cycle 1, 2 mg/kg trastuzumab was administered as a 30-minute IV infusion every week. Every 3 weeks for six cycles, beginning on Day 2 of Cycle 1 and then on Day 1 of all subsequent cycles, 75 mg/m2 docetaxel was administered as a 1-hour IV infusion, followed by carboplatin at a target area under the concentration—time curve of 6 mg/mL/min as a 30- to 60-minute IV infusion (the dose of carboplatin was calculated using a modified Calvert formula). Beginning 3 weeks after the last treatment with chemotherapy, 6 mg/kg trastuzumab was administered as a 30minute IV infusion every 3 weeks.

Trastuzumab in combination with docetaxel and carboplatin (TCH) is a non-anthracycline containing regimen and therefore testing of this regimen in study BCIRG006 offered the possibility to evaluate formally a less cardiotoxic regimen for the adjuvant treatment of early stage HER2 positive breast cancer.

Breast tumour specimens were required to show HER2 gene amplification (FISH+ only) as determined at a central laboratory.

The efficacy results from the BCIRG006, the primary endpoint of disease-free survival and the secondary endpoint of overall survival, are summarized in the following tables:

Table 34. Overview of Efficacy Analyses BCIRG006 AC→T versus AC→TH

Parameter	AC→T (N=1073)	AC→TH (N=1074)	p-value vs AC→T (log-rank)	Hazard Ratio vs AC→T** (95% CI)
Disease-free survival No.	195	134	< 0.0001	0.61
patients with event				(0.44, 0.85)*
Overall survival	80	49	***	0.58
(Death)*** No.				(0.40, 0.83)

 $AC \rightarrow T$ = doxorubicin plus cyclophosphamide, followed by docetaxel; $AC \rightarrow TH$ = doxorubicin plus cyclophosphamide, followed by docetaxel plus trastuzumab; CI = confidence interval

*The 95% CI is the repeated confidence interval (RCI) adjusted by multiple interim looks.

** Hazard ratio was estimated by Cox regression stratified by number of positive nodes and hormonal receptor status.

***Secondary endpoint

Table 35.	Overview of Efficacy Analyses BCIRG006 AC→T versus TCH
-----------	--

Parameter	AC→T (N=1073)	TCH (N=1074)	p-value vs AC→T (log-rank)	Hazard Ratio vs AC→T** (95% CI)
Disease-free survival No. patients with event	195	145	0.0003	0.67 (0.49,0.92)*
Overall survival (Death)*** No. patients with event	80	56	***	0.66 (0.47, 0.93)

 $AC \rightarrow T = doxorubicin plus cyclophosphamide, followed by docetaxel; TCH = docetaxel, carboplatin and$


trastuzumab; CI = confidence interval

*The 95% CI is the repeated confidence interval (RCI) adjusted by multiple interim looks.

** Hazard ratio was estimated by Cox regression stratified by number of positive nodes and hormonal receptor status.

***Secondary endpoint

Figure 7 Duration of Disease-Free Survival in Patients from BCIRG-006



 $AC \rightarrow T =$ doxorubicin plus cyclophosphamide, followed by docetaxel $AC \rightarrow TH =$ doxorubicin plus cyclophosphamide, followed by docetaxel plus trastuzumab TCH = docetaxel, carboplatin and trastuzumab

Metastatic Breast Cancer (MBC)

The safety and efficacy of trastuzumab were studied in a multicentre, randomized, controlled clinical trial conducted in 469 patients with HER2- overexpressing MBC who had not been previously treated with chemotherapy for metastatic disease. Patients were eligible if they had 2+ or 3+ levels of overexpression (based on a 0 to 3+ scale) by immunohistochemical assessment of tumour tissue performed by a central testing lab. Eligible patients were randomized to receive chemotherapy alone or in combination with trastuzumab given intravenously as a 4 mg/kg loading dose followed by weekly doses of trastuzumab at 2 mg/kg. For those who had received prior anthracycline therapy in the adjuvant setting, chemotherapy consisted of paclitaxel (175 mg/m² over 3 hours every 21 days for at least six cycles); for all other patients, chemotherapy consisted of anthracycline plus cyclophosphamide (AC: doxorubicin 60 mg/m or epirubicin 75 mg/m² plus 600 mg/m² cyclophosphamide every 21 days for six cycles). Compared with patients in the AC subgroups (n=281), patients in the paclitaxel subgroups (n=188) were more likely to have had the following: poor prognostic factors (premenopausal status, estrogen or progesterone receptor negative tumours, positive lymph nodes), prior therapy (adjuvant chemotherapy, myeloablative chemotherapy, radiotherapy), and a shorter disease-free interval.

Compared with patients randomized to chemotherapy alone, the patients randomized to trastuzumab and chemotherapy experienced a significantly longer median time to disease progression, a higher overall response rate (ORR), a longer median duration of response, and a higher one-year survival rate. These treatment effects were observed both in patients who received Herceptin plus paclitaxel and in those who received Herceptin plus AC, however the magnitude of the effects was greater in the paclitaxel subgroup. The degree of HER2 overexpression was a predictor of treatment effect.

The results of the study are discussed in **Table 36**.

Table 36 - Phase III Clinical Efficacy in First-Line Treatment

	Combined R	esults	Paclitax	el Subgroup	AC Subgro	oup
	Trastuzumab + Chemotherapy (n=235)	Chemotherapy (n=234)	Trastuzumab + Paclitaxel (n=92)	Paclitaxel (n=96)	Trastuzumab + AC ^a (n=143)	AC (n=138)
Primary Endpoint						
Time to Progression ^{b,c}						
Median (months)	7.6	4.6	6.9	3.0	8.1	6.1
95% confidence interval	(7.0, 9.4)	(4.4, 5.4)	(5.3, 9.9)	(2.1, 4.3)	(7.3, 9.9)	(4.9, 7.1)
p-value	0.00	01	0.00	001	0.0	003
Secondary Endpoints						
Overall Response Rate ^b						
Rate (percent)	48	32	42	16	52	43
95% confidence interval	(42, 55)	(26, 38)	(32, 52)	(8, 23)	(44, 61)	(34, 51)
p-value	0.00	02	< 0.0	001	0.1	038
Duration of Response ^{b,c}						
Median (months)	9.3	5.9	11.0	4.4	9.1	6.5
95% confidence interval	(8.0, 11.0)	(5.5, 7.0)	(8.2, >19.8)	(3.9, 5.3)	(7.2, 11.0)	(5.8, 8.0)
p-value	0.0001		0.0001		0.0025	
1-Year Survival ^c						
Percent alive	78	67	72	60	83	72
p-value	0.008	30	0.09	75	0.0	415

^a AC = anthracycline (doxorubicin or epirubicin) and cyclophosphamide.

^b Assessed by an independent Response Evaluation Committee.

^c Kaplan-Meier Estimate

Trastuzumab was also studied as a single agent in a multicentre, open-label, single-arm clinical trial in patients with HER2- overexpressing metastatic breast cancer who had relapsed following one or two prior chemotherapy regimens for metastatic disease. Of 222 patients enrolled, 68% had received prior adjuvant chemotherapy, 32% had one and 68% had received two prior chemotherapy regimens for metastatic disease, and 26% had received prior myeloablative treatment with hematopoietic rescue. Patients were treated with a loading dose of 4 mg/kg IV followed by weekly doses of trastuzumab at 2 mg/kg. The ORR (complete response + partial response), as determined by an independent Response Evaluation Committee, was 15% (with 8 patients having a complete response and 26 patients with a partial response) with a median survival of 13 months. Complete responses were observed only in patients with disease limited to skin and lymph nodes. The degree of HER2 overexpression was a predictor of treatment effect.

For information on clinical studies with trastuzumab in combination with Perjeta (pertuzumab) and docetaxel, consult the Product Monograph for Perjeta.

Metastatic Gastric Cancer (MGC)

ToGA (BO18255)

Study ToGA (BO18255) was an open-label randomized multicentre, international Phase III study of trastuzumab in combination with a fluoropyrimidine (FP) and cisplatin versus chemotherapy alone in patients with inoperable locally advanced or recurrent and/or metastatic HER2 positive adenocarcinoma of the stomach or gastro-esophageal junction. Eligibility for inclusion required patients to be HER2 positive as determined by either HER2 protein overexpression (IHC) or HER2 gene amplification (FISH), performed by a central laboratory.

At the time of conducting the ToGA (BO18255) trial, the combination of 5-FU or capecitabine and cisplatin was considered to be a standard of care in Canada.

	FP/ Cisplatin (FP) N = 290	Trastuzumab/FP/ Cisplatin (H+FP) N = 294
Sex		
Male	218 (75%)	226 (77%)
Female	72 (25%)	68 (23%)
Race		
Black	2 (<1%)	1 (<1%)
Caucasian	105 (36%)	115 (39%)
Oriental	158 (54%)	151 (51%)
Other	25 (9%)	27 (9%)
Age in years		
Mean	58.5	59.4
SD	11.22	10.75
Median	59.0	61.0
Min-Max	21-82	23-83
Weight in kg		
Mean	63.17	62.08
SD	13.034	12.594

Table 37 - Summary of Demographic Data

	FP/ Cisplatin (FP) N = 290	Trastuzumab/FP/ Cisplatin (H+FP) N = 294
Median	60.30	61.45
Min-Max	28.0-105.0	35.0-110.0
Height in cm		
Mean	166.4	166.3
SD	8.85	8.26
Median	167.0	166.0
Min-Max	128-190	146-198

The efficacy results from the ToGA (BO18255) study are summarized in **Tables 37 - 39**. Patients were recruited to the trial who were previously untreated for HER2 positive inoperable locally advanced or recurrent and/or metastatic adenocarcinoma of the stomach or gastro-oesophageal junction not amenable to curative therapy. The primary endpoint was overall survival which was defined as the time from the date of randomization to the date of death from any cause. At the time of the analysis a total of 349 randomized patients had died: 182 patients (62.8%) in the control arm and 167 patients (56.8%) in the treatment arm. The majority of the deaths were due to events related to the underlying cancer.

The addition of trastuzumab to capecitabine/5-FU and cisplatin resulted in a clinically relevant and statistically significant improvement in the primary endpoint of overall survival (p = 0.0046, Log Rank test). The median survival time was 11.1 months with capecitabine/5-FU and cisplatin and 13.8 months with trastuzumab + capecitabine/5-FU and cisplatin. The risk of death was decreased by 26% (Hazard Ratio [HR] 0.74 95% CI [0.60-0.91]) for patients in the trastuzumab arm compared to the capecitabine/5-FU arm. The results are considered by the study's independent data monitoring committee as the definitive outcome of the study.

One year after the clinical cutoff date of the definitive efficacy and safety second interim analysis, updated overall survival analysis demonstrated that 446 patients had died: 225 patients (78%) in the control arm and 221 patients (75%) in the treatment arm. The majority of the deaths were due to events related to the underlying cancer. The median survival time was 11.7 months with capecitabine/5-FU and cisplatin and 13.1 months with trastuzumab + capecitabine/5-FU and cisplatin. The risk of death was decreased by 20% (Hazard Ratio [HR] 0.80 repeated CI [0.661, 0.978]) for patients in the trastuzumab arm compared to the capecitabine/5-FU and cisplatin arm (see **Table 38** and **Figure 8**).

Analysis		Survival, 1 months	HR	p-value	
Analysis	FP N=290	(H+FP) N=294	CI***		
2 nd Interim Efficacy and Safety Analysis*	11.1	13.8	0.74 (0.573, 0.950)	0.0046	
Updated OS Analysis**	11.7	13.1	0.80 (0.661, 0.978)	0.0215	

Table 38 - Summary	v of Overall Survival Results from St	udy ToGA (BO18255) Full Analysis Set

FP: Fluoropyrimidine/cisplatin

H+FP: trastuzumab + fluoropyrimidine/cisplatin

*The OS results presented in the first row of **Table 38** are the results from the second efficacy interim analysis (clinical data cutoff date: January 7, 2009). The OS results reviewed by the Independent Data Monitoring Committee (IDMC) from the second

interim analysis based on 348 deaths crossed the pre specified statistical boundary of 0.0188 (p=0.0048) and were the definitive outcome of study ToGA (BO18255).

The OS results presented in the second row of **Table 38 are the results from the updated OS analysis one year after the clinical cutoff date of the definitive efficacy and safety second interim analysis.

*** For the purposes of maintaining confidence intervals at an overall 95% level for the multiple looks at the survival data, repeated confidence intervals (RCIs) for the hazard ratio for OS were calculated.




Figure 8 Kaplan-Meier Curve for Overall Survival*

*The Kaplan-Meier curves for the OS are the results from the updated OS analysis one year after the clinical cutoff date of the definitive efficacy and safety second interim analysis.

In trial ToGA (BO18255), post hoc subgroup analyses indicate that a positive treatment effect was limited to tumours with higher levels of HER2 protein (IHC 2+ /FISH+ and IHC 3+). At the time of the second interim efficacy and safety analysis, the median overall survival for the high HER2 expressing group was 11.8 months versus 16 months, HR 0.65 (95% CI 0.51-0.83) (see **Table 39**).

			FP	-	H+FP				
Subgroup		Patients per group	N Events	Median time	Patients per group	N Events	Median time	HR	95% Cl for HR
All		290	182	11.1	294	167	13.8	0.74	[0.60; 0.91]
HER2 Results	FISH+/IHC0 or 1+	70	45	8.7	61	43	10.0	1.07	[0.70; 1.62]
	FISH- or + or no result/IHC2+ or 3+	218	136	11.8	228	120	16.0	0.65	[0.51; 0.83]

Table 39 - Overall Survival Results by HER2 Status – IHC 0, IHC 1+ versus IHC 3+, IHC 2+/FISH+ (Full Analysis Set)

A total of 233 patients [40%] received previous treatments for gastric cancer, which included adjuvant chemotherapy, radiotherapy, and/or surgery: 130 patients [44%] in the FP + H arm and 103 patients [36%] in the FP arm. A total of 351 patients [60%] did not receive previous treatments for gastric cancer. Of these, there were 164 patients [56%] in the FP + H arm and 187 patients [64%] in the FP arm (see **Table 40**).

Table 40 - Analysis Of Overall Survival By Prior Gastric Cancer Treatment: Full Analysis Set

	FP				H+FP		
	Patient per Group	Events	Median OS (mo)	Patient per Group	Events	Median OS (mo)	Hazard Ratio ^a (95% CI)
All	290	182	11.1	294	167	13.8	0.74 (0.60, 0.91)
Prior treatment for gastric cancer							
No	187	123	10.2	164	101	12.6	0.67 (0.51, 0.88)
Yes	103	59	13.5	130	66	14.6	0.88 (0.62, 1.25)

^a Relative to fluoropyrimidine/cisplatin; based on unstratified analysis.

The results for the primary endpoint of the study ToGA (BO18255), overall survival, were supported by the improvements in the secondary efficacy parameters of PFS, time to progression, overall response rate, and duration of response. At the time of the second interim efficacy and safety analysis, for the FP+ H arm versus the FP arm, median PFS was 6.7 months versus 5.5 months; median time to progression was 7.1 months versus 5.6 months; overall response rate was 47.3% (139/294) versus 34.5% (100/290); and median duration of response was 6.9 months versus 4.8 months.

15 MICROBIOLOGY

No microbiological information is required for this drug product.

16 NON-CLINICAL TOXICOLOGY

Reference Biologic Drug

General Toxicology: The trastuzumab toxicology program addressed issues of species specificity, chronic administration, coadministration with chemotherapeutic agents, manufacturing process optimization, and changes in formulation.

Trastuzumab is specific for the human p185HER2 receptor and does not bind the corresponding rodent receptor (p185neu). The in vitro tissue binding profile of trastuzumab to monkey tissues demonstrated that the monkey was an appropriate model for comprehensive toxicity testing.

Acute Toxicity Studies: In acute dose studies, trastuzumab was well tolerated and produced no evidence of systemic toxicity at any dose tested, including the highest dose that could be delivered of a 5 mg/mL formulation. Intravenous administration of trastuzumab as a single dose of 94 mg/kg (mice), or 47-50 mg/kg (monkeys), produced no findings of toxicologic significance in any parameter evaluated.

Bridging studies conducted in monkeys to evaluate the safety and pharmacokinetics of trastuzumab, produced by optimization of the manufacturing process including a cell line change (from H2 to H13), revealed no evidence of acute toxicity or changes in pharmacokinetic disposition in monkeys. Trastuzumab produced from a subsequent manufacturing scale up and formulation change (lyophilization) resulted in comparable pharmacokinetic profiles in monkeys and had no effect on safety endpoints.

The findings from the acute toxicity studies with trastuzumab are summarized in **Table 41**.

Carcinogenicity: Trastuzumab has not been tested for its carcinogenic potential.

Multidose Toxicity Studies: In multiple-dose studies, trastuzumab was well tolerated and produced no evidence of systemic toxicity at any dose tested, including the highest dose that could be delivered of 25 mg/kg. Intravenous administration of trastuzumab as multiple intravenous doses in monkeys of up to 25 mg/kg given weekly for 26 weeks, or twice-weekly for up to 12 weeks, produced no findings of toxicologic significance in any parameter evaluated.

Some isolated changes in ECG, which followed no apparent pattern, were observed in the multiple intravenous doses study in monkeys, dosed up to 25 mg/kg weekly for 26 weeks. The following is a summary of the electrocardiographic findings that were statistically significant in this study from control. In female monkeys, at weeks 5 and 21, the Q-T interval for the 5 mg/kg dose was 0.22 seconds (Vehicle 0.18 seconds) and for the 25 mg/kg dose was 0.23 seconds (Vehicle 0.18 seconds). In male monkeys, at weeks 9 and 17, the Q-T interval for the 1 mg/kg dose was 0.16 seconds (Vehicle 0.21 seconds) and for the 25 mg/kg dose was 0.04 seconds (Vehicle 0.03 seconds). The heart rate, at week 17, for the 5 and 25 mg/kg dose, was 145 and 160 beats/minute, respectively (Vehicle 183 beats/minute). There were no statistically significant electrocardiographic findings in female monkeys at weeks 9, 13, 17 and 26, and in male monkeys at weeks 5, 13, 21 and 26. In male monkeys during the recovery phase (weeks 30 and 34), the heart rate for the 25 mg/kg dose was 190 beats/minute (Vehicle 160 beats/minute) and 180 beats/minute (Vehicle 200 beats/minute), respectively; while the Q-T interval was 0.19 seconds (Vehicle 0.22 seconds) and 0.23 seconds (Vehicle 0.19 seconds), respectively. In female monkeys, at weeks 30 and 34, the heart rate was 190 beats/minute (Vehicle 210

beats/minute) and 140 beats/minute (Vehicle 180 beats/minute), respectively; while the Q-T interval was 0.22 seconds (Vehicle 0.17 seconds) and 0.26 seconds (Vehicle 0.21 seconds), respectively for the 25 mg/kg dose.

Although, administration of trastuzumab was associated with a mild reduction in heart rate in some male monkeys receiving 5 or 25 mg/kg, this was not considered toxicologically significant since bradycardia was not present in these monkeys. There was no toxicological significance of the aberrant ventricular complexes seen in monkeys treated with trastuzumab since these were not seen broadly in all treated monkeys. Occasional abnormal complexes may be observed in normal animals.

The findings from the multidose toxicity studies with trastuzumab are summarized in Table 42.

Mutagenicity: Trastuzumab has not been associated with any evidence of mutagenic potential in a mouse micronucleus test, a bacterial mutation test, or in a chromosomal aberration assay in human lymphocytes. These studies are summarized in **Table 43**.

Reproductive and Developmental Toxicology: The results of reproductive toxicity studies conducted in female cynomolgus monkeys given trastuzumab as daily intravenous injections for 4 days followed by twice-weekly administration for the duration of the dosing period revealed no alterations in menstrual cyclicity or sex hormone profiles, and no trastuzumab-related embryotoxicity or effects on fetal development. Pregnancy did not appear to affect maternal exposure to trastuzumab.

When trastuzumab was administered during the period of organogenesis, fetal serum trastuzumab concentrations ranged from 10%-19% of maternal values. Administration during the last trimester was associated with trastuzumab fetal serum concentrations of approximately 33% of maternal concentrations. The difference in fetal serum trastuzumab concentrations obtained in the early and late gestational periods may be attributable to the time between trastuzumab administration and maternal/fetal blood sampling (e.g., samples were obtained 50 days, early gestational study, or 2 days, late gestational study, after the final trastuzumab administration). However, an increase in fetal/maternal serum concentration ratio is consistent with an increase in immunoglobulin transfer rate observed as gestation progresses in both humans and in nonhuman primates. Compared to serum concentrations, trastuzumab was detected at relatively low levels in the milk of lactating monkeys. Trastuzumab detected in the milk of lactating monkeys had no effect on neonatal growth and development from birth to one month of age when study was terminated. A summary of the reproduction studies conducted with trastuzumab is provided in **Table 44**.

Special Toxicity Studies: Specific toxicity studies performed with trastuzumab included: issue cross-reactivity studies in human and monkey tissue, immunogenicity, drug interaction, and local tolerance studies, *in vitro* hemolytic potential/blood compatibility studies, and a systemic toxicity study in mice with the formulation component trehalose. Details from these studies are provided in **Table 45**.

No gross or histopathologic changes were observed in tissues which demonstrated trastuzumab binding in the tissue cross-reactivity studies.

In addition, trehalose, a component of the lyophilized formulation, produced no evidence of clinical or anatomical toxicity when given daily to mice at intravenous doses of up to 1 g/kg. Single dose drug interaction studies in which 1.5 mg/kg trastuzumab (lower than the recommended dose) was administered intravenously with single doses of doxorubicin, cyclophosphamide, paclitaxel, or the combination of doxorubicin and cyclophosphamide, did not show any significant alterations in disposition profiles of trastuzumab, or any of the chemotherapeutic agents, that might suggest possible safety or efficacy concerns. In local tolerance studies conducted in rabbits, no gross or histopathologic evidence of irritative potential was noted following intravenous administration of the liquid or

lyophilized trastuzumab formulations at a concentration of 5 mg/mL. Both the liquid and lyophilized formulations are compatible with whole blood, serum, and plasma obtained from humans and monkey.

Study No	Study	Study Species/		Route	Dose	Lot No.	Estimated Safety Factor		Study
Study No.	Туре	Strain	No./Sex/Group	of Admin.	(mg/kg)		Body Weight Ratio	AUC _A /AUC _H	Duration
91-629-1450	Acute	Mouse/Crl:	5/M	IV	0	M3-RD175			At least
	Single Dose	CD-1 [®] (ICR)	5/F		9.4		4.7x	2.8x	2 weeks
	(GLP)	BR/VAF/Plus [™]			47		NA	NA	
					94		47x	19x	
Comments:	Trastuzumab was mice.	s well tolerated and	the no observable	effect level (NOE	_) after a singl	e intravenous b	olus injection of tras	tuzumab was 94	.0 mg/kg in
91-640-1450	Acute	Monkey /	2/M	IV	0	M3-RD175			At least
	Single Dose	Rhesus	2/F		4.7		2.4x	1x	2 weeks
	(GLP)				23.5		NA	NA	
					47		24x	12x	
Comments:	Trastuzumab wa rhesus monkeys.	s well tolerated and	the no observable	effect level (NOE	.) after a singl	e intravenous b	olus injection of tras	tuzumab was 47	.0 mg/kg in
94-173-1450ª	Acute	Monkey /	2/M	IV	0	M3-RD319			At least
	Single Dose	Rhesus	2/F		5		2.5x	NA	2 weeks
	(GLP)				50		2.5x	NA	
					50	A9806AX	2.5x	NA	
Comments:	A single intraven monkeys.	ous dose of trastuzi	umab H13 or trastu	zumab H2 up to 5	0 mg/kg was	well tolerated a	nd produced no adve	erse effects in rh	esus
94-436-1450 ^b	Acute	Monkey /	4/F	IV	1.5	M3-RD319	0.8x	NA	30 days
	Single Dose	Rhesus			1.5	C9802AX	0.8x	NA	

	(GLP)								
Comments:	-	nous administration elated differential e		-	-		of 1.5 mg/kg was	well tolerated	and produce
95-490-1450c	Acute	Monkey /	6/F	IV	1.5	M4-RD494	0.8x	NA	11 weeks
	Single Dose	Rhesus			1.5	C9807AX	0.8x	NA	
	(GLP)								
Comments:	(single dose liquic the study, and no	dy was conducted t I formulation) and tr test material-relate es between the two	rastuzumab (multi d overt clinical sig	i-dose lyophilized	formulation)) to compare their p Furthermore, there	harmacokinetic pr	rofiles. All anin	nals survived

a This study was conducted to support a liquid formulation process change from trastuzumab H2 to trastuzumab H13.

b This study was conducted to support the clinical use of trastuzumab produced by a scaled-up manufacturing process, trastuzumab (H13-12K)

c This study was conducted to support the clinical use of lyophilized trastuzumab.

				Route		Estimated Safety Factor		
Study No.	Study Type	Species/ Strain	No./Sex/Group	of Admin.	Dose (mg/kg)	Body Weight Ratio	AUC _A /AUC _H	Study Duration
91-667-1450	Multidose	Monkey /	4-6/M	IV	0			8 weeks
	(GLP)	Rhesus	4-6/F		2.35	2.4x	2x	
					11.75	12x	11x	
					23.5	24x	21x	
Comments:		olus injections of trastuzu proximately 4 weeks.	ımab at doses of up	to 23.5 mg/kg	were well to	lerated whe	n administered	twice
94-455-1450	Multidose	Monkey /	4-6/M	IV	0			8 months
	(GLP)	Cynomolgus	4-6/F		1	0.5x	0.3x	
					5	2.5x	Зx	
					25	13x	14x	
Comments:	administered t	olus injections of trastuzu to cynomolgus monkeys o es (Refer to the TOXICOLO	once a week for app	roximately 6 n	nonths. Howe	ever, some cl		-
97-333-1450	Multidose	Monkey /	4-6/M	IV	0			5 months
	(GLP)	Cynomolgus	4-6/F		1	1x	NA	
					5	5x	NA	
					25	25x	NA	
Comments:		minary evaluation of the e or female cynomolgus	•			mab produc	ed no apparen	t adverse

Table 42 - Overall Summary of Nonclinical Multidose Toxicity Studies with Trastuzumab

IV=Intravenous NA=not available

Table 43 - Overall Summary of Nonclinical mutagenicity Studies with Trastuzumab

	Chudu	Creasian/		Route		Estimated Safety Factor		Churcher
Study No.	Study Type	Species/ Strain	No./Sex/Group	of Admin.	Dose (mg/kg)	Body Weight Ratio	AUC _A /AUC _H	Study Duratior
98-024-1450	In Vivo		6/M	IV	0			24 hours
	Micronucleus	Mouse/ICR/ (CRj: CD-1,SPF)			29.5	15x	NA	
	(GLP)	(0.1). 02 2,01 1			59	30x	NA	
					118	59x	NA	
narrow cells of m 94-382-1450	Mutagenicity	Salmonella	NA	NA	0-5000			NA
94-382-1450	Mutagenicity	Salmonella	NA	NA	0-5000			NA
	(GLP)	typhimurium E. coli			µg/mL	41x ^a	NA	
oncentrations up reatments perfo presence of S-9, f	o to 5000 μg/mL rmed using a "tr ailed to produce	able to induce mutation in the absence of a ra- reat and plate" protoce e a statistically signific erefore considered to	at liver metabolic a ol. All trastuzumab ant increase in rev	ctivation system (treatments of the ertant numbers w	S-9), and 375 e test strains, hen the data	0 μg/mL in it both in the a were analyse	s presence, wi absence and in ed at the 1% le	th the
97-101-1450	Cytogenicity	Human Lymphocytes	NA	NA	0-5000			NA
	(GLP)	numan Lymphocytes			µg/mL	41x ^a	NA	
	at doses up to a matory trials.	nsidered negative for and including 5000 μg						

^aAnimals were not dosed so AUC ratios cannot be calculated, however the ratio of concentration examined in vitro/maximum average concentration observed in human circulation (123 µg/mL) is presented here

Table 44 - Overall Summary of Nonclinical Reproduction Studies with Trastuzumab

		/		_		Estimated Safety Factor		
Study No.	Study Type	Species/ Strain	No./Sex/Group	Route of Admin.	Dose (mg/kg)	Body Weight Ratio	AUC _A /AUC _H	Study Duration
95-038-1450	· · · · ·	Monkey/	6/F	IV	0			7 Menstrua Cycles
	Fertility valuation	Cynomolgus			1	1x	8.0x ^a	
	(GLP)				5	5x	2.2x ^a	
					25	25x	1.6x ^a	
95-039-1450	Embryo-Fetal	in menstrual cyclicity Monkey/	12/F	IV	0			100 days
			12/F	IV	0			100 days
	Embryo-Fetal	Cunomolaus			4	4	7 23	
	Development	Cynomolgus			1	1x 5x	7.2xª 2 2xª	
	Development (GLP)		bot docor of 1 5 -	nd 25 mg/kg cm D	5 25	5x 25x	2.2x ^a 1.8x ^a	47 and 50
Comments: Intra of gestation was in this study. Two were therefore re	Development (GLP) venous adminis well tolerated a pregnant mon eplaced. Three s on of the fetus. T		ernal toxicity, embry ng/kg group and one deaths, two in the 2	otoxicity, or terato in the vehicle cor 1.0 mg/kg dose gro	5 25 ays 20, 21, 22 ogenicity. How htrol group, d oup and one i	5x 25x 25, 27, 30, wever, five n ied without n the 25 mg,	2.2x ^a 1.8x ^a 34, 37, 41, 44, naternal death delivery or abo /kg dose group	s occurred ortion and , occurred

animal/human are presented here.

Study No.	Study Type			Route of Admin.		Estimated Safety Factor		
		Species/ Strain	No./Sex/Group		Dose (mg/kg)	Body Weight Ratio	AUC _A /AUC _H	Study Duration
91-663-1450	Tissue Cross- Reactivity (GLP)	Human Tissue	NA	NA	2.5 μg/mL 50 μg/mL	0.02x ^a 0.04x ^a	NA NA	NA
Comments:	Murine antibody staining may refle	ody trastuzumab de muMab 4D5 reacts ect methodological d an tumours are almo	in normal tissues p conditions employe	aralleling the patt ed to detect these	erns observed two antibodie	for trastuz	umab. Differen	ces in
91-686-1450	T' O		NA	NA	2.5 mg/mL	20x ^a	NA	NA
	Tissue Cross- Reactivity (GLP)	Monkey/Rhesus Tissue			0.79 mg/mL	6xª	NA	
Comments:	humanized trastu between trastuzu	ected an antigen in r izumab was similar i imab and muMab 4 ited that rhesus moi	n distribution, but D5 may be attribut	inconsistent and l ed to methodolog	ess intense. Tl ical difference	he differences in detection	es in staining o on of the two a	bserved ntibodies.
92-458-1450 ^b	Multidose		3/F	IV	5.0	2.5x	2.9x	6 months
	Immunogenicity	Monkey / Cynomolgus			5.0	2.5x	2.5x	
	(GLP)	07.101.101 <u>6</u> 03			5.0	2.5x	1.9x	

Table 45: Overall Summary of Nonclinical Special Toxicity Studies with Trastuzumab

						Estimated Safety Factor		
Study No.	Study Type	Species/ Strain	No./Sex/Group	Route of Admin.	Dose (mg/kg)	Body Weight Ratio	ht AUC _A /AUC _H	Study Duration
Comments:	variant) and trast trastuzumab (high immunogenic bas	ation of 5.0 mg/mL uzumab (arginine va n glutamine variant) ed on expected pha he cynomolgus moi	ariant) or muMab 4), trastuzumab (low armacokinetics and	1D5 in cynomolgu v glutamine variar	s monkeys wa nt), and trastu	s well tolera zumab (argir	ted. Trastuzum nine variant) we	ab, ere not
93-446-1450 ^c	Follow Up	Monkey /	3/F	IV	5.0	2.5x	NA	2 weeks
	Follow-Up Immunogenicity (GLP)	Currente a la una			5.0	2.5x	NA	
Comments:		nallenge dose of 5.0 d and was not imm						
94-241-1450	Circle Dece		3/F	IV	1.5	0.8x	NA	2 wooks
	Single-Dose Drug Interaction (GLP)	Monkey/Rhesus						3 weeks
Comments:	Drug Interaction (GLP) A single intravenc body weight basis	Monkey/Rhesus ous injection of trass s), when given alone oxan [®] , was well tole	e or in combination	with Adriamycin	° or Taxol [®] , or	when given		se on a
Comments: 91-639-1450	Drug Interaction (GLP) A single intravenc body weight basis Adriamycin or Cyt	bus injection of trass s), when given alone	e or in combination	with Adriamycin	° or Taxol [®] , or	when given		se on a
	Drug Interaction (GLP) A single intravenc body weight basis	bus injection of trass s), when given alone	e or in combination erated and produce	with Adriamycin ed no evidence of	[®] or Taxol [®] , or systemic toxic	when given		se on a of
	Drug Interaction (GLP) A single intravence body weight basis Adriamycin or Cyt Acute Local Tolerance (GLP)	ous injection of trass s), when given alone oxan [®] , was well tole Rabbit/Hra: (NZW) SPF and excipient form	e or in combination erated and produce 9/F	ed no evidence of IV	[®] or Taxol [®] , or systemic toxic 0 1.9	when given city. 1x	in combination NA	se on a of 7 days

		/		_		Estimated Safety Factor		
Study No.	Study Type	Species/ Strain	No./Sex/Group	Route of Admin.	Dose (mg/kg)	Body Weight Ratio	ight AUC _A /AUC _H tio	Study Duration
	Tolerance (GLP)	(NZW) SPF		IV	5 mg/mL	1x	NA	7 days
	(OLF)			SC	50 mg/mL	9.5x	NA	
				SC	100 mg/mL	19x	NA	
Comments:	and dilution with with 1.1% benzyl	f trastuzumab given saline to a concentr alcohol to a concen evidence of local irr	ation of 5 mg/mL, tration of 100 mg/	or given as a singl mL, or dilution wit	e subcutaneo th saline to 50	us injection	following reco	nstitution
91-668-1450	Hemolytic Potential Blood Compatibility (GLP)	Monkey/Rhesus and Human blood and plasma	NA	NA	4.7 mg/mL	38x ^a	NA	NA
Comments:	monkey erythroc Adriamycin is a re Taxol is a register	a concentration of 4 ytes and were comp egistered Trade-Mar ed Trade-Mark of Br tered Trade-Mark o	batible with human k of Pharmacia & U ristol-Myers Squibl	and rhesus monk Jpjohn S.P.A. o Company		-	of human or r	hesus
95-501-1450	Hemolytic Potential Blood Compatibility (GLP)	Monkey/Rhesus and Human blood and plasma	NA	NA	5 mg/mL	41x ^a	NA	NA
Comments:	trastuzumab con	a concentration of 5 centration) did not c nd human serum an	ause hemolysis of					

Study No.	Study Type	Species/ Strain	No./Sex/Group	Route of Admin.	Dose (mg/kg)	Estimated Safety Factor		Chudu
						Body Weight Ratio	AUC _A /AUC _H	Study Duration
96-014-1450			10/M	IV	0			2 weeks
	Multidose	Mouse/Crl: CD-1 [®]	10/F		10	35x ^d	NA	
	(GLP) with Trehalose	(ICR) BRVAF/Plus [®]			100	350x ^d	NA	
					1000	3500x ^d	NA	
Comments:		administration of tr 00 mg/kg in male and		ks was well tolerat	ted and produ	ced no adve	erse effects at o	loses up to

IV=Intravenous, NA=not available, SC=Subcutaneous, IP=Intraperitoneal

^aAnimals were not dosed so AUC ratios cannot be calculated, however the ratio of concentration applied in vitro to tissues/maximum average concentration observed in human circulation (123 µg/mL) is presented here.

^bThe immunogenic potential to two trastuzumab (H2) preparations, containing high or low levels of glutamine variant, and an arginine variant-containing trastuzumab preparation, was compared to the immunogenic potential of the murine counterpart antibody, muMAb 4D5.

^cThis study was conducted to further assess the immunogenic potential of the presence of glutamine variant in trastuzumab (H2). A single challenge dose was administered to those monkeys (in Study 92-458-1450) that had received 6 months of weekly injections of the high or low glutamine variant-containing trastuzumab (H2) preparations.

^dThe ratio of trehalose dose/projected final trastuzumab formulation trehalose dose (~2 mg/kg) is presented here.

[®] registered Trade-Marks of their respective owners.

16.1 Comparative Non-Clinical Pharmacology and Toxicology

16.1.1 Comparative Non-Clinical Pharmacodynamics

In vitro Studies

Trazimera was compared with trastuzumab-US and trastuzumab-EU in a number of in vitro binding and functional assays reflective of the mechanism of action of trastuzumab. All cell-based functional assays were conducted using human breast cancer cell lines. Trazimera was shown to bind to HER2 with similar affinity and kinetics as trastuzumab-US and trastuzumab-EU. Trazimera was also shown to have similar activity as trastuzumab-US and trastuzumab-EU on the following activities: binding to cell surface HER2, binding to FcyRl/Rlla/Rllb/Rllla (158V/F allotype)/Rlllb and FcRn, increased HER2 phosphorylation and decreased HER3 phosphorylation in cells, inhibition of cell growth, induction of ADCC activity (using primary human natural killer cells and peripheral blood mononuclear cells), and induction of low levels of apoptotic activity. While Trazimera was shown to bind to C1q, no induction of CDC activity was observed; the results were similar to those of trastuzumab-US and trastuzumab-EU.

16.1.2 Comparative Toxicology

A single-dose IV toxicokinetic/tolerability study was conducted in male mice (55 males/group) to compare the effects of Trazimera with those of trastuzumab-EU and trastuzumab-US (at 1, 10, or 100 mg/kg). Trazimera was well tolerated and its toxicokinetics, tolerability, and ADA response was similar to trastuzumab-US and trastuzumab-EU at all doses tested.

17 SUPPORTING PRODUCT MONOGRAPHS

1. ^{Pr}HERCEPTIN[®] (powder, 440 mg/vial), submission control number 235646, Product Monograph, Hoffmann-La Roche Limited. May 7, 2020

PATIENT MEDICATION INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

^{Pr}Trazimera®

Trastuzumab for Intravenous Infusion

BREAST CANCER

Read this carefully before you start taking **Trazimera** and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about **Trazimera**.

Trazimera is a biosimilar biologic drug (biosimilar) to the reference biologic drug Herceptin[®]. A biosimilar is authorized based on its similarity to a reference biologic drug that was already authorized for sale.

Serious Warnings and Precautions

Medication Errors

There is a risk of medication errors between Trazimera (trastuzumab) and Kadcyla[®] (trastuzumab emtansine). Verify with the healthcare provider that the recommended Trazimera (trastuzumab) dose and NOT Kadcyla (trastuzumab emtansine) dose is used.

Cardiotoxicity (harm to the heart)

Trazimera can result in the development of heart problems including heart failure. The appearance of heart failure can be delayed and can occur after treatment with Trazimera is completed. In early breast cancer, the incidence of cardiac dysfunction was higher in patients who received trastuzumab plus chemotherapy versus chemotherapy alone, with higher risk when trastuzumab was administered together with a taxane following an anthracycline and cyclophosphamide. In patients with breast cancer that has spread to other parts or organs of the body, the incidence and severity of cardiac dysfunction was particularly high in patients who received trastuzumab at the same time as anthracyclines and cyclophosphamide.

You should have your heart function evaluated by your doctor before and during treatment with Trazimera.

Infusion Reactions; Lung Problems

Some patients have had serious infusion reactions and lung problems; infusion reactions causing death have been reported. In most cases, these reactions occurred during or within 24 hours of receiving trastuzumab. Your Trazimera infusion should be temporarily stopped if you have shortness of breath or very low blood pressure. Your doctor will monitor you until these symptoms go away. If you have a severe allergic reaction, swelling, lung problems, inflammation of the lung, or severe shortness of breath, your doctor may need to completely stop your Trazimera treatment.

Toxicity to Fetus (Unborn Baby)

Trazimera can cause harm to the fetus (unborn baby), in some cases death of the fetus, when taken by a pregnant woman. Women who could become pregnant need to use effective birth control methods during Trazimera treatment and for at least 7 months after treatment with Trazimera. Nursing mothers treated with Trazimera should discontinue nursing or discontinue Trazimera.

What is Trazimera used for?

- Trazimera is a cancer medicine that must be prescribed by a doctor.
- Trazimera is used to slow down the growth of specific breast cancer cells that produce large amounts of HER2 protein. It is used only for patients whose tumours are growing more rapidly than normal because of a genetic problem in the cells. This occurs in about 25 to 30% of breast cancer tumours.
- If your doctor has prescribed Perjeta (pertuzumab) and the chemotherapy drug docetaxel in combination with Trazimera, you should also read the leaflet for these medications.
- Trazimera is also approved for the treatment of gastric cancer (a separate Patient Medication Information insert provides information on the use of Trazimera in gastric cancer).

When should Trazimera be used?

- Patients whose breast cancer tumour cells produce large amounts of the HER2 protein can use Trazimera.
- Trazimera is used for certain patients with early breast cancer following surgery and after chemotherapy OR following surgery and with taxane and carboplatin chemotherapy as well as for patients to whom breast cancer has spread to other parts or organs of the body.

How does Trazimera work?

- Our bodies have a natural defence system against cancer cells. When cancer cells appear, our bodies respond by making special proteins called antibodies. The antibodies attach to other proteins on the growing tumour cells. Researchers studied this to learn how to create antibodies that help with cancer treatment.
- Antibodies are now made that can target tumours to try to control the growth of cancer.
- Trazimera belongs to a family of medicines called monoclonal antibodies. It is an antibody that targets the HER2 gene to stop its activity. It attaches to the HER2 receptor on the cancer cell. When it is in place, it works to stop the growth of the cancer cells and may destroy them.

What are the ingredients in Trazimera?

Medicinal ingredients: The medicinal ingredient in Trazimera is trastuzumab. Each vial of Trazimera contains 440 mg or 150 mg trastuzumab.

Non-medicinal ingredients: Trazimera contains the following non-medicinal ingredients: L histidine, L-histidine hydrochloride monohydrate, polysorbate 20, and sucrose.

The Bacteriostatic Water for Injection supplied with Trazimera 440 mg contains benzyl alcohol.

Trazimera comes in the following dosage forms:

Trazimera is a sterile powder that will be reconstituted and given as an intravenous (IV) infusion.

Do not use Trazimera if:

• you are allergic to trastuzumab, Chinese Hamster Ovary (CHO) cell proteins, or any component of this product (see "What are the ingredients in Trazimera").

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take Trazimera. Talk about any health conditions or problems you may have, including if you:

- have ever had a bad reaction to Trazimera, benzyl alcohol, or any of the inactive ingredients;
- are allergic to other medicines, food and dyes;
- are taking any other medicines, including those not prescribed by your doctor;
- have any other illness or diseases, such as heart problems, heart disease, breathing problems or lung disease; the risk of heart problems may be increased in geriatric patients in both early breast cancer and breast cancer that has spread to other parts or organs of the body; the risk of lung disease may increase if you have taken chemotherapy drugs which are toxic for the lungs;
- have already been treated with chemotherapy drugs (especially anthracyclines such as doxorubicin, epirubicin or related drugs such as mitoxantrone) or radiation therapy;
- are pregnant, plan to become pregnant or are breast-feeding a child. Please note that a reduction in the amount of [amniotic] fluid that surrounds the developing fetus within the amniotic sac has been observed in pregnant women receiving trastuzumab;
- have difficulty breathing at rest.

This information will help your doctor and you decide whether you should use Trazimera and what extra care may need to be taken while you are on the medication.

Other warnings you should know about:

Driving and using machines

Trazimera has a minor influence on the ability to drive and use machines. Dizziness and sleepiness may occur during treatment with Trazimera. If you experience unwanted effects related to the infusion (such as itching, wheezing, dizziness, racing heart) you should not drive or operate machinery until symptoms resolve completely.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

The following may interact with Trazimera:

• Formal drug interaction studies with Trazimera have not been done in humans. Important interactions with other medications were not seen during clinical trials with trastuzumab.

How to take Trazimera:

Your doctor has prescribed Trazimera after carefully studying your condition. Other people may not benefit from taking this medicine, even though their problems may seem similar to yours.

The hospital pharmacy will prepare Trazimera so it can be used. If you are sensitive to benzyl alcohol, the Trazimera powder should be mixed with sterile water.

Verify with the healthcare provider that the recommended Trazimera (trastuzumab) dose and NOT Kadcyla (trastuzumab emtansine) dose is used.

Usual dose:

The usual dose of Trazimera depends on your body weight. Your doctor will calculate the dose for you.

How long you need to take Trazimera will depend on your response to the treatment. Your doctor will check your response regularly and decide how many treatments you will receive.

A Registered Nurse in the hospital or outpatient clinic will give you Trazimera at regular intervals (usually every 3 weeks) determined by your physician. Trazimera is not taken by mouth but given through an intravenous line. An intravenous line, or IV, is a thin, plastic tube with a needle placed in a vein in your hand or arm. When Trazimera is given intravenously, it is called an infusion.

Your first infusion of Trazimera will take about 90 minutes. If you tolerate this infusion well, your next infusions may be given in less time, usually about 30 minutes.

Overdose:

If you think you, or a person you are caring for, have taken too much Trazimera, contact a healthcare professional, hospital emergency department, or regional poison control centre immediately, even if there are no symptoms.

For information on the risk of Kadcyla overdose due to medication errors, see the Kadcyla Product Monograph.

Missed Dose:

If you miss a dose, your doctor will advise you on when your next administration of Trazimera will be.

What are possible side effects from using Trazimera?

These are not all the possible side effects you may have when taking Trazimera. If you experience any side effects not listed here, tell your healthcare professional.

Unwanted effects are possible with all medicines. Talk to your doctor, nurse or pharmacist if you are worried about side effects or find them very bothersome and report any new or continuing symptoms to your doctor immediately. Your doctor will be able to tell you what to do and may be able to help you with these side effects.

Some unwanted effects happen during the first infusion or shortly after it is completed. The effects usually do not last long but may need treatment. The infusion may be stopped and may be restarted and/or given over a longer time.

These unwanted effects related to the infusion may include:

- Itching
- Wheezing
- Dizziness
- Racing heart

Giving certain medications before the next infusion of Trazimera may prevent these unwanted effects.

In clinical studies, the most common unwanted effects were fever and chills, nausea, vomiting, diarrhea, pain, and headache. The symptoms can easily be treated. Giving certain medications before Trazimera can prevent some unwanted effects.

Less common unwanted effects are:

• Shortness of breath and water retention, which are symptoms of heart problems. These are caused by an effect on the heart muscle that reduces the strength of the pumping action of the heart. This unwanted effect is more common in women who have previously had anthracycline

chemotherapy (e.g. doxorubicin, epirubicin). Heart failure as a result of Trazimera treatment can vary in severity and may require treatment with heart medications and/or Trazimera treatment may need to be stopped.

- Shortness of breath, fatigue, or a racing heart, which are symptoms of anemia. This is caused by a temporary decrease in the number of red blood cells.
- A temporary decrease in the number of white blood cells may increase your risk of infection and diarrhea.

Difficulty breathing, fatigue and weight loss are commonly seen with lung disease.

Call your doctor immediately if you notice any of the following:

- Shortness of breath;
- Increased cough;
- Swelling of the legs as a result of water retention;
- Diarrhea if you have an extra four bowel movements each day or any diarrhea at night;
- Symptoms of infection that include:
 - fever: a temperature of 38°C or greater
 - o sore throat
 - \circ cough
 - $\circ \quad \text{any redness or swelling} \\$
 - \circ pain when you pass urine
- Symptoms of an allergic reaction include:
 - o closing of the throat
 - o swelling of lips and tongue
 - o hives
 - o rash
 - o dizziness
 - o fast heartbeat

Serious side effects and what to do about them							
	Talk to your healt	Stop taking drug and					
Symptom / effect	Only if severe	In all cases	get immediate medical help				
MOST COMMON (≥10%)							
Diarrhea: Where you have an extra four bowel movements each day or any diarrhea at night		\checkmark					
LESS COMMON (≥1% AND ≤10%)							
Heart problems: Symptoms include shortness of breath, water retention (swelling of the lower legs)		\checkmark					
Anemia (reduced number of red blood cells of the blood):							
Symptoms include: shortness of breath, racing heart, dizziness, light headedness		\checkmark					
Reduced number of white blood cells may lead to an increase chance of infection:							
Symptoms of infection include: fever (temperature above 38°C or 101°F), chills, sore throat, cough, any redness or swelling, pain when you pass your urine		\checkmark					
Lung problems: Symptoms include shortness of breath, wheezing or coughing		\checkmark					

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<u>https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html</u>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

The hospital pharmacy will store Trazimera in a refrigerator. Trazimera can be at room temperature

when the infusion is given.

Keep out of reach and sight of children.

If you want more information about Trazimera:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website: (https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-products/drug-product-database.html); Pfizer Canada ULC website (www.pfizer.ca), or by calling 1-800-463-6001.

This leaflet was prepared by Pfizer Canada ULC.

Last Revised JUN 18, 2021

PATIENT MEDICATION INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

^{Pr}Trazimera®

Trastuzumab for Intravenous Infusion

GASTRIC CANCER

Read this carefully before you start taking **Trazimera** and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about **Trazimera**.

Trazimera is a biosimilar biologic drug (biosimilar) to the reference biologic drug Herceptin[®]. A biosimilar is authorized based on its similarity to a reference biologic drug that was already authorized for sale.

Serious Warnings and Precautions

Medication Errors

There is a risk of medication errors between Trazimera (trastuzumab) and Kadcyla[®] (trastuzumab emtansine). Verify with the healthcare provider that the recommended Trazimera (trastuzumab) dose and NOT Kadcyla (trastuzumab emtansine) dose is used.

Cardiotoxicity (harm to the heart)

Trazimera can result in the development of heart problems including heart failure. The appearance of heart failure can be delayed and can occur after treatment with Trazimera is completed. In early breast cancer, the incidence of cardiac dysfunction was higher in patients who received trastuzumab plus chemotherapy versus chemotherapy alone, with higher risk when trastuzumab was administered together with a taxane following an anthracycline and cyclophosphamide. In patients with breast cancer that has spread to other parts or organs of the body, the incidence and severity of cardiac dysfunction was particularly high in patients who received trastuzumab at the same time as anthracyclines and cyclophosphamide.

You should have your heart function evaluated by your doctor before and during treatment with Trazimera.

Infusion Reactions; Lung Problems

Some patients have had serious infusion reactions and lung problems; infusion reactions causing death have been reported. In most cases, these reactions occurred during or within 24 hours of receiving trastuzumab. Your Trazimera infusion should be temporarily stopped if you have shortness of breath or very low blood pressure. Your doctor will monitor you until these symptoms go away. If you have a severe allergic reaction, swelling, lung problems, inflammation of the lung, or severe shortness of breath, your doctor may need to completely stop your Trazimera treatment.

Toxicity to Fetus (Unborn Baby)

Trazimera can cause harm to the fetus (unborn baby), in some cases death of the fetus, when taken by a pregnant woman. Women who could become pregnant need to use effective birth control methods during Trazimera treatment and for at least 7 months after treatment with Trazimera. Nursing mothers treated with Trazimera should discontinue nursing or discontinue Trazimera.

What is Trazimera used for?

- Trazimera is a cancer medicine that must be prescribed by a doctor.
- Trazimera is used for certain patients with gastric cancer that has spread to other parts or organs of the body to slow down the growth of specific gastric cancer cells that produce large amounts of HER2 protein.
- Trazimera is used in combination with chemotherapy (capecitabine or intravenous 5fluorouracil and in combination with cisplatin) for the treatment of gastric cancer that has spread to other parts or organs of the body.
- Trazimera is also approved for the treatment of breast cancer (a separate Patient Medication Information insert provides information on the use of Trazimera in breast cancer).

When should Trazimera be used?

- Patients whose gastric cancer tumour cells produce large amounts of the HER2 protein can use Trazimera.
- Trazimera is used in combination with chemotherapy (capecitabine or intravenous 5fluorouracil and cisplatin) for the treatment of gastric cancer that has spread to other parts or organs of the body in patients that have not received prior anti-cancer treatment for their disease.

How does Trazimera work?

- Our bodies have a natural defence system against cancer cells. When cancer cells appear, our bodies respond by making special proteins called antibodies. The antibodies attach to other proteins on the growing tumour cells. Researchers studied this to learn how to create antibodies that help with cancer treatment.
- Antibodies are now made that can target tumours to try to control the growth of cancer.
- Trazimera belongs to a family of medicines called monoclonal antibodies. It is an antibody that targets the HER2 gene to stop its activity. It attaches to the HER2 receptor on the cancer cell. When it is in place, it works to stop the growth of the cancer cells and may destroy them.

What are the ingredients in Trazimera?

Medicinal ingredients: The medicinal ingredient in Trazimera is trastuzumab. Each vial of Trazimera contains 440 mg or 150 mg trastuzumab.

Non-medicinal ingredients: Trazimera contains the following non-medicinal ingredients: L histidine, L-histidine hydrochloride monohydrate, polysorbate 20, and sucrose.

The Bacteriostatic Water for Injection supplied with Trazimera 440 mg contains benzyl alcohol.

Trazimera comes in the following dosage forms:

Trazimera is a sterile powder that will be reconstituted and given as an intravenous (IV) infusion.

Do not use Trazimera if:

• you are allergic to trastuzumab, Chinese Hamster Ovary (CHO) cell proteins, or any component of this product (see "What are the ingredients in Trazimera").

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take Trazimera. Talk about any health conditions or problems you may have, including if you:

- have ever had a bad reaction to Trazimera, benzyl alcohol, or any of the inactive ingredients;
- are allergic to other medicines, food and dyes;
- are taking any other medicines, including those not prescribed by your doctor;
- have any other illness or diseases, such as heart problems, heart disease, breathing problems or lung disease;
- are pregnant, plan to become pregnant or are breast-feeding a child. Please note that a reduction in the amount of [amniotic] fluid that surrounds the developing fetus within the amniotic sac has been observed in pregnant women receiving trastuzumab;
- have difficulty breathing at rest.

This information will help your doctor and you decide whether you should use Trazimera and what extra care may need to be taken while you are on the medication.

Other warnings you should know about:

Driving and using machines

Trazimera has a minor influence on the ability to drive and use machines. Dizziness and sleepiness may occur during treatment with Trazimera. If you experience unwanted effects related to the infusion (such as itching, wheezing, dizziness, racing heart) you should not drive or operate machinery until symptoms resolve completely.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

The following may interact with Trazimera:

• Formal drug interaction studies with Trazimera have not been done in humans. Important interactions with other medications were not seen during clinical trials with trastuzumab.

How to take Trazimera:

Your doctor has prescribed Trazimera after carefully studying your condition. Other people may not benefit from taking this medicine, even though their problems may seem similar to yours.

The hospital pharmacy will prepare Trazimera so it can be used. If you are sensitive to benzyl alcohol, the Trazimera powder should be mixed with sterile water.

Verify with the healthcare provider that the recommended Trazimera (trastuzumab) dose and NOT Kadcyla (trastuzumab emtansine) dose is used.

Usual dose:

The usual dose of Trazimera depends on your body weight. Your doctor will calculate the dose for you.

How long you need to take Trazimera will depend on your response to the treatment. Your doctor will check your response regularly and decide how many treatments you will receive.

A Registered Nurse in the hospital or outpatient clinic will give you Trazimera at regular intervals (usually every 3 weeks) determined by your physician. Trazimera is not taken by mouth but given through an intravenous line. An intravenous line, or IV, is a thin, plastic tube with a needle placed in a

vein in your hand or arm. When Trazimera is given intravenously, it is called an infusion.

Your first infusion of Trazimera will take about 90 minutes. If you tolerate this infusion well, your next infusions may be given in less time, usually about 30 minutes.

Overdose:

If you think you, or a person you are caring for, have taken too much Trazimera, contact a healthcare professional, hospital emergency department, or regional poison control centre immediately, even if there are no symptoms.

For information on the risk of Kadcyla overdose due to medication errors, see the Kadcyla Product Monograph.

Missed Dose:

If you miss a dose, your doctor will advise you on when your next administration of Trazimera will be.

What are possible side effects from using Trazimera?

These are not all the possible side effects you may have when taking Trazimera. If you experience any side effects not listed here, tell your healthcare professional.

Unwanted effects are possible with all medicines. Talk to your doctor, nurse or pharmacist if you are worried about side effects or find them very bothersome and report any new or continuing symptoms to your doctor immediately. Your doctor will be able to tell you what to do and may be able to help you with these side effects.

Some unwanted effects happen during the first infusion or shortly after it is completed. The effects usually do not last long but may need treatment. The infusion may be stopped and may be restarted and/or given over a longer time.

These unwanted effects related to the infusion may include:

- Itching
- Wheezing
- Dizziness
- Racing heart

Giving certain medications before the next infusion of Trazimera may prevent these unwanted effects.

In the main clinical study in gastric cancer, the most common unwanted effects which are known to be associated with both the chemotherapy drugs used in the study and with trastuzumab administration were:

- stomach disorders such as nausea, vomiting, diarrhea and constipation
- blood disorders such as neutropenia (reduced number of white blood cells) anemia (reduced number of red blood cells) and thrombocytopenia (reduced number of platelet cells (colorless blood cells that play an important role in blood clotting)).

Giving certain medications before Trazimera can prevent some unwanted effects.

Call your doctor immediately if you notice any of the following:

- Shortness of breath;
- Increased cough;

- Swelling of the legs as a result of water retention;
- Diarrhea if you have an extra four bowel movements each day or any diarrhea at night;
- Symptoms of infection that include:
 - fever: a temperature of 38°C or greater
 - o sore throat
 - o cough
 - $\circ \quad \text{any redness or swelling} \\$
 - o pain when you pass urine
- Symptoms of an allergic reaction include:
 - o closing of the throat
 - swelling of lips and tongue
 - \circ hives
 - o rash
 - o dizziness
 - o fast heartbeat

In the main clinical study in gastric cancer, serious side effects that appeared with higher frequency in trastuzumab plus chemotherapy arm versus chemotherapy arm alone are listed in the table below.

Serious si	de effects and what t	to do about them		
	Talk to your healt	Stop taking drug and		
Symptom / effect	Only if severe	In all cases	get immediate medical help	
LESS COMMON (≥1% AND ≤10%)				
Stomach problems				
• Diarrhea		\checkmark		
Vomiting				
Difficulty swallowing				
Blood disorders				
Reduced number of white blood cells		\checkmark		
leading to increased chance of				
infection; fever.				
Infections				
Infection of the lungs (pneumonia);		2		
symptoms may include symptoms of a		, v		
cold followed by high fever.				
General Disorders		1		
Fever		\checkmark		
Metabolism Disorders				
Anorexia		\checkmark		
Kidney problems				
Kidneys fail to function adequately;				
symptoms may include: decreased or		\checkmark		
normal urine output, fluid retention,				
causing swelling in your legs, ankles or				
feet, drowsiness shortness of breath,				
fatigue.				

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<u>https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html</u>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

The hospital pharmacy will store Trazimera in a refrigerator. Trazimera can be at room temperature when the infusion is given.

Keep out of reach and sight of children.

If you want more information about Trazimera:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website: (https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-products/drug-product-database.html); Pfizer Canada ULC website (www.pfizer.ca), or by calling 1-800-463-6001.

This leaflet was prepared by Pfizer Canada ULC.

Last Revised JUN 18, 2021